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Abstract 
The Office International des Epizooties (OIE) Animal Health Code categorizes bovine 
anaplasmosis as a notifiable disease. Many species of the genus Anaplasma cause anaplasmosis. 
Co-infections with two or more Anaplasma spp. occur in cattle. A competitive ELISA is 
regarded as a reliable test for identifying A. marginale-infected cattle. However, cross-reactivity 
among related Anaplasma spp. has been reported when using cELISA. In the absence of 
effective treatment strategies and vaccine availability, anaplasmosis control strategies are 
primarily focused on disease identification and prevention and development of 
chemosterilization strategies. Four studies were completed to improve the diagnosis, treatment, 
and control of bovine anaplasmosis. In the first study, a real-time qRT-PCR was developed to 
detect as few as 100 copies of 16S rRNA of both A. marginale and A. phagocytophilum in the 
same reaction. This detection limit was equitable to the minimum infective unit of one A. 
marginale bacterium. In the second study, qRT-PCR results determined needle-free injection 
was superior to needle injection for controlling iatrogenic transmission of A. marginale in cattle. 
The qRT-PCR demonstrated 100% sensitivity by 21 days post-infection and 21 days prior to 
100% sensitivity with cELISA. The third study determined the pharmacokinetic parameters of 
chlortetracycline in group fed, ruminating Holstein steers: volume of distribution (40.9 L⁄kg); 
rate constant (0.0478 h-1); dose-normalized area under the curve (0.29 h·µg⁄L); clearance (1.8 
L⁄kg⁄h); elimination half-life (16.2 h); maximum concentration/dose (4.5 ng⁄mL); and time of 
maximum concentration (23.3 h). Dose linearity was confirmed for oral chlortetracycline 
dosages of 4.4, 11, and 22 mg/kg/day. The final study established an in vivo pharmacokinetic-
pharmacodynamic relationship between chlortetracycline and anaplasmosis carrier clearance in 
bovine plasma (85.3 ng/mL). The qRT-PCR confirmed chemosterilization of all oral 
chlortetracycline-treated cattle within 49 days of treatment. Furthermore, qRT-PCR was an 
effective alternative to the subinoculation of splenectomized cattle for accurate and precise 
disease classification. The diagnosis, treatment, and control of anaplasmosis were enhanced 
through the application of qRT-PCR. Further studies are necessary for determining the 
mechanism of action between chlortetracycline binding to the 30S ribosome of A. marginale and 
carrier clearance.
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Preface 
Anaplasmosis is a complex and challenging disease for stakeholders in the cattle 
industry, foreign policy and research communities alike. Anaplasmosis, caused by Anaplasma 
marginale, is one of the most prevalent tick-transmitted, rickettsial diseases of cattle worldwide 
(Dumler et al., 2001; Kocan et al., 2003; Uilenberg, 1995). Clinical disease symptoms in adult 
cattle acutely-infected with A. marginale include, but are not limited to, anemia, fever, icterus, 
lethargy, and death (Merck, 2008; Radostits et al., 2000). In 2003, anaplasmosis was estimated to 
cost the United States cattle industry over $300 million per year (Kocan et al., 2003). Cattle 
infected with anaplasmosis following natural infection and vaccination with live Anaplasma spp. 
remain lifelong carriers. Moreover, abortion, high mortality, reduced milk production, extensive 
treatment costs, and weight loss are key economic considerations of this disease.  
Many of the current methods used for the diagnosis, treatment, eradication, and control of 
bovine anaplasmosis present many problems to the cattle industry. Historically, vaccination has 
been used to modulate disease severity. In some countries, naïve cattle are inoculated 
intravenously with bovine blood infected with Anaplasma centrale for reducing disease 
morbidity prior to infection with A. marginale. The appropriately-timed application of 
insecticides is recommended for reducing biological transmission by haematophagous arthropods 
(De Wall, 2000; Peter et al., 2005; Rodriguez-Vivas et al., 2004). Due to the lack of significant 
success with treatment strategies, vaccine availability, and problematic vector control, 
anaplasmosis control strategies should primarily concentrate on established methods for disease 
prevention.  
The findings of this PhD program of study have the potential to significantly impact 
local, interstate, and international movement of cattle between endemic and non-endemic 
regions. A highly sensitive and specific quantitative RT-PCR (qRT-PCR) assay was developed 
for the detection of A. marginale and A. phagocytophilum in the same reaction. A needle-free 
injection system was validated by the qRT-PCR for the control of iatrogenic disease 
transmission. The application of the qRT-PCR assay was instrumental in characterizing the time 
of chemosterilization as well as establishing the in vivo dose-response relationship between 
plasma drug concentration and chemosterilization.  
xvii 
 
The following literature review is subdivided into eight sections. The primary focus of 
this PhD program has been centered on anaplasmosis caused by A. marginale. Therefore, the 
focus of this literature review will be directed towards the literature as it applies to A. marginale. 
Information may be included for both A. centrale and A. phagocytophilum when relevant to the 
discussion. Furthermore, certain topics will be covered without an in depth review of the 
literature for the sake of increasing the breadth of knowledge of both the author and the reader.  
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CHAPTER 1 - Literature Review 
Etiology 
Bovine anaplasmosis, caused by Anaplasma marginale, was first described by Sir Arnold 
Theiler in South Africa in 1909 (Kocan et al., 2000). Anaplasma marginale was detected along 
the intracellular margin of infected red blood cells by light microscopic examination of stained 
blood smears. However, A. marginale is not the exclusive species of the genus Anaplasma that is 
an etiologic agent of this hemoparasitic disease in cattle (Liu et al., 2005). The causative agents 
of bovine anaplasmosis (family Anaplasmataceae) are grouped by their distinction as obligate 
intracellular bacteria that replicate within a mammalian eukaryotic host cell membrane-derived 
vacuole (Dumler et al., 2001; Rikihisa, 1991). This categorization includes the species A. bovis, 
A. centrale, A. marginale, and A. phagocytophilum. Furthermore, anaplasmosis has been 
classified as a notifiable disease by the Office International des Epizooties (OIE) in the 
Terrestrial Animal Health Code 2.4.1 (OIE, 2009).  
Anaplasma marginale receives the most attention from the cattle industry due to its 
socioeconomic impact and influence on international trade restrictions worldwide. However, the 
significance of A. marginale as an economically significant disease is frequently underestimated 
due to seasonal outbreaks and endemic stability (Rogers and Shiels, 1979). Anaplasma bovis, 
formerly known as Ehrlichia bovis, infects bovine mononuclear cells; however, these infected 
cells are rarely found in peripheral blood (Dumler et al., 2001). Anaplasma centrale, a less 
virulent cohabitant of the centralized intracellular region of the erythrocyte, is used as a live 
vaccine to reduce morbidity and mortality in cattle subsequently infected with A. marginale 
(Kocan et al., 2000). Anaplasma phagocytophilum, formerly E. phagocytophilum, infects 
myeloid cells (granulocytes and monocytes) of many mammals. Bovine anaplasmosis, cause by 
A. phagocytophilum, is typically reported as a self-resolving febrile disease of cattle (Pusterla 
and Braun, 1997). Even though A. phagocytophilum has been identified as an economically 
important disease in cattle (Hoar et al., 2008; Pusterla and Braun, 1997; Pusterla et al., 1997), the 
prevalence of this pathogen in the United States is unknown (Hoar et al., 2008). However, 
research interest has evolved for the development of disease models in cattle due to A. 
phagocytophilum being the etiologic agent of human granulocytic ehrlichiosis (de la Fuente et 
al., 2006).  
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Transmission 
Horizontal transmission  
Horizontal transmission occurs between anaplasmosis carriers to susceptible animals. The 
foremost recognized mode of horizontal transmission of bovine anaplasmosis is mediated by tick 
vectors. The tick vectors include the genera Argas, Boophilus, Dermacentor, Hyalomma, Ixodes, 
Ornithodoros, and Rhipicephalus. Biological transmission of A. marginale by ticks occurs after 
extensive multiplication in tick gut and salivary tissues (Kocan et al., 2000).The tick life cycle 
aids in the transmission of anaplasmosis. However, ticks do not acquire anaplasmosis 
transovarially. In general, ticks are multi-host feeders during development from the larval, 
nymphal, and adult stages (Vredevoe, website accessed October 1, 2009). Once a tick feeds on a 
carrier animal, tick transmission of anaplasmosis occurs intra- and transstadially. Once a female 
tick develops to the adult stage, she must engorge on a blood meal prior to mating with a male 
tick. The female tick then releases from the parasitized animal for oviposition. After oviposition, 
the female tick may die (hard ticks) or attach to another host for feeding (soft ticks). Male ticks 
are purported as the most problematic vector (Kocan et al., 2000; Stiller and Coan, 1995). This is 
due to the shorter feeding period of ticks and disease transmission during multiple feedings. The 
percentage of ticks infected during feeding is related to the circulating parasitemia (Eriks et al., 
1989; Eriks et al., 1993). However, a key clarification to the discussion is that not all isolates of 
A. marginale are tick-transmissible (Morley and Hugh-Jones, 1989a; Scoles et al., 2005).  
Anaplasma marginale differs from other Anaplasma spp. by the ability to be transmitted 
mechanically by haematophagous arthropods and blood-contaminated fomites (Kocan et al., 
2000). In a review by Ewing, 12 species of Muscidae, 8 species of Tabanidae, and 3 species of 
Culicidae were reported as mechanical vectors of A. marginale (Ewing, 1981). Mosquitos may 
also play a less significant role in transmission (Richey, 1991). In one study, tabanids were 
capable of A. marginale transmission from infected calves to splenectomized calves in as few as 
10 bites over a 2 hour time period (Hawkins et al., 1982). However, the role of tabanids as an 
anaplasmosis vector may be overemphasized due to this study being conducted on calves with 
parasitemias of 35 to 87%. In controlled studies typical of field infection, ticks have been 
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demonstrated to be more efficient vectors of anaplasmosis than Tabanidae and Muscidae on the 
order of >240-fold and >300-fold, respectively (Scoles et al., 2005; Scoles et al., 2008).  
Iatrogenic transmission  
Iatrogenic transmission of A. marginale by blood-contaminated fomites has been 
demonstrated to occur during routine animal husbandry procedures (as reviewed by Dikmans, 
1948). A non-exhaustive list of blood-contaminated fomites that may spread A. marginale are 
needles, dehorning equipment, nose tongs, tattooing tools, ear tag equipment, and castration 
devices (De Wall, 2000; Kocan et al., 2000; Rodriguez-Vivas et al., 2004). In an iatrogenic 
transmission study (Reeves and Swift, 1977), a cow was identified as an anaplasmosis carrier 
through serologic evaluation with the complement fixation test; additionally, 8 heifers were 
determined seronegative. The seropositive cow followed by 5 seronegative heifers were loaded 
into an alley system. The carrier cow was then vaccinated intramuscularly with physiologic 
saline by an automatic syringe (a conventional needle injection technique) followed by the serial 
vaccination of 5 heifers at 1 minute intervals with the same needle. The order of injection was 
recorded. The remaining heifers served as non-injected controls. At the end of a 60 day study, 
only the first heifer receiving an intramuscular injection was iatrogenically infected. These 
results are similar to the iatrogenic transmission study described in Chapter 3. However, a 
comparison was made in this study between conventional needle injection and a needle-free 
injection system. Furthermore, the iatrogenic transmission model described in Chapter 3 was a 
more robust evaluation of iatrogenic transmission with each injection technique. Following 10 
replicates of a sham intramuscular vaccination with each technique without disinfection or 
replacement of injection equipment, needle-free injection was found to be superior to 
conventional needle injection for the prevention of iatrogenic transmission of A. marginale.  
Due to all cattle not being castrated, dehorned, ear-tagged, or tattooed, it is likely that 
vaccination is the leading cause of iatrogenic transmission of A. marginale. However, disease 
prevention strategies during vaccination have been considered impractical, uneconomical, or 
potentially deleterious to the procedure (Andrews and Lamport, 1985; Makoschey and Beer, 
2004). In a survey of fifty-five large animal veterinary practices, 32% did not exchange 
hypodermic needles between each cow (Anderson and Silviera, 2008). Resources have been 
dedicated to the development of needle-free injection devices for improving the processing and 
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throughput of cattle during vaccination. Needle-free injection techniques have proven to be 
efficacious for the delivery of vaccines in cattle (Hollis et al., 2005; Huang et al., 2005; Manoj et 
al., 2004). However, research has suggested the potential for blood product transfer during the 
use of needle-free injectors for consecutive injections (Sweat et al., 2000).This potential was not 
significant enough to cause iatrogenic transmission of A. marginale during needle-free injection 
as described in Chapter 3.  
Vertical transmission  
Vertical transmission in cattle is the transfer of disease from the dam to her gestating calf 
in utero. Anaplasma marginale causes abortion in acutely infected cattle (Radostits et al., 2000). 
However, abortion is neither absolute in acutely infected cows nor in carrier cows. The 
relationship between in utero transmission and trimester of pregnancy was described in the 
literature (Zaugg, 1985). Six pregnant, susceptible cows were inoculated with a Virginia isolate 
of A. marginale during each trimester of pregnancy. Through subinoculation of splenectomized 
calves with blood samples from fetuses at various stages of development and pre-colostrally into 
intact calves, it was determined that in utero transmission occurs during the second and third 
trimesters of pregnancy. However, abortion occurred in one cow 22 days after inoculation during 
the third trimester. Unfortunately, the findings of this study were confounded by the potential for 
inadvertent contamination of fetal blood samples collected during the surgery and inability to 
infect susceptible calves after birth.  
The incidence of in utero transmission has been documented in observational studies in 
which surgical collection of blood did not occur (Bird, 1973; Potgieter and van Rensburg, 1987; 
Zaugg and Kuttler, 1984). Potgieter and van Rensburg reported an in utero transmission rate of 
7.7% in calves born to both acutely infected and carrier cows. Therefore, acute infection of the 
dam is not necessary for vertical transmission to the fetus. The in utero transmission rate of A. 
centrale in acutely infected, splenectomized cows was 30.8%. Furthermore, transplacental 
transmission of A. marginale and A. centrale was possible in each trimester of pregnancy. The A. 
marginale transmission rate is consistent with a prevalence study in 58 calves born to carrier 
cows (6.7%, data unpublished). This in utero transmission rate was as determined by the qRT-
PCR described in Chapter 2, not by serologic methods. 
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Pathogenesis 
The progression of anaplasmosis, caused by A. marginale, is typified by four stages of 
variable duration; (1) peracute/incubation, (2) acute/developmental, (3) convalescent, and (4) 
carrier (Radostits et al., 2000; Richey, 1991).The peracute phase (1) is described as the time from 
infection of a susceptible animal until a detectable parasitemia occurs (1%). The duration (4-6 
weeks) of this subclinical stage of infection is influenced by the isolate and number of infective 
A. marginale bacteria. The start of the acute phase (2), which coincides with the first signs of 
clinical disease, is signaled by an increase in body temperature. The end of the acute phase is 
signaled by the first signs of reticulocytes in the circulation. The appearance of reticulocytes 
(erythropoiesis) occurs much earlier in the acute phase in younger cattle due to a regenerative 
anemia; however, a paradoxical non-regenerative anemia is typical in older cattle. This non-
regenerative anemia observed during the acute phase is the reason why cattle > 1 year of age 
display clinical signs of anaplasmosis and have high mortality rates. The duration of the acute 
phase is generally 4-9 days. Clinical signs appear during the acute phase. Until clinical signs 
develop, the need for clinical intervention is inapparent (Alfonso et al., 1996). The period 
typified by the convalescent phase (3) is from the release of reticulocytes until normal blood 
values return. Upon the return of normal blood values, the carrier state (4) begins and continues 
until death or chemosterilization. 
A cyclic rickettsemia is a characteristic of the carrier state (Kieser et al., 1990). In the 
carrier state, the number of infected erythrocytes ranges from 104-107 per milliliter at 5 week 
intervals (Eriks et al., 1993). This steady rise and rapid decline parallels the rickettsemias level 
variation seen in the acute phase. The host immune response to A. marginale infection depends 
upon the production of anti-parasitic and anti-erythrocytic antibodies inducing the 
erythrophagocytosis of parasitized erythrocytes (Jatkar and Kreier, 1969). The mechanism by 
which anaplasmosis eludes the host immune response is unknown; however, the lack of 
conservation of gene sequences encoding Major Surface Protein (MSP) antigens of Anaplasma 
spp. has been the focus of research (de la Fuente et al., 2005). The analysis of the outer 
membrane fraction of A. marginale has led to the characterization of 6 major polypeptides: MSP-
1a, MSP-1b, MSP-2, MSP-3, MSP-4, and MSP-5 (as reviewed by Palmer and McElwain, 1995; 
Tebele et al, 1991).   
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Clinical findings 
A seasonal distribution of cattle presenting with clinical disease during the summer and 
fall is typical of infection with A. marginale. However, infection and the subsequent need for 
medical intervention is common year-round in tropical regions when naïve cattle are introduced 
into endemically stable herds. Additionally, iatrogenic transmission also necessitates the need for 
diligent attention to the symptoms of this disease and subsequent potential for year-round 
treatment.  
A differential diagnosis list includes infectious and non-infectious diseases that cause 
anemia and icterus (Table 1.1). All ages of cattle are susceptible to infection with A. marginale 
(Bird, 1973; Zaugg, 1985; Zaugg and Kuttler, 1984). However, clinical disease and mortality 
rates increase with age (Richey, 1991). Typically, cattle less than 1 year of age become infected 
without exhibiting any clinical signs of disease. As the age of cattle increases, morbidity and 
mortality rates rise during the acute phase of disease. A febrile response, which coincides with a 
detectable parasitemia, is typically the first sign of infection. Unless cattle present with clinical 
disease supported by a diagnosis of anaplasmosis caused by A. marginale, treatment is not 
warranted (Alfonso et al., 1996). Abortion caused by A. marginale occurs in acutely infected and 
carrier cows (Correa et al., 1978; Zaugg, 1985; Zaugg and Kuttler, 1984).  
Anaplasmosis, caused by A. phagocytophilum, is typified by a much shorter incubation 
period of 6.3 + 1.2 days (Pusterla and Braun, 1997). Anaplasma phagocytophilum bodies are first 
observed between 4-8 days of infection. The duration of the detectable parasitemia is 
approximately 10 days. Clinical signs include pyrexia (40.2 - 47.1°C), decreased milk 
production, respiratory distress, abnormal locomotion, and nasal discharge. However, these 
clinical signs resolve without treatment in adult cattle. Abortion is reported to occur in the last 2 
months of gestation. A list of clinical signs has been prepared for comparison between A. 
marginale and A. phagocytophilum (Table 1.2). 
Disease caused by A. centrale is typically subclinical. Additionally, splenectomized and 
intact cows that were both acutely and chronically infected with A. centrale did not abort during 
acute infection or the carrier state (Potgieter and van Rensburg, 1987). Therefore, disease caused 
by A. centrale will not be discussed.  
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Diagnosis 
Necropsy  
Post-mortem findings are typical of death caused by anemia. Generalized tissue pallor, an 
enlarged, red-brown discolored spleen, and enlarged liver and gall bladder are common findings. 
Icterus may be present depending on the time of death during the acute phase of disease. Thin 
blood film preparations can be made from the incised surface of the spleen and liver for detection 
of parasitized erythrocytes.  
First generation diagnostic methods  
Since first discovered by Theiler in 1909, the foundation for diagnosis of anaplasmosis is 
based on light microscopy, a first generation diagnostic method. First generation diagnostic 
methods rely on the growth or visualization of the organism of interest. These methods have 
limited sensitivity and lack adequate specificity to differentiate between morphologically similar 
pathogens, normal structures, and stain artifacts. A diagnosis of A. marginale infection by light 
microscopic examination of stained blood smears is made from blood collected in anticoagulant.  
A method for staining blood smears and performing percent parasitized erythrocyte 
counts is included in Chapter 3. The “feathered edge” of the blood smear is examined for 
parasitized erythrocytes. Anaplasma marginale are found along the intracellular margin of 
erythrocytes. These dense, basophilic bacteria are 0.3-1.0 µm in diameter. A minimum of 500 
erythrocytes should be examined at 1000X magnification to detect a parasitemia. If parasitized 
erythrocytes are observed, a percent parasitized erythrocyte count (PPE) should be calculated 
according to the method in Chapter 3. Anaplasma phagocytophilum infection is also detected in 
Giemsa stained blood smears at 1000X magnification. A minimum of 500 leukocytes 
(neutrophils, eosinophils and monocytes) should be examined to detect a parasitemia. 
Cytoplasmic inclusions of parasitized leukocytes are typically first observed between 5.7 + 1.0 
days post-infection and up to 15.1 + 2.8 days post-infection. The average duration of a detectable 
parasitemia is 10.4 + 2.8 days (Pusterla and Braun, 1997).  
Failure to observe blood cells parasitized with A. marginale or A. phagocytophilum does 
not rule out disease (Pusterla et al., 1997; Richey, 1991). When screening cattle for A. marginale, 
the disease incidence determined by light microscopy was only 8.9% as compared to a serologic 
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method (indirect fluorescent antibody) that determined incidence to be 68% (Akinboade and 
Dipeolu, 1984). Due to cyclic rickettsemias in carrier cattle (Eriks et al., 1989; French et al., 
1998), disease classification by light microscopic examination of stained blood smears is only 
reliable during the acute phase of infection (Gale et al., 1996a). As described in Chapter 3, the 
sensitivity of light microscopy is maximized during peak parasitemia of the acute phase of 
infection (Reinbold et al., 2009b).  
The subinoculation of naïve, splenectomized calves with up to 500 mL of whole blood 
from cattle of unknown disease status has served as the gold standard test for disease detection. 
However, this gold standard method is neither cost-effective nor is animal welfare supported. 
Therefore, the determination of A. marginale disease status has depended upon several second 
generation methods (Amerault and Roby, 1968; Barry et al., 1986; Duzgun et al., 1988; Goff et 
al., 1985; Schuntner and Leatch, 1988; Shkap et al., 1990; Winkler et al., 1987).  
Second generation diagnostic methods  
Second generation methods, which rely on the identification of cell components, 
metabolic products, or detection of antigenic components, are currently the most commonly used 
techniques for disease classification in clinical medicine and research. Several serologic tests 
have been developed with an A. marginale antigen preparation to detect antibody in carrier cattle 
(Gale et al., 1996a). Such methods include capillary tube agglutination, rapid card agglutination, 
indirect fluorescent antibody detection, complement fixation, and competitive enzyme-linked 
immunosorbent assay (cELISA). The complement fixation, rapid card agglutination, and 
cELISA are the most common methods used throughout the world (Coetzee et al., 2007; De 
Wall, 2000). Serial comparisons are often necessary to confirm or refute a diagnosis due to 
significant test sensitivity and specificity deficiencies (Boulanger et al., 1966; Coetzee et al., 
2007; Dreher et al., 2005; Strik et al., 2007). Furthermore, a distinction cannot be made between 
current infection and vaccination (Gale et al., 1996a).  
The cELISA (Anaplasma Antibody Test Kit, cELISA, VMRD Inc.; Pullman, WA) is the 
only second generation method used during this program of study. Therefore, only the cELISA 
will be discussed. The cELISA uses a 19-kDa antigen, recombinant major surface protein 5 
(MSP5) that is highly conserved among different strains of A. marginale, A. centrale, and A. 
phagocytophilum (Knowles et al., 1996). A common epitope is shared between the native protein 
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and a recombinant MSP5 fused to a maltose binding protein. This epitope is recognized by the 
monoclonal antibody AnaF16C1. The cELISA is based on the serum antibody inhibition of 
AnaF16C1 binding to MSP5 in A. marginale infected cattle.  
The common measurements of performance for test validation are sensitivity and 
specificity (Greiner and Gardner, 2000). The performance of the cELISA has been evaluated 
with varying degrees of agreement and refutation. The focus of this disparity is due, in part, to 
the % inhibition used for the negative cut-off value. The current negative cut-off 
recommendation is 30% inhibition (OIE, 2009). However, a 42% inhibition is recommended as 
the negative cut-off value in Canada (CFIA, 2006; Van Donkersgoed et al., 2006). Beyond the 
effects of the cut-off value as well as random and systematic error, differences in sensitivity and 
specificity are attributable to the reference population(s) and sampling strategy. Therefore, 
conflicting reports of method performance should be critically evaluated. The reference 
populations tested should be selected based upon varying levels of prevalence of the disease of 
interest as well as the potential for co-infection with closely related pathogens. Additionally, 
methods should be tested in animals with equitable stages of infection.  
The following studies describe the performance of the cELISA with variable negative 
cut-off values, cattle naturally and experimentally infected, and disease prevalence ranging from 
0-100%. The first evaluation of cELISA occurred during the development of the assay (Knowles 
et al., 1996). In 17 calves experimentally infected with a Florida strain of A. marginale, cELISA 
sensitivity was 88.2% using a 25% inhibition cut-off value. When using a 30% inhibition cut-off, 
the sensitivity was 82.4%. At 42% inhibition, the sensitivity was only 35.3%. Notably, the values 
reported were from samples collected between 22-31 days post-infection. As discussed in 
Chapter 3, cELISA peak sensitivity was observed at 41 days post-infection using a 30% 
inhibition cut-off. Furthermore, the false positive rate of the data in Chapter 3 would have 
decreased to 0% had a 42% inhibition cut-off been used.  
In 268 serum specimens collected from cattle located in non-endemic regions, specificity 
was demonstrated at 100% using a 25% inhibition cut-off value. In a separate study of 235 serum 
samples collected from cattle located in endemic regions, the sensitivity and specificity of the 
cELISA was evaluated with a nested PCR (Torioni de Echaide et al., 1998). The sensitivity and 
specificity of the cELISA were 96 and 95%, respectively, using a 28% inhibition cut-off value. 
No further interpretation could be made using other cut-off values due to the manner in which 
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the data was presented. Regardless of the negative cut-off value used to optimize sensitivity and 
specificity, cELISA has replaced the complement fixation and card agglutination tests as the 
accepted basis for testing cattle prior to interstate and international movement (OIE, 2009). Even 
though cELISA is the more robust test of all second generation methods, other methods are still 
offered by diagnostic laboratories (Coetzee et al., 2007; De Wall, 2000).  
In 40 steers experimentally infected with an Oklahoma isolate of A. marginale, the 
sensitivity of the cELISA was 94.8% when using a negative cut-off value of 30% inhibition 
(Coetzee et al., 2007). Study results were confirmed through the inoculation of blood into 
susceptible, splenectomized calves. Specificity was not determined due to all cattle being 
infected. The time to peak sensitivity (13 days post-infection) was shorter than the study 
described in Chapter 3 (41 days post-infection). This may be attributed to the high infective dose 
used. A decreased time of onset for a detectable parasitemia has been reported for increasingly 
high challenge doses (Eriks et al., 1989; Eriks et al., 1993; Gale et al., 1996b).  
The cELISA has been used to evaluate A. marginale chemosterilization strategies using 
oxytetracycline (Coetzee et al., 2005). In this study, 2 different preparations and 3 different 
treatment regimens using a long-acting oxytetracycline were administered to 40 steers 
persistently infected with an Oklahoma isolate of A. marginale. Samples were collected at 31 and 
60 days post-treatment. Chemosterilization failure was confirmed through the subinoculation of 
susceptible, splenectomized calves. The sensitivity of the cELISA and disease prevalence were 
100%; therefore, cELISA could not be evaluated as a tool to detect chemosterilization. In 
Chapter 5, cELISA confirmed chemosterilization success in a chlortetracycline 
chemosterilization study. However, this did not occur until anti-MSP5 antibodies had declined 
below a 30% inhibition cut-off. This confirmation was not achieved for up to 54 days after the 
time of chemosterilization confirmed by the qRT-PCR described in Chapter 2.  
Serologic cross-reactivity among closely related Anaplasma spp. has been previously 
described (Dreher et al., 2005; Strik et al., 2007). A comparison was made between the MSP5 
amino acid sequences of 1 isolate of A. centrale, 3 isolates of A. marginale, and 1 isolate of A. 
phagocytophilum (Dreher et al., 2005). The percent similarity between the A.centrale isolate and 
the A. marginale isolates was > 92%. The percent similarity between the A. centrale isolate and 
the A. phagocytophilum isolate was 65%. The percent similarity between the A. phagocytophilum 
isolate and the A. marginale isolates ranged from 63-64%. The high percent similarity of the 
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cELISA has also enabled its use for detecting antibody in cattle vaccinated with A. centrale with 
a sensitivity of 93.3% (Molad et al., 2006). In contrast, the A. phagocytophilum MSP5 was 
characterized and used to study the extent of cross-reactivity with A. marginale (Strik et al., 
2007). Their study results illustrated no serologic distinction could be made between A. 
phagocytophilum and A. marginale. Therefore, the results of the cELISA (Knowles et al., 1996; 
VMRD) must be interpreted carefully for screening field samples in areas where infection with 
A. centrale, A. marginale, and A. phagocytophilum may occur.  
The use of cELISA for screening neonatal calves post-colostrum consumption may be 
problematic. In an unpublished study, the prevalence of antibody in calves born to carrier cows 
was 66.7%. However, the prevalence was determined to be only 6.7% by the qRT-PCR 
described in Chapter 2. Pre-colostrum consumption samples were not analyzed. Therefore, the 
utility of the cELISA for screening calves for anaplasmosis is uncertain.  
Third generation diagnostic methods  
Third generation methods have evolved through the elucidation of genomic DNA and 
RNA sequences. The selection of an appropriate target for the accurate and precise diagnosis of 
disease is critical to the successful development of third generation methods. The analysis of 
genomic sequences has led to the development of nucleic acid-based techniques for the 
classification of disease status. In turn, nucleic acid-based techniques have extensively 
contributed to the understanding of anaplasmosis disease processes. Third generation methods 
offer superior sensitivity over first and second generation methods through the ability to detect 
pathogens down to the minimum biological unit for infection (Zarlenga and Higgins, 2001). 
Inadequate specificity due to cross-reactivity is not a disadvantage when using third generation 
methods. Additionally, the specificity of molecular methods has led to the development of 
multiplex methods for detecting co-infection of clinically relevant pathogens.  
The cyclic parasitemia of A. marginale in carrier cattle was first described with the use of 
a nucleic acid probe for detecting infected erythrocytes (Eriks et al., 1989). An A. marginale 
specific probe accurately hybridized with as few as 0.1 ng of genomic DNA and 500-1000 
parasitized erythrocytes in 500 mL of blood. The findings of this sensitive and specific method 
were correlated to the parasitemia level. It was determined that the parasitemia level among 
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carrier cattle was highly variable. Furthermore, this led to the hypothesis that the ability to 
transmit disease may fluctuate with parasitemia level.  
An A. marginale-specific nested PCR (nPCR), currently offered for use by the 
Washington Animal Disease Diagnostic Laboratory at Washington State University, was used to 
support the licensing of the cELISA by the United States Department of Agriculture described 
previously (Knowles et al., 1996; Torioni de Echaide et al., 1998; Valdez et al., 2002; VMRD-2; 
VMRD). This type of PCR uses a nucleic acid based probe to recognize a nucleotide sequence 
amplified during the PCR reaction. Identification was based upon the recognition of amplified A. 
marginale MSP5 DNA sequences from blood samples. The nPCR was able to detect as few as 
30 parasitized erythrocytes in 1 mL of blood. This detection sensitivity is greatly enhanced over 
the nucleic acid probe described previously. The nPCR was also used to determine 
chemosterilization success (Coetzee et al., 2005). However, the utility of the nPCR under these 
conditions was not realized during this study due to all steers not clearing infection. In a separate 
chemosterilization study, nPCR was determined to be an unreliable method for determining 
success of chemosterilization in calves due to a lack of sensitivity (Coetzee 2006). Furthermore, 
this nPCR is not recommended by the OIE due to the potential for non-specific amplification.  
Several polymerase chain reaction (PCR) methods have been developed to identify DNA 
of A. marginale (Bekker et al., 2002; Eriks et al., 1989; French et al., 1998; Gale et al., 1996b; 
Ge et al., 1995; Molad et al., 2006). However, conventional methods rely on the visualization of 
amplified product on agarose gels without the ability to accurately estimate the initial quantity of 
genetic template. The use of real-time molecular methods that combine PCR chemistry and 
fluorescent probe detection of amplified product have greatly enhanced the ability to diagnose 
disease. Real-time methods are reliably used to accurately correlate assay results to the quantity 
of initial template through regression analysis. Furthermore, these methods are capable of 
detecting more than one pathogen through the development of multiplex assays.  
Numerous real-time assays have been developed for the detection of A. marginale alone 
or in combination with other pathogens of tick-borne diseases. Simplex assays that target the 
DNA gene sequences encoding for a major surface protein (MSP1b) and groEL of A. marginale 
have been described (Carelli 2007 and Decaro 2008). The high analytical sensitivity of both 
methods provided for the detection of 10 DNA copies or 10 infective A. marginale bacteria. The 
assay described by Carelli in 2007 was proven highly specific, due to the absence of cross-
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reactivity observed with other Anaplasma spp., such as A. centrale, A. bovis, A. ovis, A. 
phagocytophilum, B. bovis, B. bigemina, T. annulata, and T. buffeli. A similarity was observed in 
the development of TaqMan based systems using the fluoresecent probe, FAM, and quencher 
molecule, BHQ, TaqMan as the simplex qRT-PCR assay described in Chapter 2. However, the 
simplex qRT-PCR assay described in Chapter 2 was only able to detect as few as 100 copies of 
16S rRNA. It is noteworthy that this inferior detection limit is equivalent to the minimum 
infective unit of a single A. marginale bacterium.  
A review of the literature found reports of methods for the detection of A. 
phagocytophilum that have been limited primarily to the diagnosis of disease in humans and 
canines by multiplex real-time methods (Courtney et al., 2004; Sirigireddy and Ganta, 2005). 
However, a real-time simplex reverse-transcriptase polymerase chain reaction (RT-PCR) assay 
was previously described in cattle for detecting 16S ribosomal RNA (16S rRNA) of A. 
phagocytophilum (Pusterla et al., 1999). Gene sequence analysis has identified highly conserved 
and specific regions of the 16S rRNA gene segment of the family Anaplasmataceae. The 
analytical sensitivity of this assay is extraordinary based upon the detection of as few as ten 16S 
rRNA molecules in a reaction. The selection of 16S rRNA was critical for the development of 
this simplex assay. Due to their role in translation of the genetic code, ribosomes, as well as 
rRNA, are present in high copy numbers. Therefore, the analytical sensitivity of the assay 
described by Pusterla et al. in 1999 was enhanced due to the high ratio of 16S rRNA:16S DNA 
(Sirigireddy and Ganta, 2005). This is a similar advantage of the qRT-PCR described in Chapter 
2.  
When developing a multiplex real-time method, the assay must be able to detect non-
equivalent molar ratios. Non-equivalent molar ratios are encountered due to differences in the 
circulating parasitemia, infection of different types of blood cells (erythrocytes versus 
leukocytes), and chronic versus acute infection. The multiplex method described in Chapter 2 is 
capable of detecting equivalent molar ratios as few as one hundred 16S rRNA molecules of A. 
marginale and A. phagocytophilum in the same reaction tube. However, the ability to detect non-
equivalent molar ratios up to 100-fold may be a limitation of the assay for simultaneous 
screening of samples for these Anaplasma spp. (Courtney et al., 2004; Sirigireddy and Ganta, 
2005). However, this could not be accurately assessed during this study due to not detecting A. 
phagocytophilum in the field samples screened. However, a simplex assay for the detection of A. 
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phagocytophilum has been described and applied in this study for the screening of samples 
whose duplex results did not agree with that of the cELISA as in a similar study (Sirigireddy and 
Ganta, 2005). Regardless, the qRT-PCR described in Chapter 2 is the only reported method for 
detecting A. marginale and A. phagocytophilum in the same reaction tube.  
The final frontier for real-time method use is in the determination of A. marginale 
chemosterilization success. However, this application had not been performed until the study 
described in Chapter 5 (Reinbold et al., 2009c). In 18 steers treated with oral chlortetracycline 
for 80 days under experimental conditions, the qRT-PCR was used to determine 
chemosterilization success in all steers by 49 days of treatment. Furthermore, the qRT-PCR 
validated a chemosterilization strategy using a single treatment of injectable oxytetracycline and 
oral chlortetracycline for 30 days. The qRT-PCR assay results were confirmed through the 
subinoculation of susceptible, splenectomized steers. When these chemosterilization strategies 
were applied in the field under conditions of natural infection, a limitation of the qRT-PCR was 
illustrated (unpublished data). This limitation was due to the suppression of the circulating 
parasitemia being less than one A. marginale bacteria in a 250 µL of plasma-free blood sample. 
However, the qRT-PCR was used to illustrate significant differences in the number of circulating 
bacteria prior to the start of treatment, end of treatment, and following a drug washout period. 
Therefore, this information may be used in studies testing the hypothesis that a lower level 
parasitemia may affect the ability to transmit disease.  
Treatment 
The treatment of acute anaplasmosis caused by A. marginale was primarily restricted to 
the supportive care of clinically ill cattle prior to the discovery and use of antimicrobials. 
However, supportive care alone is largely ineffective for reducing the mortality rate. Over time, 
antimicrobials have been used alone or in combination in anaplasmosis treatment regimens. 
Currently, there are no approved formulations for the treatment of anaplasmosis in the United 
States or Canada. Pharmacotherapeutic intervention with a carbanilide derivative (imidocarb 
dipropionate at 3 mg/kg) or tetracycline antibiotics (particularly long-acting formulations of 
oxytetracycline at 20 mg/kg bodyweight administered intramuscularly or subcutaneously) have 
decreased the mortality rate in acutely infected cattle when administered prior to the onset of an 
increasingly severe anemia (Kuttler, 1980; Radostits et al., 2000). However, the development of 
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a carrier state commonly occurs in spite of treatment and recovery from infection. The treatment 
of acutely infected cattle was not a part of this program of study. Therefore, treatment of 
clinically-ill cattle will not be discussed further in this dissertation.  
Chemosterilization 
Cattle infected with anaplasmosis following natural infection and vaccination with live 
Anaplasma spp. remain lifelong carriers (Kocan et al., 2003). Carriers are responsible for 
horizontal, iatrogenic, and vertical transmission of anaplasmosis to naïve cattle by providing a 
reservoir of infective blood for biological, mechanical, and in utero infection (Futse et al., 2003; 
Norton et al., 1983). The inability to clear the carrier state of infection of anaplasmosis in cattle 
is due to an ineffective immune response subsequent to disease challenge and lack of an 
established pharmacokinetic-pharmacodynamic relationship between plasma drug concentration 
and carrier clearance in validated chemosterilization strategies.  
Immune evasion 
The host immune response to A. marginale infection depends upon the production of 
anti-parasitic and anti-erythrocytic antibodies inducing the erythrophagocytosis of parasitized 
erythrocytes (Jatkar and Kreier, 1969). The mechanism by which anaplasmosis eludes the host 
immune response is unknown; however, the lack of conservation of gene sequences encoding 
major surface protein antigens of Anaplasma spp. has been the focus of research (de la Fuente et 
al., 2005). Six types of major surface proteins have been identified: MSP-1a, MSP-1b, MSP-2, 
MSP-3, MSP-4, and MSP-5. Evidence exists for a rapid decrease in antigen-specific T cells and 
immunologic memory following infection of cattle pre-immunized with the major surface 
protein 1a (Han et al., 2008). Other research has shown a second exposure prior to and during 
treatment did not facilitate the chemosterilization process immunologically (Kuttler, 1983). 
Furthermore, the study in Chapter 5 and the findings by others (Magonigle and Newby, 1984; 
Renshaw et al., 1976) have illustrated a loss of immunologic memory through the loss of anti-
parasitic antibody and re-infection of cattle previously chemosterilized.  
Mode of action of tetracycline antibiotics  
The absorption of tetracycline into the erythrocyte has been characterized as a simple 
diffusion process (DeLoach and Wagner, 1984). Once inside the erythrocyte, drug passes as a 
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cation through porin channels of the outer membrane of Gram negative bacteria into the 
periplasm, becomes an uncharged molecule to diffuse through the inner cytoplasmic membrane 
and reversibly binds to the 30S ribosome to inhibit protein synthesis (Chopra and Roberts, 2001). 
Tetracyclines are also known to interact with the 16S rRNA subunit (Moazed and Noller, 1987). 
However, this did not affect qRT-PCR assay performance during the study in Chapter 5.  
Efflux and ribosomal protection proteins, as well as enzymatic inactivation, are 
mechanisms of resistance to counteract the efficacy of tetracycline antibiotics during treatment. 
These mechanisms are driven by numerous resistance genes found in commensal and pathogenic 
bacteria today (Chopra and Roberts, 2001). The ability to define tetracycline resistance is 
difficult due to the frequent occurrence of mutants that are impermeable to drug uptake (Moazed 
and Noller, 1987). Furthermore, no apparent difference is distinguishable between resistance 
genes of the tetracycline family of antibiotics.  
Chlortetracycline pharmacokinetic data  
Chlortetracycline was discovered in a soil sample collected from Sanborn Field at the 
University of Missouri in Columbia, MO in 1945. In 1954, CTC was approved for use in feed for 
improving feed efficiency, growth promotion, and the treatment of CTC-sensitive pathogens 
(NADA, 065-440). Today, the label indications, based on multiple dosing regimens, are for 
increased rate of weight gain, improved feed efficiency, control of bacterial pneumonia 
associated with shipping fever complex, control of active infection of anaplasmosis, reduction of 
liver condemnation because of liver abscessation, and treatment of bacterial enteritis (2009 Feed 
Additive Compendium). The 1999 NAHMS feedlot study reported that 51.9% of all feedlots 
surveyed administer CTC as a health or production management tool to 18.2% of cattle fed. 
Operations with capacities of 1,000–7,999 head, as well as those feeding cattle weighing <318.2 
kg, tend to administer CTC to cattle more often than operations feeding >8,000 head and cattle 
weighing >318.2 kg. On average, CTC is fed 8.6 and 7.7 days to cattle weighing <318.2 and 
>318.2 kg, respectively.  
Pharmacokinetic parameters for orally administered CTC are available for preruminating 
calves, poultry, and swine (Bradley et al., 1982; Dyer, 1988; Kilroy et al., 1990; Luthman and 
Jacobsson, 1983; Nielsen and Gyrd-Hansen, 1996; Pollet et al., 1983; Wanner et al., 1991). 
Remarkably, similar information for ruminating cattle is unknown in spite of the widespread use 
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of CTC. Pharmacokinetic parameters were determined for a single, 22 mg⁄ kg dose of CTC by 
noncompartmental analysis in two-week-old, Holstein calves fed a starter concentration at 2% 
body weight plus ad libitum alfalfa hay (Bradley et al., 1982). Parameters derived for the 
conventionally fed calves were AUC0-LOQ (7.5 hr·µg/mL), t1/2 λz (17.75 h), Cl/F (1.3 L/kg/hr), and 
Vz/F (40.9 L/kg). These parameters are dissimilar to the mean parameters derived by 
noncompartmental analysis parameters for ruminating, Holstein steers that are discussed in 
Chapter 4 (Reinbold et al., 2009a); however, a separate pharmacokinetic analysis technique, 
nonlinear mixed effects modeling, reported similar results to the 1982 study by Bradley et al. 
The dissimilarity parameters derived by noncompartmental analysis is likely caused by 
significant differences in anatomy, metabolism, physiology of the test cattle, method of 
administration, and compartmental vs. noncompartmental analysis between the studies.  
Chlortetracycline and A. marginale chemosterilization  
Chlortetracycline is the only antimicrobial that has a labeled indication for anaplasmosis 
in the United States. Chlortetracycline is labeled for the “control of active infection of 
anaplasmosis caused by A. marginale susceptible to CTC in cattle in the United States” (2009 
Feed Additive Compendium). Several reports exist for the use of CTC in successful 
chemosterilization strategies. These chemosterilization regimens were assessed using 
antigen/antibody-mediated second generation diagnostic methods, such as capillary agglutination 
and complement fixation, and subinoculation of splenectomized calves (Table 5.1) (Brock et al., 
1959; Franklin et al., 1966; Franklin et al., 1967; Franklin et al., 1965; Richey et al., 1977; 
Twiehaus, 1962). These studies were: (1) performed in calves and adult cattle; (2) study animals 
were either intact or splenectomized; (3) regimens were validated in experimental and natural A. 
marginale infection; (4) treatments were either group or individualized; and (5) the average dose 
and duration were 5.21 mg/kg and 54.1 days, respectively. A key difference among these reports 
was only 5 of these regimens were confirmed through the subinoculation of susceptible, 
splenectomized calves. The remaining regimens either relied on the sensitivity and specificity of 
serological methods to determine disease status or the splenectomy of study animals. Overall, 
these regimens were similar to the study described in Chapter 5 in regard to use of a serologic 
method for determining disease status and the subinoculation of susceptible, splenectomized 
calves for confirmation of carrier clearance. However, the qRT-PCR assay definitively defined 
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the time of carrier clearance and aided in the establishment of an in vivo minimum inhibitory 
concentration (MIC) for A. marginale carrier clearance when using chlortetracycline.  
The Clinical and Laboratory Standards Institute (CLSI) has set the susceptible minimum 
inhibitory concentration (MIC) breakpoint of tetracycline antibiotics (200 mg/mL injectable 
oxytetracycline product) at 2 µg/mL when treating bovine bacterial infection caused by 
Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni (CLSI, 2008); yet, a 
similar pharmacokinetic-pharmacodynamic relationship does not exist for the treatment of 
bacterial infection caused by A. marginale. This is in part due to the inability to sustain in vitro 
cultures of A. marginale in erythrocytes (Coetzee et al., 2006; Palmer and McElwain, 1995). 
However, the continuous in vitro cultivation of A. marginale is possible in tick cell lines. The 
response of A. marginale to enrofloxacin, imidocarb, and oxytetracycline in short-term 
erythrocyte cultures was evaluated. Enrofloxacin was shown to inhibit A. marginale in a dose-
dependent manner; the effectiveness of imidocarb declined with increasing drug concentration; 
and oxytetracycline was the least effective (Coetzee et al., 2006).  
Due to the widespread use of CTC for the control of anaplasmosis in cattle, it is essential 
for an in vivo pharmacokinetic-pharmacodynamic relationship be established between plasma 
drug concentrations and carrier clearance to prevent imprudent use of antimicrobials. 
Furthermore, treatment regimens are needed to offer an alternative strategy for minimizing 
animal handling and elimination of individual treatment. The study described in Chapter 5 
illustrated an oral CTC dose of 4.4 mg/kg of bodyweight for 49 days resulted in a minimum 
inhibitory plasma drug concentration of 85.3 ng/mL. Furthermore, higher oral dosages did not 
shorten the duration of therapy.  
The mechanism for the reason why extensive duration of treatment is necessary for 
chemosterilization success is not understood. One reason for the extended duration of treatment 
is the reliance on serology to determine chemosterilization success and failure in previous 
studies. This may have been avoided if a diagnostic method, such as qRT-PCR, was used to 
detect carrier clearance on a real time basis. However, the expense of this would be cost-
prohibitive under field conditions. Other reasons that may be key contributors are the reversible 
binding of chlortetracycline to the 30S ribosome and the extensive lifespan of erythrocytes (160 
days) (Tebele et al., 1991). To my knowledge, the lifespan of a parasitized erythrocyte is 
currently unknown. The concentration of drug achieved in parasitized erythrocytes may be 
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inadequate for a bactericidal effect. Another theory would be attributable to the bacteriostatic 
effect of tetracycline antibiotics, and this theory is supported based upon the findings of the 
Coetzee et al. article in 2006. The mode of action of enrofloxacin is the inhibition of DNA 
gyrase function; therefore, it kills bacteria quickly and classifies enrofloxacin as bactericidal. In 
contrast, tetracycline antibiotics inhibit protein synthesis by reversible binding to the 30S 
ribosomal RNA subunit; therefore, the growth of the bacteria is suppressed and classifies 
tetracycline antibiotics as bacteriostatic. Finally, the inhibition of protein synthesis may prevent 
the infection of non-parasitized erythrocytes; however, parasitized erythrocytes must still be 
removed from circulation by erythrophagocytosis in the spleen.  
The missing link is the mechanism responsible for the absence of an immune response. It 
may be possible that the inhibition of protein synthesis impairs antigenic variation of MSP’s. 
This would allow the bovine immune system to recognize a conserved MSP epitope and mount 
an immune response. Ultimately, carrier clearance is influenced by an extensive drug absorption 
process, reversible binding of the tetracycline antibiotic to the 30S ribosome, an inadequate host 
immune response, and erythrophagocytosis of parasitized erythrocytes.  
Due to the duration of treatment being critical to successful chemosterilization, it is 
unknown if this use will permanently select for or facilitate the distribution of resistance 
determinants in bacterial species present in cattle production systems (Stevens et al., 1993). Two 
multidrug resistance pumps were identified in A. marginale (Brayton et al., 2005). A significant 
change was reported in antimicrobial susceptibility of enteric bacteria from cattle fed 
chlortetracycline in three consecutive, five day pulse treatment regimens at 22 mg/kg (Platt et al., 
2008). However, this change was only temporary as values returned to pre-exposure levels 
within 33 days. Due to length of treatment being critical to successful chemosterilization, it is 
unknown if this return to pre-exposure levels would be similar in situations where the duration of 
therapy is more extensive.  
Prevention 
An anaplasmosis disease control program is defined by the interaction of four key 
criteria: (1) diagnosis of disease in the herd, (2) the culling of less valuable cattle that are 
anaplasmosis carriers, (3) the treatment of cattle that are anaplasmosis carriers with 
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chlortetracycline, and (4) the prevention of disease entry or, in some cases, re-entry after a 
successful chemosterilization program (Figure 1.1).  
Vector control  
The success of a vector control program for reducing biological and mechanical 
transmission of anaplasmosis by haematophagous arthropods is based upon the appropriately-
timed application of insecticides such as arsenicals, chlorinated hydrocarbons, organophosphates, 
carbamates, formamidines, pyrethroids, and macrocyclic lactones, directly on the animal or into 
the environment (De Wall, 2000; Peter et al., 2005; Rodriguez-Vivas et al., 2004). Furthermore, 
the success of a vector control program relies on arthropod susceptibility and managed 
application of chemicals. The continuous and frequent application of insecticides is problematic 
in modern cattle production systems due to due to environmental, target resistance, economic, 
and toxicity concerns. In the event that an ideal parasiticide and vector control program is 
developed, vertical transmission should not be overlooked in programs concentrating solely on 
vector control to reduce the prevalence of anaplasmosis over time (Potgieter and van Rensburg, 
1987; Stiller and Coan, 1995).  
Vaccination  
Historically, vaccination (also referred to as premunition) with the antigenically similar 
pathogen and less pathogenic organism, A. centrale, is a common tool used in A. marginale-
enzootic regions (Palmer and McElwain, 1995). Cattle are inoculated intravenously with bovine 
blood infected with live A. centrale. Premunized cattle develop mild or inapparent infection with 
A. centrale. The infection progresses from the acute phase of disease into a persistent carrier 
state. The carrier state does not prevent subsequent infection with A. marginale. Rather, the A. 
centrale carrier status only prevents or reduces clinical disease upon challenge exposure with A. 
marginale (Kocan et al., 2000). Premunition is limited by (i) the potential for concomitant 
transmission of other blood-borne disease, (ii) transmission of emergent pathogens, (iii) 
virulence variability among geographically-diverse regions, (iv) immune response failure due to 
loss of infectivity during field transport of live A. centrale vaccine, (v) premunition-induced 
immune-mediated hemolytic anemia (Palmer and McElwain, 1995).  
Premunition has been used in many parts of the world, including Israel and South Africa, 
for more than 75 years (Kocan et al., 2000). However, this strategy is not recommended due to 
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the potential for transfer of other blood-borne pathogens and production of erythrocytic 
isoantibodies. Live vaccines that consist of bovine erythrocytes infected with Anaplasma spp. 
have been reported to cause an immune-mediated hemolytic anemia in calves born to dams 
vaccinated with an anaplasmosis vaccine of bovine blood origin. This disease is characterized by 
anemia and icterus in calves following consumption of colostrum (Dennis et al., 1970).  
This phenomenon was prevented with use of a killed vaccine, licensed under the name 
Plazvax (Schering Plough; Kenilworth, NJ, formerly Mallinckrodt), through the harvest of A. 
marginale from infected erythrocytes of cattle. However, it is only currently available under 
special permission through a state veterinarian in restricted areas of the United States (Luther, 
1999). Due to immune evasion, the need for repeated immunizations, and loss antigen-specific 
memory, the use of this serotype-specific vaccine is not advocated.  
Chemoprohylaxis  
Chlortetracycline is labeled for the control of active infection of anaplasmosis caused by 
A. marginale susceptible to CTC in cattle (2009 Feed Additive Compendium). The continuous 
feeding of CTC to naïve cattle in high risk areas is advocated during the vector season (Brock et 
al., 1957). Chlortetracycline is added to free-choice cattle feeds such as feed blocks or salt-
mineral mixes. The rate of inclusion depends on the type and weight of cattle with special use 
provisions in each scenario (Table 1.3) In an unpublished chemosterilization study of cattle 
naturally infected with A. marginale, circulating parasitemia levels were significantly decreased 
through the continuous feeding of CTC for 30 days at 4.4 mg/kg of bodyweight/day as well as 
weekly subcutaneous injections of a long-acting oxytetracycline at 20 mg/kg of bodyweight. A 
key finding in another study was the percentage of ticks infected during feeding is related to the 
circulating parasitemia (Eriks et al., 1989; Eriks et al., 1993). Therefore, the interaction between 
chlortetracycline-suppressed parasitemia in carrier cattle and the transmission of A. marginale 
deserves further attention.  
Regardless, these chemoprohylaxis practices may have the potential to inadvertently 
disrupt endemic stability by chemosterilizing infected cattle and select for or facilitate the 
distribution of resistance determinants in bacterial species present (Stevens et al., 1993). 
However, these hypotheses were not substantiated by the findings of the unpublished study or by 
others. A significant change in antimicrobial susceptibility of enteric bacteria has been reported 
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in cattle fed chlortetracycline in three consecutive, five day pulse treatment regimens at 22 
mg/kg (Platt et al., 2008). However, these values returned to pre-exposure levels within 33 days. 
Due to length of the vector season, it is unknown if a similar return to pre-exposure levels would 
be observed when the duration of therapy is more extensive. The development and liberal 
application of improved animal husbandry practices, such as needle-free injection during 
vaccination (Chapter 3), as well as establishment of an endemically stable herd (Figueroa et al., 
1998), could considerably reduce the need for tetracycline antibiotics when managing 
anaplasmosis in cattle.  
Animal husbandry  
The introduction of anaplasmosis into a previously naïve herd may lead to a 3.6% 
reduction in calf crop due to abortion, a 30% increase in cull rate from a loss of production 
characterized by herd performance benchmarks, and a 30% mortality rate in acutely infected 
cattle (Alderink and Dietrich, 1982). Current estimates of the realized economic loss of this 
scenario are unknown. However, this was estimated to be over $400 per animal over 3 decades 
ago (Alderink and Dietrich, 1982; Goodger et al., 1979).  
The repeated inter-animal use of hypodermic needles is not recommended. The needle-
free injection technique described in Chapter 3 has been shown to prevent the iatrogenic 
transmission of A. marginale. However, this system may not fit into every production system. 
Therefore, there are other techniques for preventing iatrogenic transmission. These include the 
use and exchange of single use needles and cleansing of needles via insertion into foam 
impregnated with biocide. However, these disease prevention strategies associated with 
vaccination have been considered impractical, uneconomical or are potentially deleterious to the 
success of the procedure (Andrews and Lamport, 1985; Makoschey and Beer, 2004).  
Susceptibility of cattle by species  
Breed differences are reported for peak change in packed cell volume, parasitemia level, 
and tick susceptibility (Bock et al., 1999; Jonsson et al., 2008; Wilson et al., 1980). However, all 
cattle are susceptible to infection with A. marginale. Serologic survey studies based upon the 
complement fixation test have reported a significantly greater prevalence of reactors in Bos 
taursus cattle than Bos indicus (Rogers and Shiels, 1979). Furthermore, prevalence was 
significantly influenced by age, stocking density (Rodriguez-Vivas et al., 2004), and level of B. 
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microplus tick infestation. However, sex of the animal had no influence on prevalence. These 
findings may be biased by an over-representation of Bos taurus–type cattle that are more 
susceptible to B. microplus infestation. Additionally, higher stocking densities are associated 
with higher prevalence and increased chance of transfer of developing ticks  
Endemic stability  
In the Unites States, 48 states are endemic for anaplasmosis. Current national disease 
prevalence is unknown. However, seroprevalence has been previously established in California 
(15% in 1989), Illinois (10.7% in 1986), Louisiana (11.2% in 1989), Montana (1.35% in 2003), 
Oklahoma (9.2% in 1991), and Texas (0.3% in 1982) (Alderink and Dietrich, 1982; Behymer et 
al., 1991; Hungerford and Smith, 1997; Morley and Hugh-Jones, 1989b; Rodgers et al., 1994; 
Van Donkersgoed et al., 2006). These seroprevalence reports may or may not be accurate. 
Nonetheless, the key point is that the vast majority of cattle located in these regions are 
susceptible to infection. Reports of seropositive status following colostrum ingestion by suckling 
beef calves is as high as 82% (Maas et al., 1986). Even though carrier cows may be protected 
from clinical disease, colostral antibody ingestion by calves was not protective in seropositive, 
splenectomized neonatal calves subinoculated with 5 mL of whole blood collected from a carrier 
cow (Zaugg and Kuttler, 1984). The ingestion of colostral antibodies only lengthened the 
prepatent period and delayed both the climax of parasitemia and onset of anemia. Therefore, 
anti-anaplasma antibodies provide no lasting protection in suckling calves. If infection was 
established early in the life of cattle, an inapparent infection would occur with lifelong, acquired 
immunity. Over time, this would prevent clinical disease and the subsequent economic losses 
endured by the cattle industry.  
A major disadvantage is that an endemically stable herd does not permit the comingling 
of cattle of unknown disease status or reduce trade restrictions between endemic and non-
endemic countries. Furthermore, the establishment of an endemically stable herd would have no 
effect on tick vectors. The feeding of ticks on A. marginale-immune cattle does not affect tick 
infection rates (Kocan et al., 1996). Finally, it should be noted that wild ruminants are reservoirs 
of Anaplasma spp. (Arens et al., 2003; Kuttler, 1984; Maas et al., 1981; Smith et al., 1982). Due 
to the potential interaction of domestic cattle with ticks that have previously fed on wild 
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ruminants, sporadic outbreaks of disease may still occur in anaplasmosis-free herds. The 
occurrence of this scenario may be sparse, but it should not be ignored. 
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Figures and Tables 
Figure 1.1 Elements of an anaplasmosis control program.  
 
 
 
 
20 
 
Table 1.1 Differential diagnosis list of diseases associated with similar presenting clinical signs as Anaplasma marginale and 
Anaplasma phagocytophilum (Merck, 2008; Radostits et al., 2000). 
A. marginale  A. phagocytohilum 
       
anemia  babesiosis  lymphadenopathy  bovine leukemia virus 
  blood transusion reaction    lymphosarcoma 
  cold water hemolysis    tuberculosis 
  drug-induced     actinobacillosis 
  leptospirosis     
  theileriasis  respiratory disease  infectious bovine rhinotracheitis 
      parainfluenza 
icterus  bacillary hemoglobinuria     bovine viral diarrhea virus 
  hepatotoxic plant poisoning     bovine respiratory syncitial virus 
  leptospirosis    allergic rhinitis 
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Table 1.2 Comparison of clinical signs observed with anaplasmosis caused by Anaplasma marginale and Anaplasma 
phagocytophilum (Merck, 2008; Pusterla and Braun, 1997; Radostits et al., 2000). 
    Pathogen 
 
 Clinical sign  A. marginale  A. phagocytophilum 
Subjective  mucous membrane pallor  Y  N 
  
muscle weakness  Y  Y 
  
depression  Y  Y 
  
anorexia  Y  Y 
  
respiratory distress  Y  N 
  
irritable  Y  N 
  
grossly thin and watery blood  Y  N 
  
icterus  Y  N 
  
nasal discharge  N  Y 
  
abnormal lung sounds  N  Y 
  
cough  N  Y 
  abnormal locomotion  N  Y 
       
Objective  pyrexia   up to 41°C  up to 41°C 
  
dehydration  Y  Y 
  
tachycardia  Y  Y 
  
tachypnea  Y  Y 
  
lymphadenopathy  N  Y 
  
hematocrit change   PCV 5-15%  PCV < 28% 
  
hemoglobinuria  N  Y 
  
total RBC count (10/mm)  1.5-4.0  N/A 
  
bilirubin (mg/100 mL)  0.25-7.0  N/A 
  
decreased milk production  Y  Y 
  
abortion  all trimesters  3rd trimester 
  
treatment indicated  Y  N 
  mastitis  Y  Y 
  limb edema  N  Y 
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Table 1.3 Labeled indications and rate of inclusion of chlortetracycline in free-choice cattle feeds in the United States (2009 
Feed Additive Compendium). 
Dose  Cow type  Chlortetracycline inclusion rate 
1  beef cattle <318.2 kga  350 mg/hd/day 
     
2  beef cattle >318.2 kga  1.1 mg/kg of bodyweight/day 
     
3  beef and non-lactating dairy cattleb  1.1 - 4.4 mg/kg of bodyweight/day 
     
4  cattle <318.2 kg fed in confinement for 
slaughterc  25-100 g/ton of feed with 10 - 30 g/ton of Lasalocid 
     
5  beef cattle <318.2 kg fed in confinement for 
slaughterd  25-42.2 g/ton of feed with 25 - 30 g/ton of Lasalocid 
     
6  beef cattle <318.2 kge  25 - 2,800 g/ton with 30 - 181.8 g/tom of Lasalocid 
     
7  Pasture cattle <318.2 kg (slaughter, stocker, feeder cattle, beef replacement heifers)f  25-700 g/ton of feed with 30 - 600 g/ton of Lasalocid 
     
8  Pasture cattle >318.2 kg (slaughter, stocker, feeder cattle, beef replacement heifers)f  25-1,100 g/ton of feed with 30 - 600 g/ton of Lasalocid 
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9  Pasture cattle (slaughter, stocker, feeder 
cattle, beef replacement heifers)g  500 - 4,000 g/ton of feed with 30 - 600 g/ton of Lasalocid 
          
aNote: Withdrawal times vary by manufacturer. Free-choice feed must be manufactured under a feed mill license using an FDA-
approved formulation. bLimitations: In free-choice cattle feeds such as feed blocks or sal-mineral mixes; Free-choice feed must be 
manufactured from Aureomycin Type A medicated articles, under a feed mill license using an FDA-approved formulation. 
cLimitations for use: Feed continuously in complete feed at a rate of 350 mg CTC and not less than 100 mg nor more than 360 mg 
of lasalocid sodium activity per head per day. dLimitations for use: Feed continuously in complete feed at a rate of 350 mg CTC 
and not less than 250 mg nor more than 360 mg of lasalocid sodium activity per head per day. eLimitations for use: Hand feed 
continuously at a rate of 350 mg CTC per head per day and 1 mg of lasalocid per 4.4 kg bodyweight per day with a maximum of 
360 mg lasalocid per head per day. fLimitations for use: Hand feed continuously at a rate of 350 mg CTC and not less than 60 mg 
nor more than 300 mg of lasalocid sodium activity per head per daily in atleast 2.2 kg of feed. gLimitations for use: Hand feed 
continuously for not more than 5 days to provide 4.5 mg CTC per kg bodyweight per day and not less than 60 mg nor more than 
300 mg of lasalocid sodium activity per head per daily in at least 2.2 kg of feed.  
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CHAPTER 2 - Duplex detection of Anaplasma marginale and 
Anaplasma phagocytophilum in a bovine peripheral blood sample by 
real-time reverse transcriptase-polymerase chain reaction  
Submitted for publication in the Journal of Clinical Microbiology (December 2009) 
Introduction 
Many species of the genus Anaplasma cause bovine anaplasmosis. The Office 
International des Epizooties (OIE) Animal Health Code categorizes anaplasmosis as a notifiable 
disease due to socioeconomic impact and international trade restrictions (OIE, 2009). However, 
the significance of anaplasmosis is frequently underestimated due to seasonal outbreaks and 
stability in endemic areas. Anaplasmosis, caused by Anaplasma marginale, is one of the most 
prevalent tick-transmitted, rickettsial diseases of cattle worldwide (Kocan et al., 2003). 
Vaccination with A. centrale is a common practice used to reduce disease morbidity in cattle 
subsequently infected with A. marginale (Molad et al., 2006). Infection with one Anaplasma spp. 
does not confer immunity from infection with other Anaplasma spp. Co-infection with two or 
more Anaplasma spp. occur in cattle due to ubiquitous disease susceptibility and animal 
husbandry practices such as vaccination with A. centrale.  
Although Anaplasma marginale causes significant economic and health impacts in 
infected cattle worldwide, A. phagocytophilum also causes self-limiting, economically significant 
disease in cattle within 9 days post-infection (Hoar et al., 2008; Pusterla and Braun, 1997; 
Pusterla et al., 1999). Cattle that survive acute disease become subclinical carriers of Anaplasma 
spp. and serve as reservoirs of infection for naïve cattle in spite of vaccination practices and 
treatment (Coetzee et al., 2006; Coetzee et al., 2005; Kocan et al., 2003). In the absence of 
effective treatment strategies, vaccine availability, and problematic vector control, anaplasmosis 
control strategies are primarily focused on disease identification and prevention (Reinbold et al., 
2009a).  
Disease prevention strategies are centered on reliable diagnostic testing strategies for 
accurately and precisely identifying infected cattle. The subinoculation of whole blood into 
splenectomized cattle has served as the gold standard for anaplasmosis disease classification 
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caused by A. marginale. Currently, one of the most common diagnostic techniques used in 
commercial lab settings today, cELISA, relies upon the identification of bovine anti-major 
surface protein 5 (MSP-5) antibodies that recognize the MSP5 protein epitope of A. marginale 
(Knowles et al., 1996). Due to the establishment of a carrier state post-infection, the cELISA is 
regarded as a reliable screening test for identifying A. marginale-infected cattle. However, cross-
reactivity among Anaplasma spp. has been reported when using cELISA to classify cattle 
infected with A. centrale and A. phagocytophilum (Bradway et al., 2001; Dreher et al., 2005; 
Strik et al., 2007). Additionally, the lag time between infection and anti-MSP5 antibody response 
may allow for the misclassification of cattle peracutely-infected with anaplasmosis (Coetzee et 
al., 2007; Reinbold et al., 2009a).  
The selection of an appropriate target for the accurate and precise diagnosis of disease is 
critical for the development of a robust diagnostic method. Due to their role in the translation of 
genetic code, ribosomes, as well as ribosomal RNA, are present in high copy numbers when 
compared to a single copy of DNA. The extensive conservation of the primary and secondary 
structures of rRNA implies an ancient origin of these macromolecules (Gutell et al., 1985). The 
16S rRNA gene segment is a common structure of bacterial rRNA genes of the genus Anaplasma 
(Rurangirwa et al., 2002). The 16S rRNA gene sequence has been shown to be identical among 
isolates of A. marginale (Dame et al., 1992; Dumler et al., 2001). However, sequence analysis 
has shown there are highly conserved and specific regions of the 16S rRNA gene segment of the 
family Anaplasmataceae (Sirigireddy and Ganta, 2005).  
In this study, methods are described for the development of simplex real-time qRT-PCR 
assays for identifying 16S rRNA gene sequences of A. marginale and A. phagocytophilum and a 
duplex real-time qRT-PCR assay for the simultaneous detection 16S rRNA gene sequences of A. 
marginale and A. phagocytophilum in plasma-free bovine peripheral blood samples. The duplex 
real-time qRT-PCR assay and a cELISA were also used to screen field samples from cattle 
originating from anaplasmosis endemic herds. Finally, the results of the duplex assay were used 
to evaluate the cELISA as an anaplasmosis diagnostic tool.  
Materials and Methods 
This study was approved by the Kansas State University (KSU) Institutional Animal Care 
and Use Committee (protocol #2517) and Institutional Biosafety Committee (protocol #524).  
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Primer and probe design for the RT-PCR assays  
The 16S rRNA gene sequences for A marginale and A. phagocytophilum were previously 
downloaded from the GenBank nucleotide sequence database and aligned using the University of 
Wisconsin Genetic Computer Group program, Pileup and Pretty (Sirigireddy and Ganta, 2005). 
Genera-specific regions were identified for the design of PCR primers. Species-specific regions 
were used to design TaqMan probes in real-time pathogen detection. TaqMan probes were 
designed with specific fluorescent reporter dyes and quencher molecules to facilitate the duplex 
assay (Table 1).  
A. marginale and A. phagocytophilum positive control plasmids  
A whole blood sample collected from a cow infected with the Florida isolate of A. 
marginale was previously stored at -80°C in a 50% glycerol solution at a ratio of 2 parts 
blood:1part glycerol. Genomic DNA was isolated from 300 µL of this sample using a kit 
(Puregene DNA purification kit, Gentra Systems; Minneapolis, MN) as described by the 
manufacturer’s recommendations. The isolated DNA pellet was re-hydrated with 100 µL of the 
kit-supplied DNA hydration solution and stored at -80°C.  
Genomic DNA of A. marginale was used as the template to amplify a 0.48-kb 16S rRNA 
gene segment. The PCR was performed with 200 ng of genomic DNA using the AmpliTaqPCR 
reagent kit (Applied Biosystems; Foster City, CA). Thermal cycles were defined by an initial 
denaturation cycle for 3 minutes at 94°C, 45 cycles of 94°C for 30 seconds, 52°C for 30 seconds, 
and 72°C for 3 minutes. The PCR product was resolved on a 1% agarose gel in 1X Tris-acetate 
EDTA buffer (40mmol/L Tris-acetate, 1mmol/L EDTA, pH 8.0) containing 0.1 µg/mL of 
ethidium bromide and visualized under UV light (Sambrook and Russell, 2001a). The amplicon 
was ligated into chemically competent Eschirichia coli using a cloning kit (TOPO TA Cloning-
TOP10, pCR 2.1-TOPO version U, Invitrogen Corp.; Carlsbad, CA). The E. coli were streaked 
on ampicillin-impregnated (100µg/mL) LB media plates with 20 µL of kanamycin (50 µg/mL) 
applied to the plate surface. Transformants containing the A. marginale recombinant plasmid 
were isolated and propagated anaerobically at 37°C in an LB media solution containing 
kanamycin (50 µg/mL). Glycerol stock (Sambrook and Russell, 2001b) preserved transformants 
of an A. phagocytophilum positive control plasmid were used in the development of this method 
as previously described (Sirigireddy and Ganta, 2005). Similarly, transformants of the A. 
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phagocytophilum plasmid were re-established by growth in the LB media solution. A boiling 
preparation method (Sambrook and Russell, 2001a) was used to extract plasmid DNA from the 
transformants. Plasmid DNA was linearized with a restriction enzyme digest using SpeI and 
BamHI for A. marginale and A. phagocytophilum, respectively (Sambrook and Russell, 
2001a).The sites for these restriction enzymes are located at the 3' end of the insert in the 
multiple-cloning site region of the plasmids. Each restriction enzyme was chosen due to the 
absence of a recognition sequence within the inserts. This allowed the plasmids to linearize 
downstream to the inserts and facilitated synthesis of in vitro transcripts with a T7 polymerase. 
The A. marginale plasmid insert was verified by sequencing with a thermo-sequencing reaction 
kit according to the manufacturer’s recommendations (USB Corp., Cleveland, OH).  
In vitro transcripts  
In vitro transcripts were prepared for use in the quantitative RT-PCR (qRT-PCR) assay 
development according to the following procedures. Linearized inserts of A. marginale and A. 
phagocytophilum were purified with a phenol-chloroform extraction technique (Sambrook and 
Russell, 2001b). Two micrograms of each purified linear insert was used to generate 
recombinant transcripts with a T7 polymerase kit as recommended by the manufacturer 
(MEGAscript kit, Ambion, Inc.; Austin, TX). The recombinant in vitro transcripts were purified 
free of plasmid DNA by treating with DNAseI and using an RNA purification kit (MEGAclear 
kit, Ambion, Inc.; Austin, TX).  
Real-Time qRT-PCR  
TaqMan-based real-time amplification (Huang et al., 2005; Manoj et al., 2004) was 
performed using a Smart Cycler II system (Cepheid; Sunnyvale, CA). Simplex and duplex real 
time quantitative qRT-PCR assays were developed using previously designed forward and 
reverse primers (Sirigireddy and Ganta, 2005) and TaqMan probes designed as a part of this 
study (Table 1). A commercially available RT-PCR assay kit (SuperScript III Reverse 
Transcriptase, Invitrogen Corporation; Carlsbad, CA) was used for development of the simplex 
and duplex assays. Ten-fold serial dilutions made from known quantities of the in vitro 
transcripts (ranging from 1 billion to one molecule) were analyzed in triplicate to optimize these 
assays for species specificity and duplex pathogen detection. The temperature cycles used for the 
qRT-PCR assay were: an initial cDNA generation cycle at 48°C for 30 minutes, 3 minutes at 
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94°C followed by 45 cycles of 94°C for 15 seconds, 50°C for 30 seconds, and 60°C for 60 
seconds. The RT-PCR product formation was monitored in real-time by measuring the emitted 
fluorescence associated with exponential growth of the PCR product during the log-linear phase. 
A reaction was qualified as positive for the presence of a template when seven fluorescent units 
for the emission channel of the fluorescent probe were detected. The PCR cycle at which 
fluorescence occurs, which was template concentration-dependent in the reaction, was regarded 
as the cycle threshold (Ct) value. Linear regression will be used to correlate the reported Ct value 
to the number of 16S rRNA template molecules in the 25 µL reaction.  
Evaluation of blood samples from anaplasmosis endemic herds  
Field sample collection was arranged during phone consultation with producers seeking 
recommendations for the control of anaplasmosis. The collection of samples from anaplasmosis 
endemic herds resulted in the screening of 237 cattle from northeastern and southeastern Kansas 
during September and October of 2008. These samples were collected from adult cows and bulls 
of Bos taurus influence. Samples were collected in no-additive evacuated tubes and evacuated 
tubes containing EDTA during 2008. Typically, the samples were collected on-site, transported 
on ice, and processed within 48 hours. However, some samples were shipped overnight on ice 
packs and processed within 48 hours of receipt.  
Anaplasmosis cELISA  
Serum was collected from no-additive evacuated tubes and analyzed by cELISA. A 
commercially available cELISA (Anaplasma Antibody Test Kit, cELISA, VMRD Inc.; Pullman, 
WA) was used in accordance with the method described by the OIE and recommended by the 
manufacturer (OIE, 2009; VMRD). The optical density (OD) of each well was measured by use 
of an ELISA plate reader at a wavelength of 620 nm. The percent inhibition (% I) of each sample 
was calculated by use of the following equation:  
% inhibition = 100 – [(sample OD X 100) /mean OD of negative control sample]  
A binary reporting format was used to report cELISA results. Reports with a % inhibition of < 
30% were recorded as negative (0), whereas reports that were > 30% were recorded as positive 
(1) (OIE, 2009; Strik et al., 2007; VMRD).  
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RNA extraction  
Samples collected in evacuated tubes containing EDTA were centrifuged at 2,750 X g at 
4º C for five minutes. Plasma was removed by a single use pipette while ensuring the buffy coat 
and red blood cell fraction were not disturbed. The plasma-free sample was vortexed to mix the 
cell fractions. Extraction of RNA from the homogenous, plasma-free sample occurred according 
to the manufacturer’s recommendations of a commercially available product (TRI Reagent, 
Sigma-Aldrich; Saint Louis, MO). The RNA pellet was resolubilized with 50 µL of nuclease free 
water. Samples from a known A. marginale carrier and a naïve cow were extracted and analyzed 
simultaneously for monitoring qRT-PCR assay performance and quality of the RNA extraction 
technique. Samples were stored in a -80°C freezer until analysis by qRT-PCR. Extracted samples 
were not subjected to a DNAse treatment; however, contamination was assessed by comparing 
qRT-PCR and qPCR assay results by replacing reverse-transcriptase (SuperScript III Reverse 
Transcriptase, Invitrogen Corporation; Carlsbad, CA) with taq polymerase (Platinum Taq DNA 
Polymerase, Invitrogen Corporation; Carlsbad, CA) in the optimized A. marginale simplex 
assay.  
Ratio of 16S rRNA to 16S DNA of A. marginale  
The number of 16S rRNA molecules present in Anaplasma spp. is unknown. This 
provides uncertainty for determining the minimum detection sensitivity of the assay in a 250 µL 
plasma-free sample of bovine peripheral blood. A comparison was made by extracting RNA and 
DNA from a 200 µL sample of ten plasma-free blood samples preserved in 50% glycerol as 
described previously. The extraction of RNA will proceed as described above. The extraction of 
DNA will occur using a kit (Wizard SV Genomic DNA Purification System, Promega 
Corporation; Madison, WI) according to the manufacturer’s instructions and a protocol 
modification for blood products (Promega, 2002). The extracted DNA and RNA were re-
hydrated with 500 µL of nuclease-free water.  
Stability of RNA in plasma-free blood samples stored in 50% glycerol  
The stability of RNA from whole blood samples stored in glycerol is unknown. Ten 
samples were processed on the day of sampling with the RNA extraction method described 
above and the optimized A. marginale simplex assay. Aliquots of these samples were stored in 
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50% glycerol at -80°C (as previously described) for an extended time period. Samples were 
thawed and underwent a similar extraction and analysis as the fresh samples. A percent 
difference change in frozen versus fresh RNA recovery was made following correction of the 
total RNA count of the frozen sample due to dilution during storage.  
Non-equivalent molar ratios  
Nonequivalent molar ratios of RNA may be encountered during analysis. This may 
preclude the duplex assay from detecting both pathogens during concurrent infection due to 
template competition for reaction components. The optimized duplex assay was used to compare 
detection of 100,000 molecules of A. marginale in vitro transcripts to A. phagocytophilum in 
vitro transcripts ranging from 100,000 to 1,000 molecules in triplicate.  
Data analysis  
Statistical analysis was conducted utilizing a one-way analysis of variance (ANOVA) 
procedure (Microsoft Excel 2007, Microsoft Corporation; Redmond, WA) (Martinez et al., 
2006). This statistical procedure analyzed variance for a quantitative dependent variable by a 
single independent variable to test the null hypothesis that several means are equal. An alpha 
level of < 0.05 was designated a priori for the determination of statistical significance. ANOVA 
was used to determine statistically significant differences between the ratio of 16S DNA copies 
contaminating 16S rRNA-extracted samples versus genomic DNA-extracted samples and the 
percent difference of RNA molecules recovered from fresh samples versus samples preserved in 
50% glycerol.  
Diagnostic test results were also converted to a binary format (0 = negative, 1 = positive). 
Sensitivity and specificity with 95% confidence intervals were calculated for cELISA using RT-
PCR assay results as the determinant of disease status. Additionally, one- and two-way receiver 
operator characteristic (R.O.C.) curves were constructed to illustrate the optimal negative cut-off 
values for the cELISA based upon RT-PCR assay results (Le, 2003). This was accomplished by 
evaluating cELISA % inhibition results in 10% increments beginning and ending at 0 and 90% 
inhibition, respectively.  
Agreement between diagnostic results was assessed by calculating a κ statistic at 95% 
confidence (Le, 2003). Results were compared using a software program (WinEpiscope 2.0, 
CLIVE; Edinburgh UK) in a 2 X 2 contingency table to calculate κ with the following equations:  
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  EP = [(a+b)/n · (a+c)/n] + [(c+d)/n · (b+d)/n]  
  κ = [(a+d)/n – EP] (1-EP)  
where EP is the expected proportion of equal outcomes according to chance; (a+d)/n – EP is the 
observed proportion of equal outcomes beyond chance; and 1-EP is the maximal proportion of 
agreement not due to chance. The κ statistic measures the agreement between tests on a scale 
from 0 to 1(Le, 2003).  
Results 
The target selection of these molecular diagnostic methods was based upon the expected 
high, intracellular copy number of 16S rRNA. Real-time qRT-PCR methods were developed for 
the simplex detection of A. marginale and A. phagocytophilum and a duplex assay for the 
detection of both species in a 250 µL plasma-free, bovine peripheral blood sample. In 25 µL 
reactions assembled with template from ten-fold serial dilutions of in vitro transcripts, the linear 
dynamic range of all assays ranged from 100 to 1 billion molecules (Figure 1). The number of 
reagent molecules used in the 25 µL RT-PCR assay mixtures is provided in Table 2. Linear 
regression was used to correlate the reported Ct value to the number of 16S rRNA template 
molecules in the 25 µL reaction (Table 3). Additionally, the correlation coefficient (R2) of each 
regression equation and efficiency of the RT-PCR assays were reported (Ginzinger, 2002).  
The species-specific probes accurately and precisely identified the respective template 
molecules without cross-reactivity during assay development. The duplex assay did not identify 
the in vitro transcript of A. phagocytophilum when the non-equivalent molar ratio exceeded a 10-
fold difference. When the molar ratios were set equal for analysis, the results reported a mean 
ratio (95% CI) of 1.53 (0.25,2.83):1. At the maximum allowance for detecting non-equivalent 
ratios (10-fold), the mean ratio was 12.94 (9.96,15.93):1.  
The mean ratio of A. marginale 16S rRNA to 16S DNA determined in ten field samples 
from anaplasmosis-endemic herds was 117.9 (100.7, 135.2):1. Therefore, the minimum detection 
sensitivity would be equal to the minimum infective unit of one A. marginale bacterium in 250 
µL of plasma-free bovine peripheral blood. Due to RNA samples not being DNAse-treated prior 
to analysis, an experiment was conducted to assess the level of 16S DNA contamination. The 
mean ratio of 16S rRNA to 16S DNA of A. marginale following extraction of RNA from field 
samples was 1,252 (641.4,1863.8):1. This ratio and the data gathered during non-equivalent 
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molar ratio experiments did not demonstrate the need for DNAse treatment of extracted RNA. 
Reverse-transcriptase was substituted with taq polymerase for comparison of the mean ratio of 
the qPCR results of 16S DNA-contaminated RNA samples to extracted genomic 16S DNA 
samples. The mean ratio was 1.28 (0,2.85):1. Additionally, the number of 16S DNA molecules 
was not significantly different between the extraction methods (P = 0.34). The stability of 16S 
rRNA in ten plasma-free blood samples stored in 50% glycerol for 311 days was compared to the 
original samples processed on the day of collection. The mean percent difference change 
between fresh and frozen was 32.1% (19.8,44.5); however, this difference was not statistically 
significant (P = 0.27).  
The duplex qRT-PCR assay determined the prevalence of A. marginale to be 37.6% in 
field samples; however, A. phagocytophilum was not detected (Table 4). The prevalence 
determined by the cELISA was 26.1%. The A. phagocytophilum simplex qRT-PCR assay was 
performed on a total of fourteen samples that were cELISA+/RT-PCR- (4) and randomly 
selected samples (10). Likewise, A. phagocytophilum was not detected in these fourteen samples. 
The sensitivity and specificity of the cELISA for detecting A. marginale was evaluated by the 
disease status of these cattle determined by the duplex RT-PCR assay. The cumulative sensitivity 
and specificity of the cELISA was 65.2% (55.3,75.1) and 97.3% (94.7,99.9), respectively. The 
cumulative agreement between the cELISA and duplex qRT-PCR assay was 0.655 (0.542,0.788).  
One- and two-way R.O.C. curves were constructed to evaluate the % inhibition of 
cELISA negative cut-off values for the detection of A. marginale based upon RT-PCR assay 
results (Figures 2a and 2b). A one-way R.O.C. curve determined the optimal negative cut-off 
value to be 20% inhibition. For a 20% inhibition negative cut-off value, the sensitivity and 
specificity of the cELISA was 73 and 91.2%, respectively. A 15.3% inhibition was determined to 
be the optimal negative cut-off value by  
intersection of the plots for sensitivity and specificity in a two-way R.O.C. curve. For a 
15.3% inhibition negative cut-off value, the sensitivity and specificity of the cELISA was 74.2 
and 81.2%, respectively. The negative cut-off values recommended by the R.O.C. curve analyses 
enhanced the sensitivity of the cELISA by 7.8-9% while adversely affecting the specificity by 
6.1-16.1%.  
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Discussion  
Real-time RT-PCR methods that combine reverse-transcriptase, PCR chemistry and 
fluorescent probe detection of amplified product have greatly enhanced the ability to diagnose 
disease. This study has described the development of real-time qRT-PCR assays for the detection 
of A. marginale and A. phagocytophilum alone or in combination. Duplex methods have been 
described for the simultaneous detection of A. marginale-A. centrale and A. phagocytophilum-
Borrelia burgdorferi (Courtney et al., 2004; Decaro et al., 2008). To our knowledge, this is the 
first study to describe a duplex method for the diagnosis of A. marginale and A. 
phagocytophilum from the same sample.  
The selection of an appropriate target for the accurate and precise diagnosis of disease 
was critical for the development of these anaplasmosis diagnostic methods. The selection of 
the16S rRNA gene segments enhanced the analytical sensitivity of the assay due to the high ratio 
of 16S rRNA:16S DNA. Furthermore, the extraction of RNA from a plasma-free blood sample 
ensured the maximum number of cells in a 250 µL sample were available for analysis. These 
real-time assays combined the sensitivity and specificity of conventional methods without the 
risk of environment contamination with amplified product. Furthermore, the analysis of 48 
samples can occur in less than 6 hours from the start of RNA extraction to analysis completion 
by the real-time system.  
Numerous real-time assays have been developed for the detection of A. marginale. 
However, key differences exist among these assays and the method described here. Simplex 
assays that target the DNA gene sequences encoding for a major surface protein (MSP1b) and 
groEL of A. marginale have been described (Carelli et al., 2007; Decaro et al., 2008). The high 
analytical sensitivity of both methods provided for the detection of 10 DNA copies or 10 
infective A. marginale bacteria; however, our qRT-PCR methods were able to detect as few as 
100 copies of 16S rRNA that is equivalent to the minimum infective unit of a single A. 
marginale bacterium. Similarity was observed in selection of the fluoresecent probe (FAM) and 
quencher molecule (BHQ) during TaqMan probe development for the assay detecting groEL 
(Decaro et al., 2008) and our assay.  
The detection of A. phagocytophilum by multiplex real-time methods has recently been 
limited to the diagnosis of disease in humans and canines (Courtney et al., 2004; Sirigireddy and 
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Ganta, 2005). However, a simplex assay was described in cattle for detecting A. 
phagocytophilum (Pusterla et al., 1999). Similarities exist due to the use TaqMan probes in the 
development of the assays; nevertheless, the assay described in 1999 by Pusterla et al. differs by 
the improved analytical sensitivity of the assay by detecting as few as ten 16S rRNA molecules. 
The significance of this enhanced sensitivity is unknown due to the current lack of information 
regarding the ratio of 16S rRNA:16S DNA of A. phagocytophilum.  
The correct classification of disease status is important for the collection of 
epidemiologic information and improvement of free-trade policy between endemic and non-
endemic countries. The development of a real-time method for the detection of A. marginale and 
A. phagocytophilum was influenced by the insufficient specificity of the cELISA due to cross-
reactivity among closely related Anaplasma spp. (Bradway et al., 2001; Dreher et al., 2005; Strik 
et al., 2007). Furthermore, A. centrale was not selected due to vaccination with this spp. not 
occuring in the United States. Our method described the capability of detecting as few as one 
hundred 16S rRNA molecules of these samples in the same reaction tube. Due to these 
Anaplasma spp. infecting different types of blood cells, the ability to only detect non-equivalent 
molar concentrations up to 10-fold may be problematic (Courtney et al., 2004; Sirigireddy and 
Ganta, 2005). However, this could not be accurately assessed during this study. The level of 
detection of non-equivalent molar concentrations may have been due to competition for reaction 
components. This may be a result of unequal TaqMan probe concentrations and the enhanced 
processivity of the A. marginale probe due to its shorter length by 7 bases. However, a simplex 
assay for the detection of A. phagocytophilum has been described and applied in this study for 
the screening of samples whose duplex results did not agree with that of the cELISA (Sirigireddy 
and Ganta, 2005).  
The simplex and duplex assays could serve as effective diagnostic tools for the 
epidemiologic study of A. phagocytophilum. Even though anaplasmosis caused by A. 
phagocytophilum has been identified as an economically important disease (Hoar et al., 2008; 
Pusterla and Braun, 1997; Pusterla et al., 1997), the prevalence of this pathogen in cattle in the 
United States is unknown (Hoar et al., 2008). Furthermore, the zoonotic potential of A. 
phagocytophilum, also known as human granulocytic ehrlichiosis, lends cattle to the role of 
sentinel animals for monitoring the spread of this anaplasmosis disease form from endemic to 
non-endemic regions.  
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Cattle that recover from acute anaplasmosis caused by A. marginale commonly develop 
persistent infections characterized by a cyclic rickettsemia of 5 week intervals (Eriks et al., 
1989). The ability to quantify the genetic template by regression analysis of the Ct value reported 
by the real-time simplex and duplex assays can further supplement the study of cyclic 
rickettsemias. This is further substantiated by the findings of our study of the mean ratio of 16S 
rRNA:16S DNA being 117.9 (100.7,135.2):1. Therefore, the number of A. marginale would be 
equitable to one bacterium per 118 molecules of 16S rRNA detected. Furthermore, there was not 
a significant difference in 16S DNA contamination of 16S rRNA-extracted samples compared to 
genomic 16S DNA-extracted samples (P = 0.34). This would allow for the monitoring of 16S 
rRNA:16S DNA in the same 16S rRNA-extracted sample by substituting reverse-transcriptase 
with taq polymerase in the optimized reaction mixtures as described (Table 2).  
The evaluation of the cELISA as a diagnostic tool by the results of the duplex qRT-PCR 
assay may be controversial because this qRT-PCR is not a gold standard test. However, our 
group has previously demonstrated 100% sensitivity and specificity of the qRT-PCR method 
described here in cattle with experimental A. marginale infections (Reinbold et al., 2009a) and 
carrier cattle chemosterilized with tetracycline antimicrobials (Reinbold et al., 2009b). In these 
studies A. marginale infection status was confirmed using the gold standard splenectomized 
calves. Furthermore, the approach to validation described in this study was similar to the 
interpretation of in-house data by a nested PCR that was submitted to the United States 
Department of Agriculture in support of licensure of the cELISA by Veterinary Medical 
Research & Development, Inc. (Torioni de Echaide et al., 1998; VMRD-2). In these studies, the 
sensitivity and specificity of the cELISA was reported at 95% and 98%, respectively. However, 
the OIE does not recommend the use of this nested PCR due to the potential for non-specific 
amplification (OIE, 2009). Non-specific amplification is not a disadvantage of this qRT-PCR 
assay.  
It is noteworthy that the sensitivity and specificity of the cELISA when evaluated by the 
duplex real-time qRT-PCR assay was 65.2% (55.3, 75.1) and 97.3% (94.7, 99.9), respectively. A 
similar number of cattle were screened in our study and the cELISA licensure study at 237 and 
235 cows, respectively. The difference in disease prevalence between our study and the licensure 
study was 37.6 and 64.3%, respectively. The measure of agreement (ĸ) calculated in the 
licensure study was 0.91, whereas ĸ was only 0.655 (0.542, 0.788) in our study. Furthermore, the 
47 
 
licensure study used a negative cut-off value set at 28% inhibition. In order to achieve similar 
sensitivity results, the % inhibition used as the negative cut-off value in our study would have 
needed to be set at 40%. When referring to the two-way R.O.C. curve constructed in Figure 2b, 
100% sensitivity was achieved at a % inhibition of 40%. However, the specificity at this % 
inhibition was approximately 60%. The one-and two-way R.O.C. curves constructed from the 
results of this study (Figures 2a and 2b) determined the optimal negative cut-off values to be set 
at 20% inhibition and 15.3% inhibition, respectively.  
In conclusion, a highly sensitive and specific duplex real-time qRT-PCR assay was 
developed for the detection of as few as100 copies of 16S rRNA molecules of A. marginale and 
A. phagocytophilum in the same reaction. The ability of this assay to correctly identify the 
disease status of cattle is critical for the development of anaplasmosis disease control programs. 
Furthermore, the correct classification of anaplasmosis disease status prior to export may prove 
to be an important tool for improving free-trade of cattle between endemic and non-endemic 
countries and regions. Finally, this novel, duplex assay may improve epidemiologic studies of 
anaplasmosis in cattle populations of unknown disease status.  
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Figures and Tables 
 
Figure 2.1 Target detection sensitivity and linearity with RNA concentration for the 
simplex and duplex assays. Serial 10-fold dilutions of in vitro transcripts were made from 
positive control plasmids to optimize the qRT-PCR assays.  The average Ct values from 
three independent experiments were plotted against the log number of rRNA molecules for 
optimized simplex assays detecting (a) Anaplasma marginale and (b) Anaplasma 
phagocytophilum. Equivalent molar concentrations of in vitro transcripts were used to 
optimize a real-time duplex qRT-PCR assay (c) from the average Ct values of three 
independent experiments plotted against the log number of A. marginale (white squares) 
and A. phagocytophilum (white diamonds) RNA molecules. The fluorescent emission from 
serial dilution templates for A. marginale and A. phagocytophilum are shown in the inset 
graphs of (a) and (b), respectively. 
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Figure 2.2 Determination of the optimal negative cut-off value of the cELISA through the 
construction of R.O.C. curves. (a) A one-way R.O.C. curve was constructed by plotting the 
true positive rate (sensitivity) by the true negative rate (1-specificity). The corresponding 
% inhibition is recorded adjacent to each data point. The recommended negative cut-off 
value for the one-way R.O.C. is represented as the data point located near the upper left 
portion of the graph (20%) (b) A two-way R.O.C. curve was constructed by plotting the 
sensitivity (black squares) and specificity (black diamonds) of the cELISA by the 
corresponding % inhibition. The recommended negative cut-off value for the two-way 
R.O.C. is represented by the intersection of the sensitivity and specificity plots (15.3%). 
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Table 2.1 TaqMan primers and probes used in the development of the simplex and duplex molecular assays. 
TaqMan Primers/Probes† 
 
Base Sequence 
 
Length 
 
Tm (°C) 
Anaplasma forward primer  5'- CTCAGAACGAACGCTGG -3’  17  53.3 
       
Anaplasma reverse primer  5’- CATTTCTAGTGGCTATCCC -3’  19  49.7 
       
A. marginale probe  5’- /56-FAM/CGCAGCTTGCTGCGTGTATGGT/3BHQ_1/ -3'*  22  62.8 
       
A. phagocytophilum probe  5’- /5TexRd-XN/TTGCTATAAAGAATAATTAGTGGCAGACG/3BHQ_2/ -3'*  29  55.4 
†Primers and probes were synthesized by Integrated DNA Technologies Inc.; Coralville, IA. *Base sequences are recorded with reporter and 
quencher molecules. Tm = melting temperature in 50mM NaCl. 
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Table 2.2 RT-PCR assay reaction components for each of the simplex and duplex assays. 
 
  Simplex RT-PCR assay   
Component  A. marginale  A. phagocytophilum  Duplex RT-PCR assay 
       
MgSO4  187.5 nmol  187.5 nmol  187.5 nmol 
       
each dNTP  5 pmol  5 pmol  5 pmol 
       
Anaplasma forward primer  10 pmol  10 pmol  10 pmol 
       
Anaplasma reverse primer  10 pmol  10 pmol  10 pmol 
       
A. marginale probe  11.3 pmol  —  11.3 pmol 
       
A. phagocytophilum probe   —   9.4 pmol   9.4 pmol 
Each 25 µL RT-PCR reaction mixture consisted of 23 µL of master mix from a kit (SuperScript III 
Platinum One-step Quantitative RT-PCR System, Invitrogen Corporation; Carlsbad, CA ), 8U of a 
ribonuclease inhibitor (Recombinant RNAsin, Promega Corporation; Madison, WI), and 2 µL of 
template. DNA contamination of RNA samples was assessed by replacing reverse transcriptase 
(Superscript III Reverse Transcriptase) with 2U of taq polymerase (Platinum Taq DNA Polymerase, 
Invitrogen Corporation; Carlsbad, CA ). 
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Table 2.3 RT-PCR assay optimization criteria results and regression equations for the quantification of template in a 25 µL 
reaction.  
Assay 
 
Regression equation 
 
Correlation Coefficient (R2) 
 
Efficiency 
(%) 
       
Simplex - Anaplasma marginale  
 
y = -3.4324x + 40.38  0.9973  95.59 
       
Simplex - Anaplasma 
phagocytophilum   y = -3.532x + 41.815  0.9986  91.92 
       
Diplex 
 
     
       
A. marginale  
 
y = -3.5014x + 40.744  0.9950  93.02 
       
A. phagocytophilum  
 
y = -3.5571x + 41.392   0.9965  91.04 
       
For the regression equation, y is the reported Ct value and x is the number of template molecules.  
Efficiency = -1+10(-1/slope)   
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Table 2.4 Comparison of diagnostic method results during the screening of field samples for Anaplasma marginale infection. 
Location: Northeast Kansas  Location: Southeast Kansas  Cumulative 
              
 RT-PCR + RT-PCR -    RT-PCR + RT-PCR -    RT-PCR + RT-PCR -  
              
cELISA + 15 1   cELISA + 43 3   cELISA + 58 4  
cELISA - 11 37   cELISA - 20 107   cELISA - 31 144  
                       
              
cELISA sensitivity: 57.7% (38.7,76.7) 
 
cELISA sensitivity: 68.3% (56.8,79.7) 
 
cELISA sensitivity: 65.2% (55.3,75.1) 
cELISA specificity: 97.4% (92.3,100) 
 
cELISA specificity: 97% (93.7,100) 
 
cELISA specificity: 97.3% (94.7,99.9) 
Agreement (ĸ): 0.586 (0.356,0.816) 
 
Agreement (ĸ): 0.695 (0.55,0.841) 
 
Agreement (ĸ): 0.655 (0.542,0.788) 
                            
A κ result where 0 < κ < 0.4, 0.4 < κ < 0.75, and κ > 0.75 indicates poor, good, and excellent reproducibility, respectively.  
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CHAPTER 3 - Comparison of iatrogenic Anaplasma marginale 
transmission by needle and needle-free injection techniques 
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Reinbold, J.B., Coetzee, J.F., Hollis, L.C., Nickell, J.S., Riegel, C., Christopher-Huff, J., Ganta, 
R.R., 2009b. Comparison of iatrogenic Anaplasma marginale transmission by needle and needle-
free injection techniques. Am J Vet Res (Provisional Acceptance: AJVR-09-07-0279). 
Introduction 
Anaplasmosis, caused by Anaplasma marginale, is one of the most prevalent tick-
transmitted, rickettsial diseases of cattle worldwide (Dumler et al., 2001; Kocan et al., 2003; 
Uilenberg, 1995). The Office International des Epizooties (OIE) Animal Health Code categorizes 
anaplasmosis as a notifiable disease due to socioeconomic impact and international trade 
restrictions (OIE, 2009). However, the significance of anaplasmosis is frequently underestimated 
compared with other diseases due to seasonal outbreaks and stability in endemic areas (Rogers 
and Shiels, 1979). Clinical disease symptoms in acutely-infected, adult cattle include, but are not 
limited to, anemia, fever, icterus, lethargy, and death (Radostits et al., 2000). Moreover, abortion, 
high mortality, reduced milk production, extensive treatment costs, and weight loss are key 
economic considerations of this disease. In 2003, anaplasmosis was estimated to cost the United 
States cattle industry over $300 million per year (Kocan et al., 2003).  
Historically, vaccination has been used to modulate disease severity. In some countries, 
naïve cattle are inoculated intravenously with bovine blood infected with Anaplasma centrale for 
reducing disease morbidity prior to infection with A. marginale (Kocan et al., 2003). However, 
this strategy is not used or recommended in the United States due to the potential for transfer of 
other blood-borne pathogens and production of erythrocytic isoantibodies (Dennis et al., 1970). 
A killed vaccine was previously available for use in cattle in the United States, but is currently 
available under special permission only (Luther, 1999).  
Cattle infected with anaplasmosis following natural infection and vaccination with live 
Anaplasma spp. remain lifelong carriers despite tetracycline therapy (Coetzee et al., 2006; 
Coetzee et al., 2005; Lincoln et al., 1982; Rogers and Shiels, 1979; Wilson et al., 1979). Carriers 
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are responsible for horizontal, iatrogenic, and vertical transmission of anaplasmosis to naïve 
cattle by providing a reservoir of infective blood for biological, mechanical, and in utero 
infection (Eriks et al., 1989; Futse et al., 2003; Norton et al., 1983; Potgieter and van Rensburg, 
1987; Reeves and Swift, 1977; Zaugg, 1985; Zaugg and Kuttler, 1984).  
Appropriately-timed application of insecticides is recommended for reducing biological 
transmission by haematophagous arthropods (De Wall, 2000; Peter et al., 2005; Rodriguez-Vivas 
et al., 2004). Due to the lack of significant success with treatment strategies, vaccine availability, 
and problematic vector control, anaplasmosis control strategies should primarily concentrate on 
established methods for disease prevention.  
Anaplasmosis transmission has been documented during routine animal husbandry 
practices (Reeves and Swift, 1977; Rodriguez-Vivas et al., 2004). Disease prevention strategies 
associated with vaccination have been considered impractical, uneconomical or are potentially 
deleterious to the success of the procedure (Andrews and Lamport, 1985; Makoschey and Beer, 
2004). In a survey of fifty-five large animal veterinary practices, 32% did not exchange 
hypodermic needles between each cow (Anderson and Silviera, 2008).  
Needle-free injection, which uses a pneumatic-powered system to deliver vaccines, was 
used by the United States military to vaccinate recruits following World War II. Needle-free 
injection techniques have proven to be efficacious for the delivery of vaccines in cattle (Hollis et 
al., 2005; Huang et al., 2005; Manoj et al., 2004). However, research has suggested the potential 
for blood product transfer during the use of needle-free injectors for consecutive injections 
(Sweat et al., 2000). The purposes of this study are to compare iatrogenic transmission of A. 
marginale during simulated vaccination between needle-free and conventional needle injection 
techniques and diagnostic method performance of light microscopy, competitive ELISA 
(cELISA), and an A. marginale-specific Reverse transcriptase-polymerase chain reaction (RT-
PCR) assay. 
Materials and Methods  
Animals  
This study was approved by the Kansas State University (KSU) Institutional Animal Care 
and Use Committee (protocol #2517) and Institutional Biosafety Committee (protocol #524). 
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Twenty-six preconditioned, clinically healthy Holstein steers were purchased from the KSU 
Dairy Teaching and Research Center in Manhattan, KS. The mean age + standard deviation was 
172.2 + 27.5 days at the time of study. All steers were prescreened for anti-A. marginale 
antibodies with a commercially available cELISA (Anaplasma Antibody Test Kit, cELISA, 
VMRD Inc.; Pullman, WA), as well as a novel RT-PCR for detecting a 16S ribosomal RNA 
subunit (16S rRNA) of A. marginale (Coetzee et al., 2007; OIE, 2009; Torioni de Echaide et al., 
1998; VMRD). Pre-study negative disease status was determined though interpretation of 
cELISA and RT-PCR assay results in series (Dohoo I et al., 2007).  
Housing and husbandry 
Steers were blocked by body weight and randomized to one of three treatment groups: (1) 
needle injection (ND, n=10), (2) needle-free injection (NF, n=10), and (3) a non-injected control 
group (CONT, n=5). Steers were individually housed in a biolevel-2 (BL-2) safety facility at the 
KSU Animal Research Facility. An insecticide (Ultra Boss, Schering-Plough; Summit, NJ) was 
applied upon entry into the BL-2 facility as recommended by the manufacturer’s label. A total 
mixed ration (TMR) diet was fed at 2.5% of bodyweight (as fed) divided into twice daily 
feedings. Monensin (80 g/ton) was the only antimicrobial included in the TMR. Water was 
supplied ad libitum. When handling was necessary, steers were individually restrained with a 
rope halter. Steers did not receive any antimicrobials that would potentially interfere with A. 
marginale disease transmission beginning 30 days prior to study initiation and continuing 
throughout the remainder of the study; furthermore, no procedure was permitted that was not 
outlined in the experimental design. 
Splenectomy protocol and procedure 
One steer was splenectomized and used to propagate a Virginia isolate of A. marginale. A 
hand-assisted, laparoscopic procedure was used to splenectomize this steer. Briefly, the steer was 
placed in right lateral recumbency after sedation was achieved by an intramuscular injection of 
xylazine (0.1 mg/kg), ketamine (0.1 mg/kg), and butorphanol (0.05 mg/kg). Following a local 
infusion of lidocaine hydrochloride (2%), a six centimeter paracostal incision was made centered 
over the costochondral arch and approximately three centimeters caudal to the thirteenth rib. A 
hand was placed through this hand-assist incision and used to bluntly dissect away the 
connective tissue between the spleen and the rumen until the splenic hilus was isolated. A 
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laparoscopic stapler, functioning as a ligating, dividing and stapling device (LDS), was placed 
through the left flank via a 1.5 cm incision. The intra-abdominal hand was used to guide the LDS 
unit around the vascular pedicle to apply two staples around the hilus. The spleen was then 
divided free from the rumen. The spleen was removed via the hand-assist incision. All incisions 
were closed by a routine, three layer closure. Post-operative analgesia was provided with an 
intravenous injection of flunixin meglumine (1 mg/kg). Procaine penicillin G (10,000 IU/kg) was 
administered intramuscularly for three days peri-operatively. Skin sutures were removed 
fourteen days after surgery.  
Inoculation and monitoring of splenectomized steer 
A tick transmissible Virginia isolate of A. marginale was collected from an infected cow 
and provided by Dr. Katherine Kocan, Oklahoma State University; Stillwater, OK. This fully 
characterized isolate (1978) was secured by Dr. Kocan from the United States Department of 
Agriculture Animal Parasitology Institute, Beltsville, MD (de la Fuente et al., 2003). The blood 
sample was treated with a heparin anticoagulant and prepared for overnight shipment on ice to 
KSU. 
Five milliliters of heparinized whole blood sample was used for subinoculation of the 
splenectomized steer (referred to hereafter as SPS) intravenously on the eighth day 
postoperatively. The SPS was monitored daily for clinical signs of anaplasmosis, including 
anorexia, lethargy, and fever. Whole blood samples were collected and immediately prepared for 
percent parasitized erythrocyte count (PPE) and packed cell volume (PCV) determination.  
Blood film preparation and PPE determination 
Blood films were stained with an automated unit (Hema-Tek, Ames Company; Elkhart, 
IN) using a Modified Wright stain (Kutaish, 1982; Teerasaksilp et al., 2005). The number of 
parasitized erythrocytes was determined using a Miller reticled (Riley et al., 2001). The Miller 
reticle (Miller reticle, Klarmann Rulings, Inc.; Litchfield, NH) is a large square inset with an 
additional square that is one-tenth the size of the large square. All parasitized erythrocytes in the 
large square were counted; however, only the erythrocytes present in the smaller square were 
counted. The number of parasitized erythrocytes and non-parasitized erythrocytes were recorded 
separately. A total of 1,000 erythrocytes were counted. The PPE was calculated by the following 
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equation which was modified from an equation for measuring the percent of reticulocytes under 
similar conditions (Riley et al., 2001):  
PPE (%) = [(total parasitized erythrocytes in the larger square) ÷ (total erythrocytes in the 
smaller square × 9)] x 100  
Measurement of PCV 
The PCV was determined by partially filling no-additive capillary tubes (Hemato-Clad 
Plain, Drummond Scientific Company; Broomall, PA) with blood followed by centrifugation 
at12,600 X g for ten minutes (Coetzee et al., 2007). The PCV was then determined by measuring 
(Critocaps Micro-Hematocrit Capillary Tube Reader, McCormick Scientific; Saint Louis, MO) 
the height of the red blood cell portion in comparison to the total column height.  
Serum collection and cELISA 
A commercial cELISA (Anaplasma Antibody Test Kit, cELISA, VMRD Inc.; Pullman, 
WA) was used in accordance with the method described by the OIE and recommended by the 
manufacturer (OIE, 2009; VMRD). The optical density (OD) of each well was measured by use 
of an ELISA plate reader at a wavelength of 620 nm. The % inhibition (% I) of each sample was 
calculated by use of the following equation:  
 % inhibition = 100 – [(sample OD X 100) /mean OD of negative control sample]  
Reports with an inhibition of < 30% were recorded as negative results, whereas reports that were 
> 30% were recorded as positive (OIE, 2009; Strik et al., 2007; VMRD).  
RNA extraction and RT-PCR assay 
Extraction of RNA from a plasma-free whole blood sample occurred according to the 
manufacturer’s recommendations of a commercially available product (TRI Reagent, Sigma-
Aldrich; Saint Louis, MO) with the following procedure specifications. Briefly, plasma was 
separated by centrifuging vacutainer tubes at 2,750 X g at 4º C for five minutes. Plasma was 
removed by a single use pipette while ensuring not to remove the buffy coat and red blood cell 
fraction. Two hundred microliters of plasma-free blood was transferred to a microcentrifuge 
tube. One milliliter of a monophase solution of guanidine thiocyanate and phenol was added to 
lyse the blood cells followed by vigorous vortexing. The solution then stood for ten minutes. 
Two hundred microliters of chloroform was added followed by vortexing vigorously for fifteen 
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seconds. The solution then stood for ten minutes prior to centrifuging at 12,000 x g for fifteen 
minutes at 4°C. The colorless, upper, aqueous phase of the solution was transferred to a new 
tube. Five hundred microliters of 2-propanol was added to each tube and mixed by vortexing 
briefly. The solution then stood for 10 minutes prior to centrifuging at 12,000 x g for ten minutes 
at 4°C. The supernatant was poured off and the pellet washed with 1mL of 75% ethanol. Next, 
the sample was vortexed briefly prior to centrifuging at 12,000 x g for five minutes at 4°C. The 
supernatant was poured off and allow to air dry. The RNA pellet was resolubilized with 50 µL of 
nuclease free water. Samples were stored in a -80°C freezer until analysis by RT-PCR.  
A simplex, real-time qRT-PCR assay was developed for the identification of 16S rRNA 
of A. marginale using previously designed forward and reverse primers and a TaqMan probe 
designed as a part of this study (Sirigireddy and Ganta, 2005). The forward and reverse primer 
sequences (Integrated DNA Technologies Inc.; Coralville, IA) were 5′-
CTCAGAACGAACGCTGG-3′ and 5′-CATTTCTAGTGGCTATCCC-3′, respectively. The 
TaqMan probe sequence (Integrated DNA Technologies Inc.; Coralville, IA) was 5'-/56-
FAM/CGCAGCTTGCTGCGTGTATGGT/3BHQ_1/-3'. A commercially available, 23 µL RT-
PCR assay mixture (SuperScript III Reverse Transcriptase, Invitrogen Corporation; Carlsbad, 
CA) included 10 pmol of each of the TaqMan forward and reverse primers; 5 pmol of each 
dNTP; 187.5 nmol of MgSO4; 11.3 pmol of A. marginale probe; and 8U of ribonuclease inhibitor 
(Recombinant RNAsin, Promega Corporation; Madison, WI). Two microliters of template were 
added for a 25 µL final volume. The temperature cycles used for the RT-PCR assay were: an 
initial complementary DNA generation cycle at 48°C for 30 minutes, 3 minutes at 94°C followed 
by 45 cycles of 94°C for 15 seconds, 50°C for 30 seconds, and 60°C for 60 seconds.  
An in vitro transcript of A. marginale plasmid DNA was prepared for use in the RT-PCR 
assay development. Three micrograms of plasmid DNA were digested with the restriction 
enzyme SpeI. SpeI-digested plasmid DNA was used to generate recombinant transcripts with a 
T7 RNA polymerase as outlined in the kit protocol (T7 MEGAscript High-Yield Transcription 
Kit, Ambion Inc.; Austin, TX). Ten-fold serial dilutions (ranging from 1 billion to one molecule) 
of the in vitro transcript were analyzed in triplicate to optimize the assay in a commercially 
available real-time quantitative polymerase chain reaction (qPCR) system (SmartCylcer II, 
Cepheid; Sunnyvale, CA). The RT-PCR product formation was monitored in real-time by 
measuring the emitted fluorescence in the extension phase of the PCR cycles within the real-time 
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PCR system. A reaction was qualified as positive for the presence of a template when it detects 
seven fluorescent units for the emission channel of the fluorescent probe. The PCR cycle at 
which fluorescence occurs, which is dependent on the concentration of the template in the 
reaction, was regarded as the cycle threshold (Ct) value. In 25 µL reactions assembled with 
template from the ten-fold serial dilutions, the standard curve of the assay ranged from 100 to 1 
billion molecules (Figure 3.1). Linear regression was used to quantify the number of 16S rRNA 
template molecules in the 25 µL reaction based upon the corresponding Ct value with the 
following equation:  
    y = -3.4324x + 40.38  
where y is the reported Ct value and x is the number of template molecules. The correlation 
coefficient (R2) for the regression equation was 0.9973. The efficiency of the RT-PCR assay was 
95.6% (Ginzinger, 2002). Samples from a known A. marginale carrier and a naïve cow were 
extracted and analyzed simultaneously for monitoring assay performance and quality of the 
rRNA extraction technique.  
Injection system preparation and simulated vaccination 
The needle-free injection system (Pulse 250 Needle-free Injection System, Felton 
International, Lenexa, KS) was primed with a 1L bag of sterile saline solution (0.9% NaCl, B. 
Braun Medical Inc.; Irvine, CA) according to the manufacturers recommendations. The 
pneumatic pressure was metered to 80 psi for delivery of 2 mL of saline intramuscularly in cattle 
weighing < 227.3 kg. Similarly, a multi-dose syringe (Ideal Instruments Pro-Shot 50cc Pistol 
Grip Syringe, Durvet Inc. Animal Health Products; Blue Springs, MO) was prepared with a 50 
mL aliquot of saline acquired from the 1L bag previously described. The syringe was fitted with 
a single use, 1.7 X 25 mm hypodermic needle (Beckton Dickinson and Company; Franklin 
Lakes, NJ) and preset to deliver a 2 mL injection.  
The transmission study initiated when a PPE of 2.0% developed in the SPS. For the 
provision of preemptive analgesia due to receiving multiple injections, the SPS was 
premedicated with an intravenous injection of flunixin meglumine (1 mg/kg) fifteen minutes 
prior to restraint. A halter was used to extend and secure the head of the SPS for provision of 
lateral exposure of the neck. Ten, naïve steers previously randomized to the ND treatment group 
were individually restrained adjacent to the SPS. A sham vaccination with 2 mL of sterile saline 
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(0.9% NaCl) was delivered intramuscularly into the left lateral cervical muscle of the SPS with 
the hypodermic needle fitted to the multi-dose syringe. The same needle and syringe were then 
utilized within sixty seconds to vaccinate a naïve steer from the ND group in the ipsilateral 
muscles of the neck as the SPS. This two step procedure was repeated until ten naïve steers in the 
ND treatment group were sham vaccinated ipsilaterally by needle injection. Similarly, the 
contralateral (left) cervical muscles of the SPS were injected with the needle-free injection 
system for the ten naïve calves in the NF treatment group. Briefly, the tip of the needle-free 
injection system apparatus was placed against the hide of the SPS. The apparatus was agitated in 
a circular motion to clear hair from between the apparatus and the epidermis. Manual, downward 
pressure was used to engage and ready the apparatus for injection. Finally, the injection trigger 
was depressed for release of the saline injection. This process was immediately repeated on a NF 
steer. This multi-stage procedure was repeated until ten naïve steers in the NF treatment group 
were sham vaccinated ipsilaterally by needle-free injection. Five calves in the CONT treatment 
group served as non-injected, sentinel steers. No injection site was disinfected nor was any 
injection apparatus exchanged or disinfected during either procedure. One operator performed 
the injections for each system used.  
Steers were monitored daily for signs of illness. Disease status was monitored semi-
weekly throughout a 61 day study period by light microscopy, cELISA, and RT-PCR as 
previously described here within.  
Agreement and Statistical analysis 
Data were entered into a software package (Microsoft Excel 2007, Microsoft 
Corporation; Redmond, WA) for subsequent calculations and manipulation. Geometric mean and 
geometric coefficient of variation (Geo CV%) were calculated for data acquired from responses 
recorded from diagnostic test results. Diagnostic test results were also converted to a binary 
format (0 = negative, 1 = positive). Sensitivity and specificity with 95% confidence intervals 
were calculated for light microscopy, cELISA, and RT-PCR for each time point (n = 25).  
Agreement between diagnostic results of each semi-weekly sampling was assessed by 
calculating a Kappa statistic (κ) statistic (Le, 2003). Results were compared using a software 
program (WinEpiscope 2.0, CLIVE; Edinburgh UK) in a 2 X 2 contingency table to calculate κ 
with the following equations:  
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  EP = [(a+b)/n · (a+c)/n] + [(c+d)/n · (b+d)/n]  
  κ = [(a+d)/n – EP] (1-EP)  
where EP is the expected proportion of equal outcomes according to chance; (a+d)/n – EP is the 
observed proportion of equal outcomes beyond chance; and 1-EP is the maximal proportion of 
agreement not due to chance. The κ statistic measures the agreement between tests on a scale 
from 0 to 1. A calculated κ result, where 0 < κ < 0.4, indicates poor reproducibility. Good and 
excellent reproducibility is indicated when 0.4 < κ < 0.75 and κ > 0.75, respectively. When κ 
could not be determined because of a lack of concordant results in 2 or more 2 X 2 cells, an 
overall proportion of agreement was calculated by dividing the sum of concordant test results by 
the number of samples tested (Le, 2003).  
The association between disease outcome and the three diagnostic testing regimens was 
analyzed by generalized linear mixed models and generalized estimating equations (PROC 
Glimmix and PROC Genmod, SAS version 9.1, SAS Institute, Inc.; Cary, NC). Proper methods 
were employed to take into account the lack of independence among repeated observations of the 
same animal over time. A semi-parametric survival analysis (Stata v10.1; Stata Corp LP, College 
Station, TX) was performed to take into account the time variable of when each respective 
diagnostic test first detected A. marginale. A Kaplan-Meier survival analysis (non-parametric) 
(Stata v10.1; Stata Corp LP, College Station, TX) was performed on the raw data depicting the 
amount of time elapsed post-injection prior to positive outcomes for each of the three testing 
regimens. An alpha level of 0.05 was observed throughout the study for evaluating statistically 
significant differences. 
Results 
Prior to enrollment in the study, all steers were confirmed negative for anaplasmosis with 
the cELISA and an A. marginale-specific RT-PCR assay. No adverse reaction due to surgery was 
observed in the SPS. The SPS was subinoculated with 5 mL of a heparinized whole blood 
sample that had a parasitemia of 8.1% and PCV of 30%; however, rRNA molecule count was not 
determined in the inoculum used due to heparinization of the collected sample.  
The time elapsed from the subinoculation of the SPS to the development of a PPE equal 
to 2% was thirty-four days. The PPE, PCV and number of 16S rRNA molecules were 2%, 23% 
and 8.9 x109 upon study initiation, respectively. No adverse reactions were observed due to 
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injection method used. Currently, there are no indications suggesting the use of flunixin 
meglumine neither predisposes cattle to clotting disorders nor were any such complications noted 
after administration. The SPS was euthanized forty-five days after subinoculation due to 
anorexia, lethargy, and pyrexia; however, no other steer was removed from the study.  
Upon study completion, 60% of the steers in the ND treatment group were positive for 
the bovine anaplasmosis pathogen, A. marginale, based upon the results of cELISA, light 
microscopy and RT-PCR. The order of injection of steers infected in the ND treatment group 
was first, second, fourth, sixth, seventh, and tenth. All steers in the NF and CONT groups 
remained negative for anaplasmosis throughout the study. A significant difference in the number 
of steers infected with A. marginale occurred between ND and NF treatments (P < 0.05) as well 
as ND and CONT (P < 0.05).  
The predicted model-adjusted probability of becoming infected when comparing ND to 
NF and ND to CONT was 0.6 + 0.16 and 0.65 + 0.18, respectively. Since all cattle in the NF and 
CONT treatment groups remained negative to A. marginale, the model-adjusted probabilities of 
testing positive for A. marginale was zero. The odds of becoming infected with A. marginale due 
to ND treatment were 44.6 (19.5,101.8) times (P < 0.05) more likely than NF and CONT.  
The RT-PCR assay identified 120 molecules of 16S rRNA (Table 3.1) in one infected 
steer as early as 9 days post-injection (DPI) (Figure 3.2). The sensitivity of the RT-PCR assay 
was consistent in identifying steers infected with A. marginale in successive samplings. The peak 
sensitivity (100%) of the RT-PCR assay occurred at 20 DPI and sustained through 61 DPI. The 
peak number of 16S rRNA molecules recovered from 250 µL of plasma-free, whole blood (1.6 X 
108) occurred at 41 DPI. Positive assay results did not occur for the CONT and NF groups with 
the RT-PCR assay. 
The cELISA identified one positive steer at 13 DPI (Figure 3.2); however, sensitivity of 
cELISA was observed to be inconsistent during the four successive samplings. No infected steer 
was identified by the cELISA at 16 DPI. The steer identified at 20 DPI was not the infected steer 
identified at 13 DPI. The cELISA did not demonstrate consistent sensitivity until 34 DPI. The 
peak sensitivity (100%) of the cELISA occurred at 41 DPI and sustained through 61 DPI. This 
coincided with the peak number of 16S rRNA molecules identified by the RT-PCR assay and a 
decreasing PCV (Table 3.1).  
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The PPE determination through examination of stained blood smears by light microscopy 
identified one infected steer as early as day 16; however, this steer was not consistently identified 
until day 34. Interestingly, the peak sensitivity of light microscopy (41 DPI) coincided with the 
peak sensitivity of cELISA, peak in rRNA molecules identified with RT-PCR, and the decline in 
PCV (Table 3.1). Furthermore, the odds of testing positive for A. marginale infection using light 
microscopy are only 0.5 times (P < 0.05) as likely as cELISA.  
A comparison was prepared to illustrate the variability of diagnostic method performance 
and agreement during the peracute, acute, and chronic stages of infection (Table 3.2). Sensitivity 
was inadequate among all methods during the peracute phase post-injection. However, RT-PCR, 
cELISA and light microscopy detected an infected steer on days 9, 13 and 16 post-injection. 
Peak sensitivity was recorded on days 20, 41, and 41 post-injection for RT-PCR, cELISA and 
light microscopy, respectively. Diagnostic sensitivity was sustained for the cELISA and RT-
PCR; however, sensitivity of light microscopy decreased to zero by day 57 post-injection. RT-
PCR was the only diagnostic method that maintained 100% specificity throughout the study. 
Poor specificity was demonstrated by the cELISA due to eight false positive assay results for 
steers in the CONT and NF groups on days two (1), thirteen (2), sixteen (1), twenty-three (3), 
and thirty (1) DPI. The % inhibition recorded for each of these false positive results was between 
30 and 40%. The odds of an A. marginale infected steer testing positive with the RT-PCR assay 
was 1.34 (P = 0.07) times more likely than with cELISA. Agreement was determined between 
the cELISA and RT-PCR (2 test) as well as the result of all three diagnostic methods (3 test). 
However, a proportion of concordance (0.76) was calculated on 0, 2 and 6 DPI due to a lack of 
concordant results in 2 or more cells in the 2X2 contingency table. The sensitivity and specificity 
for each of these test days were 0% and 100%, respectively. Kappa was calculated for the 
remainder of results occurring on 9 through 61 DPI. Perfect agreement occurred on day 41 when 
making a 2 and 3 test comparison; however, an exceptional level of agreement was only 
sustained through the remainder of the study when comparing the RT-PCR and cELISA. At 61 
DPI, the 2 and 3 test agreement were 0.75 (0.53,0.97) and 1 (0.72,1.28), respectively.  
The imprecision of diagnostic test results reported for the six steers infected with A. 
marginale in the ND group was calculated as the Geo CV% of the geometric mean (Table 3.1). 
The Geo CV% for RT-PCR at peak sensitivity (20 DPI) was greater than 15% (17%). However, 
this estimate did not exceed 22% throughout the study once infected steers were detected. The 
72 
 
Geo CV% for light microscopy, cELISA and RT-PCR at 41 DPI, which corresponds to the 
greatest three test agreement (1), were 68%, 43.2%, and 1.8%, respectively. The lowest estimates 
occurred at 48 DPI, 61 DPI and 44 DPI for light microscopy, cELISA, and RT-PCR responses, 
respectively.  
Results from the semi-parametric survival analysis were expressed as hazard ratios. 
Hazard ratios were interpreted similarly as odds ratios, assumed to be proportional over time and 
represented the effect of a unit change in the predictor on the frequency of the outcome (Le, 
2003). The hazard ratio of cattle testing positive to A. marginale in the ND group by RT-PCR 
when compared to cELISA and light microscopy was 1.15 (P = 0.06) and 1.58 (P < 0.05), 
respectively. Likewise, the hazard ratio of cattle testing positive to A. marginale in the ND group 
by cELISA when compared to RT-PCR and light microscopy was 0.74 (P=0.06) and 1.86 
(P<0.05), respectively. Conversely, light microscopy was shown to be the least likely to find 
positive animals across the study period as the hazard ratio of cattle testing positive to A. 
marginale in comparison to RT-PCR and cELISA was 0.74 (P<0.05) and 0.81 (P<0.05), 
respectively. A Kaplan-Meier survival analysis was performed on raw data comparing the three 
diagnostic regimens (Figure 3.3). At 0 DPI, the risk of infection is 1 for all steers exposed. 
However, this risk reduced over time as the A. marginale infected steers were identified.  
Additionally, the semi-parametric survival analysis was also used to test the significance 
of the injection sequence among the ND treatment group. Once the needle was contaminated 
post-exposure to the SPS, the steers that subsequently tested positive for A. marginale was the 
first, second, fourth, sixth, seventh, and tenth animals in the ND group. The hazard ratio for the 
sequence of injection (0.96; P>0.05) indicated the hazard of becoming positive to A. marginale 
was the same across all animals in the ND treatment group. Therefore, the sequence of injection 
was not associated with testing positive to A. marginale.  
To further validate the results of the diagnostic methods, fifteen naïve steers from the NF 
and CONT groups were intravenously inoculated with five milliliters of whole blood from one of 
each of the six steers iatrogenically infected with the Virginia isolate of A. marginale. All fifteen 
steers became infected with A. marginale due to intravenous inoculation as determined by 
interpretation of cELISA, light microscopy and RT-PCR results in series. The four remaining 
steers were not challenged due to subsequent enrollment in a separate study. 
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Discussion 
Anaplasmosis presents many problems to the cattle industry due to complications with 
disease control, eradication and treatment. When vaccinating cattle of unknown disease status, 
hygienic animal husbandry techniques are highly recommended. Although repetitive needle use 
among cattle is not suggested, this practice still occurs today. It may be argued that a cattle 
population with an endemic and stable disease prevalence may be advantageous due to 
minimizing clinical disease in adult cattle. However, this approach does not permit the 
comingling of cattle of unknown disease status. Another disadvantage would be the transmission 
of other blood-borne pathogens of cattle. If anaplasmosis disease prevalence is allowed to 
increase, culling practices may be amplified as well as trade restrictions intensified between 
endemic and non-endemic countries due to the current use of unreliable diagnostic methods.  
This study was designed to vigorously challenge the utility of needle-free injection for 
the control of anaplasmosis transmission among cattle during vaccination. Needle-free injection 
was validated as a tool for controlling horizontal transmission of A. marginale. Additionally, a 
novel RT-PCR assay was evaluated for detecting A. marginale in bovine peripheral blood 
samples. This data set is clinically relevant due to the potential spread of A. marginale to naive 
cattle during routine animal husbandry practices as well as identifying the deficiencies in the 
sensitivity and specificity of currently available diagnostic methods. To our knowledge, this is 
the first report to evaluate needle-free injection techniques for the control of iatrogenic 
transmission of anaplasmosis as well as determine the performance of first, second and third 
generation diagnostic methods at sequential time points following a single exposure to A. 
marginale in cattle.  
Needle transmission of anaplasmosis from a known carrier to susceptible cattle has been 
documented (Reeves and Swift, 1977). In that report, only 1 out of 5 animals was infected. 
Furthermore, the authors described the ability to visually detect blood contamination on the 
needle between injections. In this study, 6 out of 10 animals were infected. Blood contamination 
on the single use needle was only visible prior to the injection of the last naive calf in the ND 
injection group. Otherwise, the needle appeared to be safe to use for multiple injections. Due to 
the random pattern of transmission and lack of statistical significance associated with injection 
sequence, the repetitive use of a needle among cattle of unknown disease status should be 
regarded as unacceptable. Furthermore, the fact that 60% of steers exposed to an A. marginale 
74 
 
contaminated needle became infected following an intramuscular injection leads to the 
hypothesis that this route of infection may be very common in current production systems.  
The transmission of blood components during needle-free injection techniques has been 
documented (Sweat et al., 2000). This is apparently negligible when concerned with 
anaplasmosis disease transmission under the conditions of this study. The vaccination of the SPS 
prior to the injection of each steer in the NF group robustly challenged the potential for 
iatrogenic transmission of a Virginia isolate of A. marginale with needle-free injection. 
However, the utility of needle-free injection is unknown under situations where anaplasmosis 
carriers may have a PPE greater than 2%. Similar or worse conditions are reasonably unlikely to 
be encountered under field conditions. However, it may be necessary to account for the temporal 
association of previous vaccinations, disease prevalence and the timing of vaccination in regard 
to the seasonal distribution of clinical cases when applying needle-free injection techniques. 
Furthermore, it should be noted that disease resistance among breeds has not been shown to exist 
(Bock et al., 1999; Jonsson et al., 2008; Wilson et al., 1980).  
The use of needle-free injection in production settings will aid in the reduction of 
biohazard waste, alleviate operator injury due to accidental needle puncture and eliminate the 
possibility of  needle contamination due to vaccination in consumable meat products while 
maintaining processing rates that are necessary for minimizing handling and stress in cattle. Even 
though needle-free injection is superior to needle injection for preventing iatrogenic transmission 
of A. marginale, it is recommended that due care be observed to avoid the unwarranted 
vaccination of cattle that might occur as a result of improper cleansing of previously used 
vaccine products from the injection system (Makoschey and Beer, 2004). Further studies are 
necessary to fully evaluate the utility of needle-free injection for the control of other blood-borne 
diseases of cattle.  
Upon study completion, the prevalence of anaplasmosis was 24%. It may be argued that 
the evaluation of sensitivity and specificity among the diagnostic methods included in this study 
be interpreted with caution due to the small study population and low number of infected steers; 
however, the accurate and precise diagnosis of anaplasmosis has historically been problematic 
due to diagnostic methods that lack adequate sensitivity and specificity (Bradway et al., 2001; 
Coetzee et al., 2007; Dreher et al., 2005; Gonzalez et al., 1978; Strik et al., 2007). Therefore, it is 
important to describe the inequality of these diagnostic methods.  
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First generation diagnostic methods rely on the growth or visualization of the organism of 
interest. These methods have limited sensitivity and lack adequate specificity to differentiate 
between morphologically similar pathogens, normal structures, and stain artifacts. During this 
study, light microscopy was proven to be unreliable due to false negative results. This was due to 
the low level of circulating rickettsemias encountered. Even though all steers infected with A. 
marginale were accurately classified during the study, light microscopy only demonstrated 100% 
diagnostic sensitivity at 40 DPI.  
Second generation methods, which rely on the identification of cell components, 
metabolic products, and detection of antigenic components, are currently the most commonly 
used techniques for disease classification in clinical medicine and research. One disadvantage of 
these methods is the potential for cross-reactivity among coexisting diseases. Due to similarity 
among MSP5 surface proteins, cross-reactivity when using cELISA has been reported among A. 
marginale, Anaplasma centrale and Anaplasma phagocytophilum (Dreher et al., 2005; Strik et 
al., 2007). The cELISA demonstrated improved and sustainable sensitivity over light 
microscopy. However, cELISA did not demonstrate 100% sensitivity until 41 DPI in the ND 
group. The disadvantage of this technique is the cut-off value used to classify disease status. A 
cut-off of > 30% inhibition was used in this study to classify a steer as disease positive. This 
level led to multiple false positive results in the NF and CONT groups. However, the sensitivity 
of this assay at the earlier time points would have been compromised if a 40% inhibition had 
been used.  
Third generation methods utilize nucleic acid-based techniques for the classification of 
disease status. These methods offer superior sensitivity and specificity over first and second 
generation methods. This study is not the first to develop or use a nucleic acid-based technique 
for the diagnosis of A. marginale in bovine peripheral blood samples (Carelli et al., 2007; Decaro 
et al., 2008; Eriks et al., 1989; Figueroa et al., 1998; Ge et al., 1997; Ge et al., 1995; Goff et al., 
1990; Hoar et al., 2008; Molad et al., 2006; Torioni de Echaide et al., 1998). However, it is the 
first of its kind to use a real-time, quantitative RT-PCR method to identify 16S rRNA of A. 
marginale. The advantages of this assay are the enhanced sensitivity of identifying rRNA targets 
that are present in higher quantities than a single copy of DNA per organism; the ability to 
quantify the genetic template; the need for polyacrylamide gel electrophoresis is no longer 
required; and this assay could serve as a substitute for the subinoculation of splenectomized 
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cattle with blood from cattle of unknown disease status. The major disadvantage is the cost of the 
reagents and equipment as well as the necessity of modern elements that may not be readily 
accessible.  
The RT-PCR assay demonstrated 100% sensitivity by 20 DPI. This is a marked 
improvement over light microscopy and cELISA for diagnosis in the prepatent period; however, 
false negative assay results occurred due to the inability of RT-PCR to detect disease prior to 20 
DPI in 250 µL of plasma-free blood samples. Due to the performance of the diagnostic methods 
used during this study, the authors would recommend repeated sampling of cattle of unknown 
disease status on a 3 week and 6 week interval when using the RT-PCR assay and cELISA, 
respectively. However, light microscopy would not be recommended for determining disease 
status in unknown cattle.  
Anaplasmosis is a complex and challenging disease for stakeholders in the cattle 
industry, foreign policy and research arenas. Due to the lack of significant success with treatment 
strategies, vaccine availability, and problematic vector control, anaplasmosis control strategies 
should primarily concentrate on established methods for disease prevention. This data set is 
clinically relevant due to the potential spread of A. marginale to naive cattle during routine 
animal husbandry practices as well as illustrating the deficiencies in the sensitivity and 
specificity of currently available diagnostic methods. Our results identified needle-free injection 
as a superior method for controlling the iatrogenic transmission of anaplasmosis. Furthermore, a 
novel, A. marginale-specific RT-PCR assay has the potential to significantly impact the future of 
disease classification prior to local, interstate, or international movement of cattle between 
endemic and non-endemic countries. 
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Figures and Tables 
Figure 3.1 RT-PCR assay detection sensitivity and linearity with RNA concentration. Serial 
10-fold dilutions of an in vitro transcript made from Anaplasma marginale plasmid DNA. 
The average Ct values from three independent experiments were plotted against the log 
number of rRNA molecules (a). The log10 2 and log10 9 correspond to 100 and 1 billion 
molecules of 16S rRNA, respectively. The correlation coefficient (R2) and equation of the 
line are 0.9973 and y = -3.4324 + 40.38, respectively. The fluorescent emission from serial 
dilution templates is shown (b). 
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Figure 3.2 Diagnostic method Se for RT-PCR (white boxes), cELISA (black diamonds), and 
light microscopy (white triangles) for six steers iatrogenically infected with a Virginia 
isolate of Anaplasma marginale in the ND injection group. 
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Figure 3.3 A Kaplan-Meier survival estimate derived from the results of six steers 
iatrogenically infected with a Virginia isolate of Anaplasma marginale in the ND injection 
group for the RT-PCR assay (bold line), cELISA (dashed line) and light microscopy 
(shaded line). 
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Table 3.1 Geometric mean and Geo CV% for each diagnostic test result response and PCV 
derived from the analysis of six steers iatrogenically infected with a Virginia isolate of 
Anaplasma marginale in the ND injection group (n = 6). 
DPI  
Light 
microscopy▲  cELISA▲  RT-PCR*  PCV 
0  0% (--)0  12.87% (25.9)6  0 (--)0  34.29% (5.4) 6 
2  0% (--)0  15.04% (30.9)6  0 (--)0  35.36% (9.69) 6 
6  0% (--)0  3.39% (122.4)6  0 (--)0  31.78% (6.1) 6 
9  0% (--)0  10.3% (75.6)6  1.2x102 (--)1  31.94% (6.84) 6 
13  0% (--)0  13.31% (77.0)6  1.8x103 (8.9)4  31.3% (5.3) 6 
17  0% (--)0  14.96% (36.5)6  1.9x103 (13.5)5  30.11% (6.84) 6 
20  0% (--)0  21.29% (70.8) 6  4.2x104 (17.0)6  32.14% (4.61) 6 
23  0% (--)0  40.18% (53.5)6  4.8x105 (19.0)6  29.98% (4.17) 6 
27  0% (--)0  27.1% (243.4)6  5.7x106 (21.8)6  30.63% (5.3)6 
30  0.1% (--)1  44.84% (94.2)6  3.3x107 (20.4)1  30.41% (8.6)6 
34  0.42% (119.1)3  45.31% (170.2)6  8.7x107 (10.1)1  30.44% (6.8)6 
37  0.75% (96.3)3  61.43% (73.1)6  1.4x108 (2.7)6  28.41% (8.6)6 
41  0.55%  (68.0)6  69.34% (43.2)6  1.6x108 (1.8)6  25.92% (14.8)6 
44  0.24% (219.9)5  85.51% (18.9)6  1.4x108 (1.2)6  25.6% (8.0)6 
48  0.14% (52.1)2  88.55% (10.7)6  1.0x108 (4.8)6  27.06% (9.9)6 
51  0.1% (--)1  79.57% (8.4) 6  8.4x107 (10.9)6  27.37% (10.9)6 
54  0.1% (--)1  79.57% (11.3)6  5.0x107 (15.5)6  28.53% (10.9)6 
57  0% (--)0  82.59% (9.7 6  2.9x107 (15.6)6  29.03% (0.7)6 
61  0% (--)0  84.65% (12.1)6  1.9x107 (17.4)6  30.26% (7.3)6 
 
The numbered superscripts indicate the total number of non-zero values included in the 
calculation of the geometric mean and Geo CV%. ▲Data were divided by 100 prior to calculating 
the geometric mean and geometric coefficient of variation; however, the geometric mean was 
again multipled by 100% for reporting. *The number of 16S rRNA molecules recovered from 
250 µL of plasma-free, whole blood. 
81 
 
Table 3.2 Diagnostic method performance as determined by the calculated sensitivity and specificity with 95% confidence 
intervals for each diagnostic method used during the 61 day study (n=25). 
  Light microscopy  cELISA  RT-PCR  Agreement 
DPI
†
 
 
Se (%)  Sp (%) 
 
Se (%)  Sp (%) 
 
Se (%)  Sp (%) 
 
2 test (ĸ)  3 test (ĸ) 
9 
 
0  100 
 
0  100 
 
16.7  100 
 
0.12  0.08 
(--,--)
±
  (--,--)
±
 (--,--)
±
  (--,--)
±
 (0,46.5)  (100,100) (0,0.25)  (0,0.17) 
13 
 
0  100 
 
16.7  89.5 
 
66.7  100 
 
0.43  0.31 
(--,--)
±
  (--,--)
±
 (0, 46.9)  (75.7, 100) (28.9,100)  (100,100) (0.16,0.69)  (0.11,0.50) 
16 
 
16.7  100 
 
0  94.7 
 
83.3  100 
 
0.47  0.4 
(0 ,46.5)  (100,100) (--,--)
±
  (84.7,100) (53.5,100)  (100,100) (0.22,0.73)  (0.20,0.59) 
20 
 
0  100 
 
16.7  100 
 
100  100 
 
0.68  0.49 
(--,--)
±
  (--,--)
±
 (0,46.5)  (100,100) (100,100)  (100,100) (0.42,0.94)  (0.30,0.69) 
23 
 
0  94.7 
 
83.3  84.2 
 
100  100 
 
0.79  0.57 
(--,--)
±
  (84.7,100) (53.5,100)  (67.8,100) (100,100)  (100,100) (0.52,1.1)  (0.35,0.80) 
27 
 
0  94.7 
 
66.7  100 
 
100  100 
 
0.88  0.62 
(--,--)
±
  (84.7,100) (28.9,100)  (100,100) (100,100)  (100,100) (0.61,1.16)  (0.40,0.84) 
30 
 
16.7  94.7 
 
66.7  94.7 
 
100  100 
 
0.83  0.64 
(0,46.5)  (84.7,100) (28.9,100)  (84.7,100) (100,100)  (100,100) (0.55,1.11)  (0.42,0.86) 
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34 
 
50  94.7 
 
83.3  100 
 
100  100 
 
0.94  0.81 
(10,90)  (84.7,100) (53.5,100)  (100,100) (100,100)  (100,100) (0.67,1.22)  (0.58,1.03) 
37 
 
50  94.7 
 
83.3  100 
 
100  100 
 
0.94  0.81 
(10,90)  (84.7,100) (53.5,100)  (100,100) (100,100)  (100,100) (0.67,1.22)  (0.58,1.03) 
41 
 
100  100 
 
100  100 
 
100  100 
 
1  1 
(100,100)  (100,100) (100,100)  (100,100) (100,100)  (100,100) (0.72,1.28)  (0.77,1.23) 
44 
 
83.3  100 
 
100  100 
 
100  100 
 
1  0.96 
(53.5,100)  (100,100) (100,100)  (100,100) (100,100)  (100,100) (0.72,1.28)  (0.74,1.19) 
48 
 
33.3  100 
 
100  100 
 
100  100 
 
1  0.84 
(0,71.1)  (100,100) (100,100)  (100,100) (100,100)  (100,100) (0.72,1.28)  (0.62,1.07) 
51 
 
50  100 
 
100  100 
 
100  100 
 
1  0.88 
(10,90)  (100,100) (100,100)  (100,100) (100,100)  (100,100) (0.72,1.28)  (0.66,1.11) 
54 
 
33.3  100 
 
100  100 
 
100  100 
 
1  0.84 
(0,71.1)  (100,100) (100,100)  (100,100) (100,100)  (100,100) (0.72,1.28)  (0.69,1.07) 
57 
 
0  100 
 
100  100 
 
100  100 
 
1  0.75 
(--,--)
±
  (--,--)
±
 (100,100)  (100,100) (100,100)  (100,100) (0.72,1.28)  (0.53,0.97) 
61 
 
0  100 
 
100  100 
 
100  100 
 
1  0.75 
(--,--)
±
  (--,--)
±
 (100,100)  (100,100) (100, 100)  (100,100) (0.72,1.28)  (0.53,0.97) 
 
Se= sensitivity. Sp= specificity. 
†
Values for 0, 2, and 6 DPI were omitted from the table due to a lack of concordant results in 2 or more 
cells in the 2X2 contingency table. For each of these time points, the calculated proportion of concordance was 0.76 with a Se and Sp 
of 0 and 100%, respectively. 
±
The 95% confidence interval was not calculated due to a lack of concordant results in 2 or more cells in 
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the 2X2 contingency table. The 2 test (κ) is a comparison of agreement between the cELISA and RT-PCR assays exclusively. 
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CHAPTER 4 - Plasma pharmacokinetics of oral chlortetracycline in 
group fed, Holstein steers in a feedlot setting 
Published in the Journal of Veterinary Pharmacology and Therapeutics (July 2009); Reinbold, 
J.B., Coetzee, J.F., Gehring, R., Havel, J.A., Hollis, L.C., Olson, K.C., Apley, M.D., 2009a. 
Plasma pharmacokinetics of oral chlortetracycline in group fed, ruminating, Holstein steers in a 
feedlot setting. J Vet Pharm Ther DOI: 10.1111/j.1365-2885.2009.1116.x. 
 
Introduction 
Chlortetracycline HCl (CTC) has served a pivotal role in profitable livestock production 
since its discovery in 1945. CTC is one of the many broad-spectrum tetracycline antibiotics 
widely used in veterinary medicine. This antibiotic was first approved for use in feed on June 23, 
1954, for improving feed efficiency, growth promotion, and the treatment of CTC-sensitive 
pathogens (NADA 065-440, Freedom of Information Summary 
http://www.fda.gov/cvm/FOI/552.htm; NAHMS (Swine 2006), 2006; NAHMS (Feedlot 1999), 
1999). Today, the label indications, based on multiple dosing regimens, are for increased rate of 
weight gain, improved feed efficiency, control of bacterial pneumonia associated with shipping 
fever complex caused by susceptible Pasteurella spp., control of active infection of anaplasmosis 
caused by susceptible Anaplasma marginale, reduction of liver condemnation because of liver 
abscessation, and treatment of bacterial enteritis caused by susceptible Escherichia coli (Feed 
Additive Compendium, 2008). The 1999 NAHMS feedlot study reported that 51.9% of all 
feedlots surveyed administer CTC as a health or production management tool to 18.2% of cattle 
fed. Operations with capacities of 1000–7999 head, as well as those feeding cattle weighing 
<318.2 kg, tend to administer CTC to cattle more often than operations feeding >8000 head and 
cattle weighing >318.2 kg. On average, CTC is fed 8.6 and 7.7 days to cattle weighing <318.2 
and >318.2 kg, respectively. 
Pharmacokinetic parameters for orally administered CTC are available for preruminating 
calves, poultry, and swine (Bradley et al., 1982; Luthman & Jacobsson, 1983; Pollet et al., 1983; 
Dyer, 1988; Kilroy et al., 1990; Wanner et al., 1991; Nielsen & Gyrd-Hansen, 1996). However, 
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similar information for ruminating cattle is scarce in peer-reviewed literature. As a result of the 
controversial use of CTC for improved feed efficiency and growth in bovine diets at levels that 
have been erroneously termed ‘subtherapeutic’, this antimicrobial has been implicated as a 
potential variable for the promotion of antimicrobial resistance. 
The Clinical and Laboratory Standards Institute (CLSI) has set the susceptible minimum 
inhibitory concentration (MIC) breakpoint of tetracycline antibiotics (200 mg⁄ mL of injectable 
oxytetracycline product) at 2 µg ⁄ mL when treating bovine bacterial infection caused by 
Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni (CLSI 2008 ); yet, it is 
unknown if currently approved dosages and treatment regimens applied in modern production 
systems achieve this recommended concentration in bovine plasma. To evaluate these 
breakpoints in relation to in-feed CTC regimens, a study was conducted to determine the 
pharmacokinetic parameters of CTC in ruminating cattle under group fed conditions in a feedlot 
setting.  
Materials and Methods 
This study was approved by the Kansas State University (KSU) Institutional Animal Care 
and Use Committee (IACUC protocol #2517). 
Experimental cattle and animal husbandry 
A total of 18 preconditioned, clinically healthy Holstein steers were purchased from the 
KSU dairy farm in Manhattan, KS, USA. The steers were housed in three pens in a dry lot 
located at the KSU Juniatta Beef Cattle research facility. One month prior to the start of the 
experiment, the steers were acclimated to a total mixed ration diet consisting of the following 
ingredients listed in descending quantity; wheat middling pellets, liquid molasses, cracked corn, 
loose cottonseed hulls, extender pellets, monensin (80 g ⁄ ton), limestone, salt, corn gluten meal 
pellets, vitamin A, zinc sulfate, and dried distiller’s grains. The diet was fed at 2.5% of body 
weight (as fed) divided into twice daily feedings. Water was supplied ad libitum. When handling 
was necessary, the steers were individually restrained with a head gate and a rope halter. This 
study was conducted concurrently with an Anaplasma marginale chemosterilization study.  
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Oral chlortetracycline preparation 
A commercial chlortetracycline product (Aureomycin 50 Granular®; Alpharma Animal 
Health, Bridgewater, NJ, USA) was purchased for the formulation of a CTC topdress prepared 
by the KSU feed mill. A final concentration of 591.0; 1477.3; and 2954.4 mg of CTC per kg of 
ground corn carrier was used for the 4.4, 11, and 22 mg⁄ kg dosages administered during the 
study, respectively. These respective drug concentrations ensured that a similar total quantity of 
topdress was fed (kg) regardless of the dosage administered. 
Treatment groups and administration 
Steers were randomized by initial body weight and assigned to a 4.4, 11, or 22 mg⁄ kg per 
os, multi-dose CTC treatment (n = 6⁄ treatment). Steers were collectively 314 ± 29.9 days 
old and weighed 312.4 ± 47.1 kg, 309.5 ± 43.6 kg, and 303.5 ± 47.2 kg, for the 4.4, 11, and 22 
mg⁄ kg treatment groups, respectively. Twelve linear feet (3.7 m) of feed bunk space (0.61 m⁄ 
head) was used per treatment group. The daily dietary ration and CTC dosages were determined 
using the mean weight of the treatment group, which was taken bi-weekly. Daily dosage and 
ration were divided equally and administered twice daily for 80 days (160 total doses ⁄ group). 
Residues from the previous treatment were noted in a daily log sheet; however, observed 
residues were not removed or weighed. If plasma collection coincided with scheduled treatment, 
the plasma samples were collected prior to treatment administration. The feed bunk was 
inspected prior to each treatment. 
Plasma collection 
Plasma samples were collected throughout the 83-day study period; at 12-hour intervals 
on days 0–7, twice weekly on days 8–77, and every 4hours on days 80–83, according to the 
following standard procedures. Blood samples were collected via jugular venipuncture into a 
vacutainer tube containing lithium heparin (BD Vacutainer, Franklin Lakes, NJ, USA). Samples 
were stored on ice until plasma separation, which was performed by centrifuging the vacutainer 
tubes containing the plasma at 2750 g at 4°C for 5 minute. Plasma was separated and stored at -
80 °C until analysis. Samples were analyzed <11 months after collection. A freezer stability 
evaluation was not performed. 
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Sample analysis 
A novel solid phase extraction (SPE) and ultrahigh performance liquid chromatography-
mass spectroscopy ⁄ mass spectroscopy (UPLC-MS ⁄ MS) method was developed for the analysis 
of CTC in bovine plasma. Frozen samples were thawed at room temperature with 0.15 mL of 
plasma transferred to a new tube. Fifty microliters of doxycycline solution (3200 ng ⁄ mL of 
doxycycline), functioning as a structurally related internal standard, was added to each sample. 
Ten microliters of phosphoric acid was added followed by vortexing for 20 sec. Next, 150 µL of 
de-ionized water (Di) was added and vortexed for 20 sec. The analyte and internal standard were 
isolated from bovine plasma by SPE using 10 mg, 1 mL Waters HLB cartridges (Waters OASIS 
Extraction Products; Waters Corporation; Milford, MA, USA). The cartridges were first 
conditioned with 0.5 mL of >99% methanol, then with 0.5 mL of Di. Then, samples were 
transferred to the cartridges and allowed to elute freely. The cartridges were washed with 0.5 mL 
of 5:95 > 99%methanol: Di (v:v) and allowed to elute freely. Then, the cartridges were dried 
under high vacuum for 10 minute. The elutant was separated by adding 0.3 mL of methanol 
(>99% purity) to each cartridge and collected into a new collection tube. Finally, 150 µL of the 
elutant was transferred to a UPLC-MS ⁄ MS vial. Electrospray ionization and MS-MS analysis 
were carried out using a Waters Acquity TQD Tandem Quadrupole UPLC-MS ⁄ MS system 
(Waters Corporation). While operating in positive ion mode, chromatographic separation was 
achieved using a 1.7-µm, 1.0 X 50 mm C18 analytical column (Waters Acquity UPLC BEH; 
Waters Corporation). A gradient elution from 95% of 0.1% trifluoroacetic acid: 5% acetonitrile 
to 5% of 0.1% trifluoroacetic acid: 95% acetonitrile was utilized in the analysis. Identification 
and quantitation were established on the following transitions: m⁄ z 479–154 for CTC and m⁄ z 
445–321 for doxycycline. A 2-minute run time and a 3-minute cycle were used in the method. 
Quality controls of known concentrations were analyzed during sample analysis to monitor 
method performance. The method was proven to be accurate and precise across a linear dynamic 
range of 50–1000 ng ⁄ mL. The limit of detection and limit of quantitation (LOQ) were 20 and 50 
ng ⁄ mL, respectively. The precision and accuracy for 36 quality controls instrumented over 
eighteen analytical runs were found to be <9% and 98.5%, respectively. Re-analysis of 
individual samples occurred if the coefficient of variation (CV %) for the known concentration 
of the internal standard was >15%. 
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Pharmacokinetic analysis 
 Noncompartmental pharmacokinetic analysis (NCA) using a commercial software 
package (WINNONLIN 5.2, Pharsight Academic License; Pharsight Corporation, Mountain View, 
CA, USA) was performed by treatment group on individual steer data derived from data 
subsequent to the final treatment offered. The variables determined were the partial area under 
the curve (AUC) calculated from the time of the final dose to the next regularly scheduled dose 
(AUCfinal–next) using the linear trapezoidal rule, clearance (Cl ⁄ F) calculated using AUCfinal–next, 
apparent volume of distribution during the elimination phase (Vz ⁄ F), elimination rate constant 
(kz), and elimination half-life (t1 ⁄ 2 λz). The maximum drug concentration (Cmax) achieved at steady-
state and time to Cmax (Tmax) was determined from the data after the time of the final dose. This 
method for determining Cmax is equitable to the peak concentration achieved with these dosing 
regimens and method of drug administration. Data for drug concentration–time curves were also 
fit to a one-compartment open model with first order absorption and elimination by nonlinear-
mixed effects (nonlinear mixed effects modeling, NLMEM) modeling with a commercially 
available software program (WinNonMix; PharSight, Mountain View, CA, USA). No covariates 
were used in model development. The choice of the model was based on minimizing values for 
Akaike’s information criterion, Schwarz’s Bayesian Criterion, and ML Log Likelihood; reduced 
variability of the parameter estimates; evaluation of agreement for predicted vs. observed plasma 
CTC concentrations; and uniformity of residual plots. The model estimated two primary 
parameters; apparent volume of distribution (mL ⁄ kg) and a rate constant (h-1) for both 
absorption and elimination. Because of the inability to determine absolute bioavailability (F) for 
orally administered treatments, the parameters for the apparent volume of distribution and 
apparent clearance are reported as V⁄ F and Cl ⁄ F, respectively, for NCA and NLMEM. The 
following secondary parameter estimates were generated during compartmental analysis; dose-
normalized AUC (AUC ⁄ D), elimination half-life (t1 ⁄ 2), maximum concentration (Cmax), and time 
of maximum concentration (Tmax). The residual variability was described by a proportional 
error structure model: 
    y = f + fε      (1) 
where y and f are the observed and predicted plasma drug concentrations, respectively. ε 
represents the randomly distributed terms with a mean (0) and variance (σ). Samples with 
95 
 
concentrations below the LOQ were not included in either pharmacokinetic analytical method. 
The geometric CV% for parameters derived by NCA was calculated according to the 
following equation: 
   Geo CV% = exp(ln(geometric standard deviation))^2 · 100%  (2) 
The calculation of CV% for NLMEM is different because of the standard error of the mean being 
used in place of the standard deviation of the mean. 
 
 
Statistical analysis 
Statistical analysis was conducted by using a one-way analysis of variance (ANOVA) 
procedure (Microsoft Excel 2007; Microsoft Corporation; Redmond, WA, USA) (Martinez et al., 
2006). This statistical procedure analyzes variance for a quantitative dependent variable by a 
single independent variable to test the null hypothesis that several means are equal. Treatment 
group was designated as the independent variable. An alpha level of < 0.05 was designated a 
priori for the determination of statistical significance. ANOVA was used to determine 
statistically significant differences between treatment groups for the pharmacokinetic parameters 
reported by NCA and NLMEM; furthermore, dose linearity was determined by comparing the 
AUCfinal–next ⁄ D and the dose-normalized peak drug concentration (Cmax ⁄ D) among treatment 
groups determined by NCA. 
Results 
Steers in the CTC treatment groups were not significantly different with respect to body 
weight at the initiation of the study (P = 0.943). Additionally, no significant difference in body 
weight (P = 0.93) was detected at the completion of the study. Oral administration of all 
treatments was well-tolerated. No steers were removed from the study. Feed bunk spatial 
allocation of 0.61 m⁄ head (24 inches ⁄ head) was sufficiently adequate to allow each steer equal 
opportunity to consume the daily ration and treatment during the study. 
The original (CV %) estimates for the NCA-derived parameters suggest that the data 
were not normally distributed (data not shown). This is because of a high level of inter-individual 
variability observed. Therefore, the geometric mean and Geo CV% for pharmacokinetic 
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parameter data derived by NCA are reported in Table 1. Statistically significant differences by 
treatment were not detected among the parameters reported by NCA. Dose linearity was 
confirmed with ANOVA by a comparison of the AUCfinal–next ⁄D (P = 0.91) and Cmax ⁄ D (P = 
0.73) parameter estimates. 
A one-compartment model, where the absorption rate constant was equal to the 
elimination rate constant, was fit to the data using NLMEM. This modeling method was selected 
as it weights each data point by the inverse of the variance of each data point when modeling 
sparse and rich data sets (Proost & Eleveld, 2006). This weighting technique made it possible to 
fit a model to highly variable data. Model goodness of fit was not improved by not setting the 
absorption rate constant equal to the elimination rate constant (data not shown). To simplify the 
model, the absorption rate constant was set equal to the elimination rate constant. Goodness of fit 
scatter plots for the model are presented in Figs 4.1 & 4.2. Figure 4.1 demonstrates the 
relationship between the observed and the model-predicted concentrations for CTC. The 
distribution of the observed data around the model-predicted concentrations suggests that the 
final model fits the observed data; however, a systematic overestimation of lower peak 
concentrations was observed in the scatter plot of weighted residuals vs. predicted plasma drug 
concentration in Figure 4.2. 
Primary and secondary pharmacokinetic parameter estimates with calculations for 
standard error and CV are listed in Table 2. When considering CV as a measurement of 
precision, the primary parameters, V⁄ F and K, were estimated with high precision at 3.125% and 
4.184%, respectively; furthermore, these estimates are more precise based on the CV estimates 
reported for NCA. The secondary parameter estimates for AUC⁄ D, Cl ⁄ F, t1 ⁄ 2, and Tmax were 
similarly precise at 2.207%, 2.035%, 2.022%, and 2.023%, respectively; however, the estimate 
for Cmax was less precise at 18.32%. The overall imprecision of the NLMEM estimates tended to 
be less than comparably transformed Geo CV% estimates derived by NCA. 
Semi-logarithmic scatter plots of plasma drug concentration–time curves were graphed 
for each of the CTC treatment groups with an overlay of the NLMEM model-predicted 
concentration estimates for the population ±2 SD (Figs 4.3–4.5). Oral administration of CTC in 
group fed, ruminating steers resulted in high inter- and intra-individual variability in observed 
plasma drug concentrations in all treatments; however, the model-predicted normal distribution 
of drug concentrations included the vast majority of the observed data points. This indicates that 
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a one-compartment open model with first order absorption and elimination, where the absorption 
rate constant was equal to the elimination rate constant, is an adequate model for calculating 
dosage and treatment regimens that achieve target plasma concentrations for ruminating steers 
fed in a feedlot setting. Because of dose-linearity and the reliability of the model, dose 
adjustments can be prepared for targeted plasma drug concentrations within the range of dosages 
studied. 
 
Discussion 
Because of the widespread use of CTC in ruminating cattle, it is essential that these 
pharmacokinetic parameters be reported in the literature. The dosage regimens selected were 
necessary for study design fulfillment of a concurrent Anaplasma marginale chemosterilization 
study. The daily ration and treatment were offered in a similar manner to feedlot situations; 
however, feed bunk spatial allocations are approximately 0.23 m⁄ head in typical commercial 
settings as opposed to 0.61 m⁄ head in this study (Montgomery et al., 2008). This change in 
practice was implemented to ensure equal access for all steers to the daily ration and CTC 
provided in the treatment. 
The distribution of the ration and treatment was similar along the length of the feed bunk. 
It was assumed that steers would have similar observed plasma drug concentrations; however, 
high inter- and intra-individual variability was observed in plasma drug concentrations, as 
demonstrated in Figs. 4.3–4.5, and dose-related parameter estimates (AUCfinal–next, Cl⁄ F, Cmax, 
and Vz ⁄ F) in Table 1. Partitioning of the treatment may have occurred during ration 
consumption because of the treatment being offered as a topdress. This could lead to individual 
steers having the opportunity to consume more drug as compared with that by other steers. It 
may be possible that a threshold variability in treatment intake existed for time spent at the feed 
bunk to allow the steers that remained longer at the feed bunk to be exposed to more drug; 
however, this was not a measured covariate during the study. Additionally, the rumen may be a 
drug depot where variable amounts of CTC are presented to the small intestine for absorption 
based on hydration of rumen contents and physical fill. Twice-daily feed bunk evaluations were 
recorded in regard to complete or incomplete consumption of the ration and treatment. For 
plasma drug concentrations corresponding to incomplete consumption of the treatment, no 
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recognizable pattern was observed for a decrease or subsequent increase in plasma drug 
concentration. This is in part a result of the majority of occurrences happening during the twice-
weekly sampling period, infrequency of the occurrence, and minimal quantity remaining; 
however, the length of the elimination half-life and the potential for the rumen to serve as a drug 
depot may have played an additional significant role in suppressing a recognizable pattern.  
Divalent cations, as well as the addition of citric acid, have been shown to decrease and 
increase the absorption of CTC, respectively (Bradley et al., 1982; Luthman & Jacobsson, 1985). 
Citric acid was not an ingredient in the ration; however, divalent cations, specifically represented 
as calcium in limestone, were present in the diet. The static addition of calcium was necessary 
for homeostasis of normal metabolic processes and physiologic growth (Ross et al., 1994; 
Montgomery et al., 2004). The potential phenomenon of decreased absorption, caused by the 
binding of CTC to divalent cations, was assumed to be homogenous among all steers in this 
study.  
The fed status and dietary feed ingredients may play a significant role in altering plasma 
drug concentration. In swine studies, fed pigs had lower bioavailability and mean plasma drug 
concentrations than fasted pigs (Kilroy et al., 1990; Nielsen & Gyrd-Hansen, 1996). Plasma drug 
concentrations are decreased in milk-fed calves as opposed to increased concentrations in calves 
fed citric acid in milk-replacer (Bradley et al., 1982; Luthman & Jacobsson, 1985). Furthermore, 
similar results were demonstrated when swine were fed calcium and citric acid (Wanner et al., 
1991). Further studies are necessary to establish a relationship between plasma drug 
concentrations with fed or fasted status and feed ingredients.  
Noncompartmental analysis was used to determine individual pharmacokinetic 
parameters of each treatment group. NLMEM was used to characterize the experimental data 
with a one-compartment open model with first order absorption and elimination. Although the 
data set was relatively rich at some periods during the study, the data were highly variable. 
Fitting a compartmental model using standard nonlinear regression methods was not successful 
because the algorithms were unable to converge as a result of the high, nonsystematic variability 
of the data. NLMEM was able to fit a model to the data and provide more precise parameter 
estimates as the method analyzes all the pharmacokinetic profiles at once and the data are 
weighted by their variance. As a result of the parameters not being skewed by a small number of 
outliers, NLMEM is known to give superior parameters estimated for data that is not normally or 
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log-normally distributed (Tam et al., 2003). Parameters estimated by other methods of nonlinear 
regression can be easily skewed by a small number of outliers because of each data point 
influencing the output equally. Furthermore, analyzing all data points and parameters at one time 
will increase the number of independent data points (degrees of freedom) that can be used to 
determine the central tendency and dispersion of the parameter estimates while accounting for 
the variance in the system. This also enhances the robustness of estimates with NLMEM 
methods over conventional nonlinear regression methods. 
An overestimation of the lower plasma drug concentrations by NLMEM is demonstrated 
in Fig. 4.2. A more complex model may have characterized lower concentrations more 
accurately; however, a simpler model was chosen for the advantage of accurately estimating the 
higher concentrations that are likely to possess more clinically relevant information when 
compared with a more complex model that may accurately estimate lower concentrations. 
Pharmacokinetic parameters determined by NCA and NLMEM in this study were compared with 
other data derived from the literature. Two-week-old, conventionally fed (starter concentration at 
2% body weight plus ad libitum alfalfa hay) Holstein calves were administered a single, 22 mg⁄ 
kg dose of CTC by ruminal intubation (Bradley et al., 1982). Parameters derived for the 
conventionally fed calves are AUC0-LOQ (7.5 hr·µg/mL), t1/2 λz (17.75 h), Cl/F (1.3 L/kg/hr), and 
Vz/F (40.9 L/kg). The geometric mean for the 22 mg/kg treatment group derived by NCA are 
AUCfinal-next (0.99 hr·µg/mL), t1/2 λz (37.2 h), Cl/F (11.1 L/kg/h), and Vz/F (13.5 L/kg). Mean 
pharmacokinetic parameters determined by NLMEM are AUC/D (0.29 h·µg/mL), t1/2 (16.2 hr), Cmax 
(4.5 ng/mL), Cl/F (1.8 L/kg/h), and V/F 40.9 (L/kg). The dissimilarity of NCA-derived parameters 
is likely caused by significant differences in anatomy, metabolism, physiology, method of 
administration, and compartmental vs. noncompartmental analysis between the studies. 
Metabolic differences would be attributable to total body water and fat, as well as decreased 
bone density, of the 14-dayold calves compared with that of the 314-day-old steers in this study. 
Although the pyloric groove is likely to be open, conventionally fed, 14-day-old calves do not 
have a fully functional rumen. This incongruence in anatomy and physiology would affect the 
absorption of CTC because of differences in presentation of the drug to the small intestine. The 
similarities between parameters derived by NLMEM and that for the conventionally fed calves 
are remarkable. One possible explanation is these parameters were estimated by a one-
compartment model for both studies. This may account for the shorter half-life compared with 
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NCA, as t1 ⁄ 2 λ is calculated from the terminal phase of the time-concentration curve that is not 
considered in the one-compartment model. 
An intravenous study was not performed in conjunction with the current study. The 
median F for the conventionally fed calves in the Bradley et al. study was calculated at 4.5% 
(±2.2%). In swine, F has been calculated at 17.88% (±5.3%) and 11% (±5%) (Kilroy et al., 1990; 
Nielsen & Gyrd-Hansen, 1996). Although the conventionally fed calves may not have a fully 
functional rumen, there appears to be a remarkable difference in oral F for CTC when comparing 
monogastric and ruminant species. Future studies are necessary to determine the absolute 
bioavailability of CTC in ruminating cattle. 
Currently, CLSI has determined a concentration of 2 µg ⁄ mL for tetracycline antibiotics 
(200 mg⁄ mL injectable oxytetracycline products) as a susceptible MIC for the treatment of 
bacterial infection caused by M. haemolytica, P. multocida, or H. somnii. This CLSI breakpoint 
is much higher than the observed plasma drug concentrations achieved with oral CTC in this 
study. In addition to different pharmacokinetic profiles, pharmacodynamic targets for extended 
duration antimicrobial regimens have not been established; therefore, susceptibility testing 
results should be interpreted with caution for in-feed CTC. The preferred susceptibility testing 
procedure would be an extended-range, dilution plate system that determines susceptibility as 
low as 0.5 µg ⁄ mL. It is also important to recognize that the inhibition of the pathogen growth 
curve may occur below the MIC which inhibits visible growth in the laboratory. Basing all 
interpretations of potential disease prevention or treatment activity on plasma drug concentration 
vs. in-vitro MIC values may lead to an underestimation of the utility of an antibiotic treatment 
regime in a production setting. The use of CTC at sub-MIC concentrations has been shown to be 
effective in reducing the incidence and effects of bovine respiratory disease (BRD) (Nanduri et 
al., 2005). This study demonstrated that a concentration of 0.25 µg ⁄ mL in vitro reduced the 
development of clinical lesions from BRD through inhibition of Mannheimia haemolytica 
leukotoxin A expression. Under the conditions of this study, the 11 and 22 mg⁄ kg ⁄ day treatment 
groups reached this level that would be necessary for inhibition of Mannheimia haemolytica 
leukotoxin A expression in vivo. The dose-linearity of this drug across treatments suggests that 
higher plasma drug concentrations may be achieved by feeding higher dosages of CTC to 
ruminating steers. The data derived from this research could be used, with other in vivo studies, 
to support a new animal drug application (NADA) to the Food and Drug Administration Center 
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for Veterinary Medicine (FDA CVM) for the labeled use of inhibiting M. haemolytica leukotoxin 
A expression in ruminating cattle. 
Current literature remains deficient in information regarding oral bioavailability in 
ruminating cattle. Until a sufficient body of scientific knowledge for a complete pharmacokinetic 
and pharmacodynamic profile of CTC is formed, the use of this antibiotic as a tool in profitable 
cattle production will continue to be a target of special interest groups for the removal of the 
FDA-approved, labeled use of CTC in animal feed. The NLMEM compartmental model could be 
a useful tool to simulate plasma drug concentrations for different dosage and treatment regime 
scenarios as well as the projected variability of the population. Recently, a population 
pharmacokinetic (PPK) study was established as a successful tool for gathering pharmacokinetic 
information in large populations of cattle (>100 head) (Fu et al., 2008). In addition to that study, 
the information gathered in this study, as well as the use of NLMEM techniques typical of PPK 
studies, could provide the framework for PPK research of CTC in group fed, ruminating cattle. 
Future studies of this kind are necessary to bridge the gap between experimentally derived data 
and confirmatory studies applied under normal conditions (Sheiner, 1997).
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Figures and Tables 
Figure 4.1 Scatter plot of observed plasma drug concentration vs. predicted plasma drug 
concentration predicted by nonlinear mixed effects modeling for chlortetracycline 
hydrochloride in ruminating Holstein steers (n = 18). 
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Figure 4.2 Scatter plot of weighted residuals versus predicted plasma drug concentration 
by NLMEM for chlortetracycline hydrochloride in ruminating, Holstein steers (n=18). 
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Figure 4.3 Plasma drug concentration of chlortetracycline hydrochloride administered at 
4.4 mg⁄kg/day p.o. to ruminating, Holstein steers (n=6) with NLMEM model-predicted drug 
concentration for the population (+/- 2 SD). 
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Figure 4.4 Plasma drug concentration of chlortetracycline hydrochloride administered at 
11 mg⁄kg/day p.o. to ruminating, Holstein steers (n=6) with NLMEM model-predicted drug 
concentration for the population (+/- 2 SD). 
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Figure 4.5 Plasma drug concentration of chlortetracycline hydrochloride administered at 
22 mg⁄kg/day p.o. to ruminating, Holstein steers (n=6) with NLMEM model-predicted drug 
concentration for the population (+/- 2 SD). 
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Table 4.1 Geometric mean and coefficient of variation (Geo CV%) of pharmacokinetic parameters derived by NCA for 
chlortetracycline hydrochloride administered p.o. 
Parameter 
 
Units 
 4.4 mg/kg 
(CV%)±  
11 mg/kg 
(CV%)±  
22 mg/kg 
(CV%)± 
 
p-value 
AUC%Extrap  %  29.7 (20.5)  17.8 (26.5)  19.8 (46.7)  0.06 
AUCfinal-next  h·µg/mL  0.20 (9.5)  0.52 (29.9)  0.99 (35.5)  -- 
AUCfinal-
next/D† 
 
h·µg/mL 
 
0.046 (--)  0.047 (--)  0.045 (--)  0.91 
Cl ⁄F  L/kg /h  10.9 (32.0)  10.6 (43.4)  11.1 (59.1)  0.51 
Cmax*  ng/mL  97.7 (9.5)  267.8 (25.4)  485.9 (26.8)  0.77 
λz 
 1/h  0.0197 (0.4)  0.0195 (0.2)  0.0186 (13.2)  0.99 
t½ λz  h  35.2 (--)  35.5 (--)  37.2 (--)  -- 
Tmax  h  38.4 (0.002)  42.1 (0.00)  41.5 (0.008)  0.73 
Vz ⁄F  L/kg  12.8 (5.8)  15.2 (12.8)  13.5 (37.2)  0.77 
± n= 6; † Reported estimate is the dose-normalized partial AUC
 
calculated from the time of the final dose to 
the next scheduled dose (AUCfinal-next/D); *Reported estimate for Cmax is derived from steady state 
concentrations.  
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Table 4.2 Pharmacokinetic parameter estimates derived by NLMEM for chlortetracycline hydrochloride administered p.o. 
Parameter  Estimate±  Standard Error  CV (%) 
Primary       
V/F (L/kg)  40.92  1.28  3.125 
K (h-1)  0.0478  0.002  4.184 
  
    
 
Secondary       
AUC/D† (h·µg/mL)  0.29  0.0064  2.207 
Cl/F (L/kg/h)  1.8  36.914  2.035 
t1/2 (h)  16.174  0.327  2.022 
Cmax/D (ng/mL)  4.502  0.044  18.32 
Tmax (h)  23.334  0.472  2.023 
  
    
 
Interindivdual variability  CV (%)     
V/F (L/kg)  8.68%     
K (h-1)  16.87%     
± n= 18; † Reported estimate is the dose-normalized AUC (AUC/D). 
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CHAPTER 5 - Establishment of the in vivo pharmacokinetic 
relationship between chlortetracycline and anaplasmosis carrier 
clearance using three oral treatment regimens  
Submitted to Veterinary Microbiology (September 2009). 
Introduction 
Anaplasmosis, caused by Anaplasma marginale, is one of the most prevalent tick-
transmitted, rickettsial diseases of cattle worldwide (Kocan et al., 2003). The Office International 
des Epizooties (OIE) Terrestrial Animal Health Code categorizes anaplasmosis as a notifiable 
disease due to socioeconomic impact and international trade restrictions (OIE, 2009). However, 
the significance of anaplasmosis is frequently underestimated due to seasonal outbreaks and 
stability in endemic areas (Brock et al., 1957). Breed differences are reported for peak change in 
packed cell volume, parasitemia level, and tick susceptibility (Bock et al., 1999; Jonsson et al., 
2008; Wilson et al., 1980). However, all cattle are susceptible to infection with A. marginale.  
Cattle infected with anaplasmosis following natural infection and vaccination with live 
Anaplasma spp. remain lifelong carriers (Kocan et al., 2003). Carriers are responsible for 
horizontal, iatrogenic, and vertical transmission of anaplasmosis to naïve cattle by providing a 
reservoir of infective blood for biological, mechanical, and in utero infection (Futse et al., 2003; 
Norton et al., 1983; Reinbold et al., 2009b).  
Anaplasmosis chemosterilization regimens using chlortetracycline hydrochloride (CTC) 
have been assessed using antigen/antibody-mediated second generation diagnostic methods, such 
as capillary agglutination and complement fixation, and subinoculation of splenectomized calves 
(Table 5.1) (Brock et al., 1959; Franklin et al., 1966; Franklin et al., 1967; Franklin et al., 1965; 
Richey et al., 1977; Twiehaus, 1962). This is problematic due to deficiencies in sensitivity and 
specificity of second generation methods (Coetzee et al., 2007; Goff et al., 1990; Gonzalez et al., 
1978) as well as animal welfare concerns associated with the use of splenectomized cattle. 
Furthermore, the time from commencement of therapy to chemosterilization is currently 
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unknown. CTC is only labeled for the control of active infection of anaplasmosis caused by A. 
marginale susceptible to CTC in cattle in the United States (2009 Feed Additive Compendium).  
The Clinical and Laboratory Standards Institute (CLSI) has set the susceptible minimum 
inhibitory concentration (MIC) breakpoint of tetracycline antibiotics (200 mg/mL injectable 
oxytetracycline product) at 2 µg/mL when treating bovine bacterial infection caused by 
Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni (CLSI, 2008); yet, a 
similar pharmacokinetic relationship does not exist for the treatment of bacterial infection caused 
by A. marginale. The purpose of this study was to identify a practical and efficacious CTC 
chemosterilization regimen and diagnostic testing strategy to determine therapeutic success. The 
specific objectives were to (1) evaluate A. marginale chemosterilization regimens using oral 
chlortetracycline antibiotics at different dosages; (2) establish the pharmacokinetic relationship 
between chlortetracycline and chemosterilization and determine the time of chemosterilization; 
and (3) determine the susceptibility of chemosterilized steers to re-infection with the original 
Virginia isolate.  
Materials and Methods 
Twenty-five preconditioned, Holstein steers were enrolled in this study under Kansas 
State University (KSU) Institutional Animal Care and Use Committee protocol #2517 and KSU 
Institutional Biosafety Committee protocol #524. Six of these steers were iatrogenically infected 
with a Virginia isolate of A. marginale by a contaminated, 1.7 X 25 mm hypodermic needle in a 
previous iatrogenic transmission study (Reinbold et al., 2009b). Nineteen steers were confirmed 
negative for anaplasmosis by a commercially available cELISA and an A. marginale-specific 
RT-PCR assay. In order to assemble a group of 21 steers chronically infected with A. marginale, 
fifteen naïve steers were randomly assigned to receive a 5 mL intravenous inoculation of whole 
blood from an iatrogenically infected steer 48 days prior to study initiation. The whole blood 
inoculum samples were collected into separate evacuated tubes containing K2EDTA from each 
iatrogenically infected steer prior to subinoculation. The four remaining naïve steers were 
splenectomized 36 days prior to the study to serve as disease transmission sentinels during 
treatment.  
Steers were randomized by body weight and assigned to a (1) 4.4 mg/kg/day (LD; n=6); 
2) 11 mg/kg/day (MD; n=6); 3) 22 mg/kg/day (HD; n=6) CTC treatment groups; or 4) placebo 
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treatment group (CONTROL; n=7). The LD, MD and HD treatment groups each consisted of 
five infected steers and one splenectomized steer. The CONTROL group consisted of six 
infected steers and one splenectomized steer. Steers were collectively 314 ± 29.9 days old and 
weighed 312.4 ± 47.1, 309.5 ± 43.6, 303.5 ± 47.2 and 320.8 ± 29 kg for the LD, MD, HD and 
CONTROL treatment groups, respectively. Four dry lot pens located at the KSU Juniatta Beef 
Cattle research facility accommodated the treatment groups.  
A commercial CTC product (Aureomycin 50 Granular; Alpharma Animal Health, 
Bridgewater, NJ, USA) was purchased for the formulation of a CTC top dress prepared by the 
KSU feed mill. A final concentration of 591.0; 1477.3; and 2954.4 mg of CTC per kg of ground 
corn carrier was used for the LD, MD, and HD dosages administered, respectively. These 
respective drug concentrations ensured that a similar total quantity of top dress was fed (kg) 
regardless of the dosage administered. The CONTROL group received the ground corn carrier as 
a placebo based upon the average weight of top dress fed to the CTC-treated groups. 
Steers were acclimated to a total mixed ration diet over a one month period pre-study. 
During the study, this diet was rationed twice daily at 1.25% (as fed) of the average pen weight. 
The daily dietary ration and CTC dosages were determined using the mean weight of the 
treatment group, which was taken bi-weekly. Daily dosage and ration were divided equally and 
administered twice daily for 80 days (160 total doses ⁄group). The daily ration and top dress 
treatment were distributed evenly along 3.7 m of a concrete feed bunk (0.61 m⁄ head). The feed 
bunk was inspected prior to each treatment. Residues from the previous treatment were noted in 
a daily log sheet; however, observed residues were not removed or weighed. Water was supplied 
ad libitum. When handling was necessary for the collection of venous blood samples, the steers 
were individually restrained with a head gate and rope halter. If sample collection coincided with 
scheduled treatment, samples were collected prior to treatment administration. 
Sample collection and analysis 
cELISA—Blood was collected from the jugular vein with evacuated tubes containing no 
additive. Serum was removed and analyzed for antibody against A. marginale by a commercially 
available cELISA in accordance with the method described by the OIE and recommended by the 
manufacturer (OIE, 2009; VMRD). The optical density of each sample was measured by an 
ELISA plate reader at a wavelength of 620 nm. The optical density was used to calculate a 
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percent inhibition (% inhibition). Samples were considered negative for anaplasmosis if the % 
inhibition was <30%. All samples with a % inhibition >30% were considered positive (Coetzee 
et al., 2007; OIE, 2009; Strik et al., 2007; VMRD).  
Real time RT-PCR assay—Two hundred and fifty microliters of plasma-free whole blood 
sample was removed from blood samples collected from the jugular vein with evacuated tubes 
containing K2EDTA. The plasma-free whole blood sample was used to extract RNA using a 
commercially available product according to manufacturer recommendations (TRI Reagent, 
Sigma-Aldrich; Saint Louis, MO). The RNA sample was rehydrated with 50 µL of nuclease–free 
water. An A. marginale-specific real-time RT-PCR assay was used to detect and quantify a 
highly conserved and specific region of 16S ribosomal RNA subunit (16S rRNA) as previously 
described (Reinbold et al., 2009b). The RT-PCR was optimized over a linear, dynamic range 
with one hundred to one billion molecules of 16S rRNA template that correspond to cycle 
threshold (Ct) values from 10 to 35, respectively. Linear regression was used to quantify the 
number of 16S rRNA template molecules in the 25 µL reaction based upon the corresponding Ct 
value with the following equation: 
    y = -3.4324x + 40.38 (1)  
where y is the reported Ct value and x is the number of template molecules. The correlation 
coefficient (R2) for the regression equation was 0.9973. Samples from a known A. marginale 
carrier and a naïve cow were extracted and analyzed simultaneously for monitoring assay 
performance and quality of the RNA extraction technique.  
Light microscopic examination of stained blood smears—Blood films were prepared 
from whole blood collected from the jugular vein in evacuated tubes containing K2EDTA. Blood 
films were stained with an automated unit (Hema-Tek, Ames Company; Elkhart, IN) using a 
Modified Wright stain. A total of 1,000 erythrocytes were counted in each sample. 
Plasma drug concentration analysis—Plasma drug concentrations were determined from 
whole blood samples collected from the jugular vein with evacuated tubes containing lithium 
heparin. Plasma was subjected to solid phase extraction and analysis with an ultrahigh 
performance liquid chromatography-mass spectroscopy ⁄ mass spectroscopy method as 
previously described (Reinbold et al., 2009a). The limit of quantitation of the method was 50 
ng/mL. Plasma drug concentrations > 50 ng/mL were reported and used for analysis. 
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Evaluation of chemosterilization  
A heparinized, 10 mL whole blood sample was collected from each steer in the LD, MD 
and HD treatment groups. Heparinized whole blood samples were pooled within each treatment 
group to compose a 50 mL final volume. Fifty milliliters of a whole blood sample was used to 
intravenously subinoculate the splenectomized calf assigned to the respective treatment group 
during the 80 day study. The disease status of the splenectomized steers was evaluated weekly by 
cELISA, light microscopic examination of stained blood smears and RT-PCR assay.  
Determining susceptibility to re-infection  
After chemosterilization was achieved, steers confirmed negative for A. marginale by 
subinoculation of splenectomized calves were monitored until the reported % inhibition of the 
cELISA declined below 40%. Five steers were exposed to re-infection with a frozen stabilate 
prepared from the same Virginia isolate of A. marginale. This stabilate was prepared from a 
splenectomized steer used to propagate the isolate in vivo for the previous iatrogenic 
transmission study (Reinbold et al., 2009b). The stabilate was prepared 280 days prior to the time 
of exposure from a heparinized, whole blood sample with a 2% parasitemia. The parasitemia at 
the time of collection was 2.0%. Four milliliters of stabilate was used to intravenously inoculate 
five chemosterilized steers. The disease status of the chemosterilized steers was evaluated by 
cELISA, light microscopic examination of stained blood smears and RT-PCR assay.  
Chemosterilization of CONTROL group  
Upon validation of chemosterilization results for the LD, MD, and HD treatment groups, 
chemosterilization was assessed in the CONTROL treatment group with a single, subcutaneous 
injection of a long-acting oxytetracycline (Tetradure 300, Merial Limited, Duluth, GA) at 20 
mg/kg followed by 30 days of treatment with CTC at 4.4 mg/kg/day (Figure 5.4). The CTC 
treatment preparation and administration was similar to the LD treatment group. Samples were 
collected on days 0, 10, 17, 24, 31 and 38 for analysis by cELISA and RT-PCR. Plasma drug 
concentrations were not determined during this treatment.  
Statistical analysis  
Data were entered into a software package (Microsoft Excel 2007, Microsoft 
Corporation; Redmond, WA) for subsequent calculations and manipulation. Geometric mean and 
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CV% were calculated for data acquired from responses recorded from diagnostic assay results. 
Diagnostic assay results were converted to a binary format (0 = negative, 1 = positive). 
Sensitivity and specificity with 95% confidence intervals were calculated for cELISA and RT-
PCR for each time point. Results were compared using a software program (WinEpiscope 2.0, 
CLIVE; Edinburgh UK) in a 2 X 2 contingency table. Agreement between diagnostic results of 
each semi-weekly sampling was assessed by calculating a κ statistic (Le, 2003). The κ statistic 
measures agreement on a scale from 0 to 1.  
The association between chemosterilization and diagnostic assay results were analyzed 
by generalized linear mixed models and generalized estimating equations (PROC Glimmix and 
PROC Genmod, SAS version 9.1, SAS Institute, Inc.; Cary, NC). Proper methods were 
employed, when necessary, to take into account the lack of independence among repeated 
observations of the same animal over time. A semi-parametric survival analysist was performed 
to analyze the variation when each respective diagnostic assay first detected A. marginale 
clearance. A non-parametric, Kaplan-Meier survival analysis (Stata v10.1; Stata Corp LP, 
College Station, TX) was performed on raw data depicting the time elapsed prior to RT-PCR 
negative outcomes for each of the antibiotic treatment regimens. An alpha level of 0.05 was 
observed throughout the study for evaluating statistically significant differences. 
Results 
The mean weight among treatment groups was not significantly different at the initiation 
(P = 0.943) and completion of treatment (P = 0.93). The initial RT-PCR assay results between 
iatrogenically infected steers and subinoculated steers were significantly different (P < 0.0001). 
However, the RT-PCR assay results were not significantly different after randomization (P = 
0.16). There were no statistically significant differences in cELISA results prior to randomization 
(P = 0.86). One splenectomized steer was removed from the study due to death caused by post-
surgical hemorrhage from an aneurysm of the splenic vein. This complication reduced the 
CONTROL group to six, A. marginale infected steers.  
When evaluating the time of chemosterilization by the RT-PCR assay, the LD, MD and 
HD groups were chemosterilized following 46, 46 and 49 days of CTC treatment, respectively. 
Chlortetracycline treatment was significantly associated with RT-PCR assay results (P = 0.018). 
There was no significant difference when comparing LD to MD (P= 0.07) and MD to HD (P = 
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0.30); however, a significant difference was detected between LD and HD (P = 0.005). The 
estimated risk of chemosterilization based upon RT-PCR assay results for the LD, MD and HD 
treatment groups were 0.735 (0.726,0.744), 0.746 (0.737,0.755) and 0.753 (0.744,0.761), 
respectively. The cELISA did not confirm chemosterilization until 18, 54 and 18 days after the 
completion of the 80 day CTC treatment regime in the LD, MD, and HD treatment groups, 
respectively (Figure 5.2). CTC treatment was not significantly associated with cELISA results (P 
= 0.43). The estimated risk of chemosterilization based upon cELISA results for the LD, MD and 
HD treatment groups were 0.658 (0.636,0.679), 0.671 (0.650,0.692) and 0.676 (0.655,0.697) 
respectively.  
Diagnostic method performance was calculated for the cELISA and RT-PCR assay 
throughout the 80 day study (Table 5.2). The cELISA demonstrated 100% sensitivity throughout 
the study. However, cELISA specificity was imprecise for days 14 through 80 of treatment. This 
imprecision was likely caused by the continued presence of anti-A. marginale antibodies 
following chemosterilization. Furthermore, the positive predictive value of the cELISA was 
reduced accordingly on days 14 through 80 during treatment. The specificity of the RT-PCR was 
100% throughout the study. However, RT-PCR sensitivity was inaccurate during days 18 
through 39 of treatment. This was likely caused by low parasitemia levels encountered as a result 
of treatment. Furthermore, the negative predictive value was reduced accordingly on days 18 
through 39 of treatment.  
Diagnostic method agreement (ĸ) was negatively influenced by persistent antibody levels 
and a reduction in parasitemia during treatment. Agreement was perfect on days 0 through 11 of 
treatment. However, agreement reduced accordingly until peak reduction was reported on days 
49 through 53 of treatment. The agreement at the end of the 80 day treatment was 0.44.  
Oral administration of all treatments was well tolerated throughout the study. Feed bunk 
spatial allocation of 0.61 m/head was adequate to allow each steer equal opportunity to consume 
the daily ration and treatment. However, a remarkable level of intra- and inter-individual 
variability was observed within treatment groups (Figure 5.3). The geometric mean (CV%) of 
plasma drug concentrations collected on days 4 through 53 of the study for the LD, MD, and HD 
treatment groups were 85.3 (28), 214.5 (32), and 518.9 (40) ng/mL for samples, respectively. 
This data suggests a concentration independent pharmacokinetic relationship between 
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chemosterilization and plasma drug concentration where time above the minimum inhibition 
concentration is required for chemosterilization.  
The CONTROL group was not chemosterilized during the 80 day study. However, these 
steers were subsequently chemosterilized with a single, subcutaneous injection of a long-acting 
oxytetracycline followed by 30 days of treatment with CTC at 4.4 mg/kg/day (Figure 5.4). 
Plasma drug concentrations were not determined during this treatment.  
Chemosterilization, as assessed by the cELISA and RT-PCR assays, was confirmed 
through subinoculation of splenectomized steers. Three splenectomized steers, subinoculated 
with a pooled blood samples collected from chemosterilized steers 50 days after the end of the 80 
day study, were monitored for 6 weeks by cELISA, light microscopy, and RT-PCR. No change 
in disease status of the splenectomized steers was detected by these methods. Similarly, there 
was no change in disease status of a splenectomized steer subinoculated with blood collected 
from the CONTROL group 12 days after chemosterilization with oxytetracycline and CTC.  
Results from the semi-parametric survival analysis were expressed as hazard ratios. 
Hazard ratios, interpreted similarly as odds ratios, were assumed to be proportional over time and 
represent the effect of a unit change in the predictor on the frequency of the outcome (Le, 2003). 
The hazard ratio of cattle chemosterilized by multi-modal treatment of the CONTROL group 
using oxytetracycline and CTC when compared with CTC alone in the LD, MD and HD groups 
were 5.67 (1.4, 23.2; P < 0.016), 5.4 (1.4, 21.5; P = 0.016) and 7.6 (1.7, 33.0; P = 0.007), 
respectively. A Kaplan-Meier survival analysis depicts the time elapsed prior to RT-PCR 
negative outcomes for each of the antibiotic treatment regimens (Figure 5.6).  
Five steers previously infected in an iatrogenic transmission study were re-infected by a 
stabilate of the Virginia isolate of A. marginale used to infect these steers (Reinbold et al., 
2009b). An immune response was detected by the cELISA 10 days after exposure in all steers. 
Re-infection was detected as early as 10 days, but by 24 days of exposure in all steers. A 
splenectomized steer subinoculated with a pooled blood sample collected from the re-infected 
steers was monitored by cELISA, light microscopy, and RT-PCR for change in disease status. 
Re-infection was confirmed by positive results in all methods within 21 days following 
subinoculation.
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Discussion 
This study has established multiple chemosterilization regimens using chlortetracycline 
for the clearance of persistent infection with A. marginale, as assessed with the Virginia isolate. 
The dose and length of treatment of these strategies differ from previous studies (Brock et al., 
1959; Franklin et al., 1966; Franklin et al., 1967; Franklin et al., 1965; Richey et al., 1977; 
Twiehaus, 1962). Dosages were selected based upon a chlortetracycline pharmacokinetic study 
reporting dose linearization of plasma drug concentrations among the CTC dosages prescribed in 
this study (Reinbold et al., 2009a). Accordingly, these dosages were prescribed to determine if 
dose combined with a fixed duration of treatment affected the rate of chemosterilization. 
These CTC treatment regimens resulted in plasma drug concentrations that successfully 
chemosterilized steers persistently infected with A. marginale. However, these plasma drug 
concentrations were less than the minimum inhibitory concentration recommended for the 
treatment of bacterial infection caused by M. haemolytica, P. multocida, or H. somnii (CLSI, 
2008). Therefore, the success of an A. marginale chemosterilization strategy should not be based 
upon the aforementioned minimum inhibitory concentration. A key finding of this study is the 
pharmacokinetic relationship between plasma drug concentration and chemosterilization. This 
relationship illustrated that carrier clearance was not influenced by higher dosages of CTC; 
furthermore, 4.4 mg/kg was the minimum effective dose necessary to chemosterilize cattle 
infected with A. marginale. Indeed, a difference in RT-PCR assay results, which were used to 
determine the time of chemosterilization, was detected between the LD and HD treatment 
groups. However, the authors do not recommend the usage of higher doses when formulating a 
chemosterilization strategy due to all CTC-treated groups being chemosterilized between 46 and 
49 days of treatment. 
A clinically and statistically significant difference was observed when comparing CTC 
treatment alone to a regime using a combination of oral and injectable tetracycline antibiotics. 
This was likely due to the time of maximum concentration occurring earlier when a 300 mg/mL 
preparation of oxytetracycline (4.7 h) (Dowling and Clark, 2003) is administered than with the 
LD (38.4 h), MD (42.1 h) and HD (41.5 h) treatments (Reinbold et al., 2009a). 
The absorption of tetracycline into the erythrocyte has been characterized as a simple 
diffusion process (DeLoach and Wagner, 1984). Once inside the erythrocyte, drug passes as a 
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cation through porin channels of the outer membrane of Gram negative bacteria into the 
periplasm, becomes an uncharged molecule to diffuse through the inner cytoplasmic membrane 
and reversibly binds to the 30S ribosome to inhibit protein synthesis (Chopra and Roberts, 2001). 
Tetracyclines are also known to interact with the 16S rRNA subunit (Moazed and Noller, 1987). 
However, this did not affect RT-PCR assay performance during the study. 
Efflux and ribosomal protection proteins, as well as enzymatic inactivation, are 
mechanisms of resistance to counteract their efficacy during treatment. These mechanisms are 
driven by numerous resistance genes found in commensal and pathogenic bacteria today (Chopra 
and Roberts, 2001) The ability to define tetracycline resistance is difficult due to the frequent 
occurrence of mutants that are impermeable to drug uptake (Moazed and Noller, 1987). 
Furthermore, no apparent difference is distinguishable between resistance genes of the 
tetracycline family of antibiotics. 
CTC is only labeled for the control of active infection of anaplasmosis caused by A. 
marginale susceptible to CTC in cattle in the United States (2009 Feed Additive Compendium). 
The continuous feeding of CTC to naïve cattle in high risk areas for anaplasmosis infection is 
advocated during the vector season (Brock et al., 1957). However, this practice may have the 
potential to inadvertently disrupt endemic stability by chemosterilizing infected cattle and select 
for or facilitate the distribution of resistance determinants in bacterial species present (Stevens et 
al., 1993). A significant change was reported in antimicrobial susceptibility of enteric bacteria 
from cattle fed chlortetracycline in three consecutive, five day pulse treatment regimens at 22 
mg/kg (Platt et al., 2008). However, this change was only temporary as values returned to pre-
exposure levels within 33 days. Due to length of treatment being critical to successful 
chemosterilization, it is unknown if this return to pre-exposure levels would be similar in 
situations where the duration of therapy is more extensive. The development and application of 
improved animal husbandry practices (Reinbold et al., 2009b), as well as establishment of an 
endemically stable herd (Figueroa et al., 1998), could considerably reduce the need for 
tetracycline antibiotics when managing anaplasmosis in cattle. However, the existence of an 
endemically stable herd does not permit the comingling of cattle of unknown disease status or 
reduce trade restrictions between endemic and non-endemic countries. 
The host immune response to A. marginale infection depends upon the production of 
anti-parasitic and anti-erythrocytic antibodies inducing the erythrophagocytosis of parasitized 
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erythrocytes (Jatkar and Kreier, 1969). The mechanism by which anaplasmosis eludes the host 
immune response is unknown; however, the lack of conservation of gene sequences encoding 
major surface protein antigens of Anaplasma spp. has been the focus of research (de la Fuente et 
al., 2005). Evidence exists for a rapid decrease in antigen-specific T cells and immunologic 
memory following infection of cattle pre-immunized with the major surface protein 1a (Han et 
al., 2008). The chemosterilization process was not facilitated immunologically by a second 
exposure prior to and during treatment (Kuttler, 1983). Furthermore, our study and the findings 
by others (Magonigle and Newby, 1984; Renshaw et al., 1976) have illustrated a loss of 
immunologic memory through the loss of anti-parasitic antibody and re-infection of cattle 
previously chemosterilized. 
The mechanism for the extensive duration of treatment necessary for chemosterilization 
success is unknown. The reversible binding of the 30S ribosome and lifespan of parasitized 
erythrocytes may be key contributors to this phenomenon. However, the concentration of drug 
achieved in parasitized erythrocytes may be inadequate for a bactericidal effect. It may be likely 
the inhibition of protein synthesis may prevent the infection of non-parasitized erythrocytes. 
However, parasitized erythrocytes must still be removed from circulation by erythrophagocytosis 
in the spleen. Ultimately, carrier clearance is influenced by an extensive drug absorption process, 
reversible binding of the tetracycline antibiotic to the 30S ribosome, an inadequate host immune 
response, and erythrophagocytosis of parasitized erythrocytes. 
Previously recommended oral CTC chemosterilization regimens established with second 
generation diagnostic methods have inadequate sensitivity and specificity for accurately and 
precisely determining disease status (Coetzee et al., 2007; Goff et al., 1990; Gonzalez et al., 
1978). Second generation methods most commonly used in the literature to determine 
anaplasmosis disease status in clinical medicine and research, such as capillary agglutination, 
complement fixation and cELISA, identify cell components, metabolic products, and detection of 
antigenic components. However, there is a body of evidence that suggests these methods are 
non-specific among related Anaplasma spp. (Bradway et al., 2001; Dreher et al., 2005; Richey et 
al., 1977; Strik et al., 2007). The results of this study illustrated the insufficient specificity of 
cELISA for identifying true negative cattle at the time of chemosterilization. The % inhibition (< 
30%) used for the cELISA negative cut-off value in this study was previously set to optimize 
sensitivity (Coetzee et al., 2007; OIE, 2009; Strik et al., 2007; VMRD). However, the use of a 
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cut-off set at a greater % inhibition would do little to improve the specificity of this diagnostic 
method under the circumstances of this study. Indeed, the cELISA did eventually confirm a 
negative disease status. The time delay involved would make third generation diagnostic 
methods more attractive. However, the use of cELISA does offer a practical and cost effective 
way for veterinarians and producers to determine chemosterilization success. 
A novel and quantitative third generation method, RT-PCR, was validated for 
determining chemosterilization in this study. The advantages of the RT-PCR assay were the 
ability to precisely identify the time of chemosterilization (specificity), enhanced sensitivity as a 
result of identifying high copy numbers of 16S rRNA versus a single cellular DNA copy 
(Sirigireddy and Ganta, 2005); and quantification of the 16S rRNA template. The disadvantages 
were the cost of the reagents and equipment as well as the necessity of modern elements. 
The RT-PCR assay demonstrated improved sensitivity and specificity over cELISA. 
However, this is not the first study to compare second and third generation diagnostic methods 
during a chemosterilization strategy. A previous chemosterilization study reported sensitivity and 
specificity deficiencies of cELISA and a nested PCR (Coetzee et al., 2006). The validity of 
diagnostic results of this and previous chemosterilization studies were validated through the 
subinoculation of whole blood into splenectomized calves. However, the RT-PCR assay could be 
considered as a tool for the reduction of animal pain and suffering by serving as a reliable 
substitute to the subinoculation of splenectomized cattle. 
Anaplasmosis is a complex and challenging disease for stakeholders in the cattle 
industry, foreign policy and research communities alike. Many of the current methods used for 
the diagnosis, treatment, eradication and control of bovine anaplasmosis present many problems 
to the cattle industry. A highly sensitive and specific RT-PCR assay was instrumental in 
characterizing the time of chemosterilization as well as establishing the pharmacokinetic 
relationship between plasma drug concentration and chemosterilization in vivo. Due to the 
widespread use of CTC for controlling and treating anaplasmosis in cattle, it is essential these 
effective plasma drug concentrations be reported in the literature to prevent imprudent use of this 
antibiotic. These treatment regimens offer an alternative strategy for minimizing animal handling 
and eliminate individual treatment. Furthermore, this study identifies a viable chemosterilization 
and testing strategy that could be considered as an alternative to culling valuable cattle infected 
with A. marginale. Ultimately, the findings of this study have the potential to significantly 
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impact local, interstate, and international movement of cattle between endemic and non-endemic 
regions.
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Figures and Tables 
Figure 5.1 Diagram of the study design and decision tree analysis used to determine disease 
status. 
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Figure 5.2 Comparison of the rate of chemosterilization detected by an Anaplasma marginale -
specific RT-PCR assay following 80 days of treatment with placebo in the CONTROL group 
(open circles; n=6) and oral chlortetracycline in the LD (open diamonds; n=5), MD (open 
squares; n=5), and HD (open triangles; n=5) groups. Data points are represented as the inverse 
of the geometric mean of the Ct value reported during analysis. The geometric CV% is 
included as error bars for the CONTROL group. 
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Figure 5.3 Comparison of the rate of antibody decline against Anaplasma marginale 
detected by cELISA. The data series represented are the CONTROL (crosses; n=6), LD 
(open diamonds; n=5), MD (open squares; n=5), and HD (open triangles; n=5) treatment 
groups. Data points are represented as the geometric mean of the % inhibition reported 
during analysis. The geometric CV% is included as error bars for the CONTROL group. 
Commonly used cut-off points for disease status interpretation are represented as 30% 
inhibition (- · · -) and 40% inhibition (- · -). The cumulative time to chemosterilization 
detected by the RT-PCR assay is represented on the x-axis (closed circle). The end of 
treatment is represented on the x-axis (closed square). Negative values on the x-axis refer to 
the days of CTC treatment whereas positive values represent the days observed after the 
end of treatment. 
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Figure 5.4 Comparison of plasma drug concentrations achieved with 4.4, 11, and 22 
mg/kg/day of oral chlortetracycline in the LD (open diamonds; n=6), MD (open squares; 
n=6), and HD (open triangles; n=6) treatment groups, respectively. Data points are 
represented as the geometric mean and CV% (error bars) of plasma drug concentrations 
reported during analysis. The cumulative time to chemosterilization detected by the RT-
PCR assay is represented (closed circle) on the x-axis. A geometric mean is included for 
plasma drug concentrations recorded on days 4 through 53 of treatment in the LD (85.3 
ng/mL; -), MD (214.5 ng/mL; - · -), and HD (518.9 ng/mL; - · · -) treatment groups 
(n=90/treatment). 
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Figure 5.5 Comparison of the rate of chemosterilization detected by an Anaplasma 
marginale -specific RT-PCR (open diamonds) and antibody decline against A. marginale 
detected by cELISA (open triangles) in six steers treated with a subcutaneous injection of a 
long-acting oxytetracycline (300 mg/mL) at 20 mg/kg and 30 days of treatment with oral 
chlortetracycline at 4.4 mg/kg/day. The end of treatment with CTC treatment is indicated 
(closed circle) on the x-axis. Data points are represented as the geometric mean and CV% 
(error bars) of results reported during analysis.  
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Figure 5.6 A Kaplan-Meier survival analysis derived from RT-PCR assay results for the 
LD (— —), MD (– – –), HD (···), and multi-modal treatment of the CONTROL group (—) 
for illustrating the probability of a positive RT-PCR assay result over time. 
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Table 5.1 Comparison of previously reported Anaplasma marginale chemosterilization strategies in cattle treated with 
chlortetracycline hydrochloride. 
Study  Cattle  
Dose 
(mg/kg)  
Duration 
(days)  Method  Infection  
Group 
Treatment  Test  
Confirmed 
with 
subinoculation 
                 
1 
  
26 Adults, 
intact   
4.4   30 
  
In 
ration   Natural   
Y   CF 
  
Yes* 
                 
2 
 
60 Adults, 
intact  
2.2  30 
 
Range 
Cubes  
Natural  Y 
 
CF, 
CA  
No 
 
60 Adults, 
intact  
2.2  60 
 
Range 
Cubes  
Natural  Y 
 
CF, 
CA  
No 
 
60 Adults, 
intact  
5.5  30 
 
Range 
Cubes  
Natural  Y 
 
CF, 
CA  
No 
 
60 Adults, 
intact  
5.5  60 
 
Range 
Cubes  
Natural  Y 
 
CF, 
CA  
No 
  
60 Adults, 
intact   
11   30 
  
Range 
Cubes   
Natural   Y 
  
CF, 
CA   
No 
                 
3 
 
3 Adults, intact  11  60 
 
In 
ration  Experimental  
Y  CF  Yes 
 
7 Adults, intact  5.5  60 
 
In 
ration  Experimental  
Y  CF  Yes 
 
4 Adults, intact  3.3  60 
 
In 
ration  Experimental  
Y  CF  Yes 
                 
4  
1 Calf, intact  2.2  41  In 
ration  Experimental  Y  
CF, 
CA  No
#
 
 
8 Calf, intact  1.1  45  Hand fed  Experimental  N  
CF, 
CA  No
#
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1 Calf, 
splenectomized  1.1  90   
Hand 
fed   Experimental   N   
CF, 
CA   No
#
 
                 
5  
10 Adults, 
intact  
11  30  Hand-fed  
6 Natural,4 
Experimental  
N  CF  No 
  
10 Adults, 
intact   
11   60   Hand-fed   
Natural 
  
N   CF   Yes 
                 
6 
  
10 Adults, 
intact   
1.1   120   In 
ration   Natural   N   CF   Yes 
Studies 1, 2, 3, 4, 5 and 6 were reported by Twiehaus 1962; Franklin et al., 1966; Brock et al., 1959; Franklin et al., 1967; Franklin et al., 
1965; and Richey et al., 1977, respectively. CA = capillary agglutination; CF = complement fixation; * = only 1 head splenectomized; # = 
treated calves were splenectomized 75 days after treatment ended. 
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Table 5.2 Comparison of diagnostic method performance for the cELISA and RT-PCR assays as determined by the calculated 
sensitivity (%), specificity (%), positive predictive value (%), negative predictive value (%), and agreement (κ) during an 80 
day Anaplasma marginale chemosterilization study (n=24). 
  cELISA  RT-PCR   
Day  
Se 
(%)  
Sp 
(%)  PPV (%)  NPV (%)  
Se 
(%)  
Sp 
(%)  PPV (%)  NPV (%)  Agreement (κ) 
0  *  *  *  *  *  *  *  *  1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4  *  *  *  *  *  *  *  *  1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7  *  *  *  *  *  *  *  *  1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11  *  *  *  *  *  *  *  *  1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14  *  75  95.2  *  *  *  *  *  0.92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18  *  60  90.5  *  84.2  *  *  62.5  0.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
21  *  60  90.5  *  84.2  *  *  62.5  0.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25  *  60  90.5  *  94.7  *  *  83.3  0.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28  *  42.9  81  *  82.4  *  *  70  0.64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
32  *  37.5  76.2  *  87.5  *  *  80  0.66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
35  *  30  66.7  *  91.7  *  *  92.3  0.66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
39  *  25  57.1  *  66.7  *  *  75  0.46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
42  *  25  57.1  *  *  *  *  *  0.63 
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46  *  17.6  33.3  *  *  *  *  *  0.46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
49  *  16.7  28.6  *  *  *  *  *  0.41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
53  *  16.7  28.6  *  *  *  *  *  0.41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
56  *  22.2  30  *  *  *  *  *  0.44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
60  *  22.2  30  *  *  *  *  *  0.44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
63  *  22.2  30  *  *  *  *  *  0.44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
67  *  22.2  30  *  *  *  *  *  0.44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
70  *  22.2  30  *  *  *  *  *  0.44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
75  *  16.7  28.6  *  *  *  *  *  0.42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
77  *  22.2  30  *  *  *  *  *  0.44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80  *  22.2  30  *  *  *  *  *  0.44 
n = 24; Se = Sensitivity; Sp = Specificity; PPV = Positive Predictive Value; NPV = Negative Predictive Value; * indicates the cell 
value is 100%. 0 < κ < 0.4 = poor reproducibility; 0.4 < κ < 0.75 = good reproducibility; and κ > 0.75 = excellent reproducibility. 
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CHAPTER 6 - Implications for further research 
The qRT-PCR described in Chapter 2 has proven to be a robust diagnostic method for 
determining A. marginale disease status in cattle. Furthermore, the qRT-PCR was demonstrated 
as a replacement for the subinoculation of splenectomized cattle for the confirmation of study 
results. Additionally, a robust UPLC-MS ⁄ MS method has been described for monitoring CTC 
plasma drug concentrations (Chapter 4). From these novel diagnostic and quantification 
techniques developed in this dissertation, two novel studies will be modestly described in 
relation to future research implications. 
Assessment of horizontal A. marginale transmission with a tick vector 
subsequent to feeding on a chlortetracycline-treated, carrier calf 
Introduction:  
Specific host vector relationships have previously been elucidated in ticks for the 
transmission of A. marginale in cattle (Kocan et al., 2000). Ticks have been demonstrated to be 
more efficient vectors of anaplasmosis than Tabanidae and Muscidae on the order of >240-fold 
and >300-fold, respectively (Scoles et al., 2005; Scoles et al.,2008). Additionally, the percentage 
of ticks infected during feeding is related to the circulating parasitemia (Eriks et al., 1989; Eriks 
et al., 1993). However, research has not been performed to determine the transmission rate of A. 
marginale by ticks subsequent to feeding on carrier cattle treated with CTC. The gathering of 
this data is imperative due to the chemoprophylactic use of CTC during the vector season (Brock 
et al., 1957). 
 Phase I:  
Nine Holstein calves weighing an average of 200 kg will be purchased and screened for 
A. marginale infection with the qRT-PCR. One naive calf will be infected with the tick 
transmissible Virginia isolate of A. marginale as described in Chapter 3. A carrier state will be 
established and confirmed through monitoring of the parasitemia level with the qRT-PCR. Upon 
confirmation of the carrier state, Phase II will begin. 
 
139 
 
Phase II:  
The carrier calf will be treated with the labeled dose of 350 mg of CTC per day as 
described in Table 1.3. Four days will elapse to ensure a steady-state plasma drug concentration 
has been achieved. Then, a total of 120 adult male, Dermacentor variablis ticks will be placed on 
the carrier calf and allowed to feed until self-detachment. Ticks will be stored for 1 week to 
allow multiplication of A. marginale in gut and salivary tissues. The parasitemia of the carrier 
calf will be monitored daily to assess the change in parasitemia levels prior to and during 
treatment with CTC. The CTC plasma drug concentration will be monitored with the UPLC-MS ⁄ 
MS method (Chapter 4). A correlation (R2) will be made between the change in parasitemia and 
CTC plasma drug concentration by regression analysis for the dose administered. Indeed, the 
limitation of this correlation will be an n=1. However, this will be a gathering of preliminary data 
for the monitoring of this scenario under field conditions. 
 
Phase III:  
Ten ticks will be transferred to each of the 8 naïve, non-medicated calves and allowed to 
feed until self-detachment to assess disease transmission success or failure. The remaining ticks 
(40) will be mounted, sectioned, and screened for infection by light microscopy. The prevalence 
of infection in these ticks will be used to estimate the prevalence of infection in the ticks feeding 
on the naïve calves. After 60 days, transmission success/failure will be determined through 
analysis of blood samples by the qRT-PCR.  
 
Addendum to protocol:  
If tick transmission is successful under the conditions of this study, then Phases I and II 
will be repeated in a separate group of calves and ticks. However, Phase III will be altered to 
include the treatment of the new group of 8 naïve calves with the dose and the conditions as 
described in Phase II for the carrier calf. This will assess the ability of infected ticks to transmit 
infection to calves treated with a labeled dosage of CTC. 
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Conclusion:  
Valuable information will be gathered in regard to the utility of feeding CTC to an 
endemically unstable group of calves during the tick vector season for prevention of horizontal 
transmission. 
 
Discovery of the mechanism of carrier clearance in cattle fed chlortetracycline 
during chemosterilization 
Introduction:  
The mode of action of tetracycline antibiotics was described in Chapter 1 for Gram 
negative bacteria (Chopra and Roberts, 2001). However, the mechanism of carrier clearance 
subsequent to the interaction of CTC with the 30S ribosome of A. marginale is unknown. It is 
imperative to understand this relationship in order to elucidate the future direction of 
anaplasmosis chemosterilization research efforts and the treatment of other pathogenic bacteria 
with tetracycline antibiotics. 
Phase I:  
Sixteen Holstein calves weighing an average of 200 kg will be purchased and screened 
for A. marginale infection with the qRT-PCR. Each naive calf will be infected with the tick 
transmissible Virginia isolate of A. marginale as described in Chapter 3. A carrier state will be 
established and confirmed through monitoring of the parasitemia level with the qRT-PCR. Upon 
confirmation of the carrier state, Phase II will begin. 
Phase II: 
 Carrier calves will be randomly assigned to a (1) CTC treatment group (4.4 mg/kg of 
bodyweight/day for 45 days (n = 8) or (2) a placebo-treated, control group (n = 8). The 
parasitemia and plasma drug concentration of all calves will be monitored on a daily basis by the 
qRT-PCR (Chapter 2) and UPLC-MS ⁄ MS methods (Chapter 4), respectively. The 16S rRNA: 
16S DNA ratio will also be monitored in the same sample extracted for RNA analysis as 
described in Chapter 2. A flow cytometric method will be used at each time point to assess the 
viability of A. marginale bacteria as previously described in (Coetzee et al., 2006). Finally, a 
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protocol modification will be developed to monitor CTC concentration in the intra-erythrocytic 
compartment as compared to the vascular compartment. 
Conclusion:  
At the completion of the 45 day study, the purpose of this study is to assess the potential 
change in A. marginale intracellular metabolism relative to treatment administered. The rate and 
time of carrier clearance will be monitored with the qRT-PCR. A correlation (R2) will be made 
between the change in metabolism according to treatment administered and the 16S rRNA: 16S 
DNA data. A correlation will also be made between the change in metabolism detected by the 
qRT-PCR and the viability of A. marginale bacteria assessed with the flow cytometric method. 
The plasma and intra-erythrocytic drug concentrations will be used to determine 
pharmacokinetic parameters during treatment. Furthermore, an attempt will be made to establish 
a relationship between plasma drug concentration, intra- erythrocytic drug concentration, A. 
marginale viability, and chemosterilization. If a relationship can be established, then it may be 
concluded that the cytotoxic effects of chlortetracycline contribute to the mechanism of carrier 
clearance. If no relationship can be established, then it may be concluded that an unknown 
mechanism contributes to the mechanism of carrier clearance. 
 
Research conclusions and practical implications 
 
The study in Chapter 2 described the development of real-time qRT-PCR assays for the 
detection of A. marginale and A. phagocytophilum alone or in combination. This is the first study 
to describe a duplex method for the diagnosis of A. marginale and A. phagocytophilum from the 
same sample. The selection of the16S rRNA gene segments enhanced the analytical sensitivity of 
the assay due to the high ratio of 16S rRNA:16S DNA. Furthermore, the extraction of RNA from 
a plasma-free blood sample ensured the maximum number of cells in a 250 µL sample were 
available for analysis. The correct classification of disease status is important for the collection 
of epidemiologic information, development of anaplasmosis disease control programs, and 
improvement of free-trade policy between endemic and non-endemic countries.  
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Anaplasmosis presents many problems to the cattle industry due to complications with 
disease control, eradication and treatment. When vaccinating cattle of unknown disease status, 
hygienic animal husbandry techniques are highly recommended. The study in Chapter 3 was 
designed to vigorously challenge the utility of needle-free injection for the control of 
anaplasmosis transmission among cattle during vaccination. Needle-free injection was validated 
as a tool for controlling iatrogenic transmission of A. marginale. Additionally, the A marginale-
specific qRT-PCR assay was evaluated for detecting A. marginale in bovine peripheral blood 
samples. This data set is clinically relevant due to the potential spread of A. marginale to naive 
cattle during routine animal husbandry practices as well as identifying the deficiencies in the 
sensitivity and specificity of cELISA. This study is the first report to evaluate needle-free 
injection techniques for the control of iatrogenic transmission of anaplasmosis as well as 
determine the performance of first, second and third generation diagnostic methods at sequential 
time points following a single exposure to A. marginale in cattle.  
Due to the widespread use of CTC in ruminating cattle, it is essential these 
pharmacokinetic parameters be reported (Chapter 4). Current literature remains deficient for oral 
bioavailability in ruminating cattle. Until a sufficient body of scientific knowledge for a 
complete pharmacokinetic and pharmacodynamic profile of CTC is formed, the use of this 
antibiotic as a tool in profitable cattle production will continue to be a target of special interest 
groups for the removal of the FDA-approved, labeled use of CTC in animal feed. Recently, a 
population pharmacokinetic (PPK) study was established as a successful tool for gathering 
pharmacokinetic information in large populations of cattle (> 100 head) (Fu et al., 2008). In 
addition to that study, the information gathered in the present study, as well as the use of 
nonlinear mixed effects modeling techniques typical of PPK studies, could provide the 
framework for PPK research of CTC in group fed, ruminating cattle. Future studies of this kind 
are necessary to bridge the gap between experimentally-derived data and confirmatory studies 
applied under normal conditions (Sheiner, 1997).  
The study in Chapter 5 established multiple chemosterilization regimens using CTC for 
the clearance of persistent infection with A. marginale, as assessed with the Virginia isolate. 
These treatment regimens offer an alternative strategy for minimizing animal handling and 
eliminates individual treatment. However, these plasma drug concentrations were less than the 
minimum inhibitory concentration recommended for the treatment of bacterial infection caused 
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by M. haemolytica, P. multocida, or H. somnii (CLSI, 2008). Therefore, the success of an A. 
marginale chemosterilization strategy should not be based upon the aforementioned minimum 
inhibitory concentration. A key finding of this study was the pharmacokinetic relationship 
evaluated among 3 doses of CTC in a fixed treatment regimen. Furthermore, this study identified 
a viable chemosterilization and testing strategy that could be considered as an alternative to 
culling valuable cattle infected with A. marginale. The qRT-PCR was instrumental in 
characterizing the time of chemosterilization as well as establishing the pharmacokinetic 
relationship between plasma drug concentration and chemosterilization in vivo. 
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